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The oxidative modification of lipids containing polyunsaturated fatty acids results in a 
wide diversity of reactive products, including short-chain aldehydes, which can covalently 
modify proteins, a process called lipoxidation, and affect their function. The detection of 
lipoxidation adducts is extremely challenging due to their low abundance, so there is a need 
for new detection methods. Using the model proteins lysozyme and human serum albumin, 
five reporter ions for acrolein modification, eight for 4-hydroxyhexenal and one for 2-
chlorohexadecanal were found by LC-MS/MS-based label-free method. Subsequently, a 
targeted multiple reaction monitoring method was developed as a potential tool for the 
identification and characterization of these modifications of human serum albumin in 
biological samples. Comparison between three different chromatographic methods for the 
separation of intact proteins unmodified or modified by short-chain aldehydes demonstrated 
that anion exchange chromatography was the best method for protein isoform separation 
while reverse phase chromatography was the best for the separation of lipoxidized proteins. 
To understand the cellular effects of lipoxidation by small aldehydes, two cellular 
proteins were studied. The Cys328-mediated effect of short-chain aldehydes on vimentin 
organization was evaluated by confocal microscopy, which showed that aldehydes caused 
vimentin aggregation around the nucleus, and Cys328 was important in both assembly of 
the filament network and as a target for lipoxidation. The effect of short-chain aldehydes on 
the glycolytic enzyme pyruvate kinase was also studied, and this protein was found to be 
highly susceptible to modification; under pathophysiological concentrations acrolein, 
malondialdehyde and 4-hydroxyhexenal were able to inhibit its activity in a time- and dose-
dependent manner. Similar inhibition was observed in breast cancer cells, altering cellular 
metabolism and suggesting that these aldehydes may contribute to mechanisms of 
tumorigenesis. Overall, this work has improved the analytical tools for detecting protein 
lipoxidation, as well as understanding of its functional effects. 
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1.1. Lipids and lipid peroxidation products 
1.1.1. Lipids 
Lipids are a group of biomolecules that embraces a diversity of molecules with different 
structural features and different functions. Lipids are described as amphipathic small 
molecules that may originate entirely or in part by carbanion based condensation of 
thioesters (in the biosynthesis of fatty acyls, glycerolipids, glycerophospholipids, 
sphingolipids, saccharolipids, and polyketides) or by carbocation-based condensations of 
isoprene units (for prenol and sterol lipids). These eight lipid categories are further 
subdivided on the basis of chemical structures (Figure 1.1) [1]. 
 
Figure 1.1. Lipid categories according to the LIPID MAPS lipid-classification system. 
Fatty acids are carboxylic acids with aliphatic chains between 4 and 28 carbons long, 
which can be either saturated or unsaturated. Saturated fatty acids have no double bonds 
and therefore are less susceptible to oxidative damage. Palmitic acid (16:0) is one of the 
most common saturated fatty acid in cells and in fatty foods. 
Unsaturated fatty acids have up to 5 double bonds and are susceptible to oxidation. 
Polyunsaturated fatty acids can be divided into two groups: ω3 and ω6 according to the 
position of their double bonds (the number of carbons from the CH3 end) [2]. The carboxylic 
acid (COOH) is considered the beginning of the chain while the methyl (CH3) is the end of 
the chain. The ω3 fatty acids have a double bond at the third carbon atom from the end of 
the carbon chain [3]. The ω3 essential fatty acids for humans are α-linolenic acid (ALA, 
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18:3), eicosapentaenoic acid (EPA, 20:5), and docosahexaenoic acid (DHA, 22:6) (Figure 
1.2) [4]. Humans get these fatty acids through the diet from fish and plant sources. Linolenic 
acid is the dietary precursor of longer ω3 polyunsaturated fatty acids (PUFA) as EPA and 
DHA [5]. Some studies relate the ingestion of ω3 fatty acids with beneficial effect to health 
including mediating inflammation [6]. The oxidation of EPA produces E-resolvins, and 
oxidation of DHA leads to several other beneficial lipid mediators such as D-resolvins, 
protectins and maresins. All of these lipid mediators are known for their pro-resolution role 
in inflammation [7]. 
ω6 Fatty acids have a double bond at the sixth carbon atom from the methyl end. These 
are known for their pro- and anti-inflammatory roles. During inflammation, ω6 fatty acids are 
converted to eicosanoids that bind to receptors and initiate reactions promoting cell repair 
[8]. As for ω3, some of the ω6 fatty acids are also classified as essential since humans 
cannot synthesize them. Linoleic acid (LA, 18:2) is an essential fatty acid and it is precursor 
for other ω6 fatty acids including the arachidonic acid (AA, 20:4) (Figure 1.2). This fatty 
acid is involved in a variety of inflammatory processes since it is the precursor of pro-
inflammatory molecules. Via the enzymatic action of COX1/2 and 5-lipoxygenase, AA it 
gives rise to prostaglandins and leukotrienes respectively [9]. 
 
 
Figure 1.2. Structure of three ω3 and two ω6 unsaturated fatty acids. Example of ω3 fatty acids 
are linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and of ω6 
fatty acids are linoleic acid (LA) and arachidonic acid (AA). 
 
Fatty acids can be found as free molecules but mostly they are found esterified to a 
glycerol appearing as, for example, phospholipids. Phospholipids (PL), are the major 
component of a cell membrane due to their characteristic amphipathicity [10] and are 
responsible for maintaining membrane stability and integrity [11]. This lipid category 
includes glycerophospholipids and sphingolipids. Glycerophospholipids, commonly referred 
to as phospholipids, come from phosphatidic acid and have an ester linkage at the sn-2 and 
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sn-1 positions to two fatty acids as well as a polar head linked to glycerol third carbon by a 
phosphodiester bond [12]. Depending on the polar head, phospholipids can be divided into 
six categories. These are phosphatidic acids (PA), phosphatidylcholines (PC), 
phosphatidylethanolamines (PE), phosphatidylserines (PS), phosphatidylglycerols (PG) 
and phosphatidylinositol (PI) (Figure 1.3). 
 
 
Figure 1.3. Structure of glycerophospholipids. R1 and R2 represent fatty acyl chains esterified to 
the glycerol. X correspond to the different polar heads. 
Sometimes, instead of an ester bond, the fatty acids are linked to glycerol by a vinyl 
ether bond; plasmalogens are the phospholipids characterized by the presence of an ester 
linkage at the sn-2 position but a vinyl ether linkage at the sn-1 position (Figure 1.4). These 
molecules are resistant to the action of phospholipases since they only recognize and 
cleave ester bonds. 
  
 
Figure 1.4. Structure of glycerophospholipids holding an ether bond instead of an ester bond. 
A-plasmalogens with a vinyl ether bond; B- ether lipid (Platelet-activating factor (PAF)). 
Several studies have reported the importance of a specific lipid environment for the 
correct functioning of membrane proteins [12]. Although some proteins depend on being 
surrounded by a specific lipid shell, some multimeric proteins specifically bind individual 
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lipids that are important for the structure of these protein complexes [13]. Recent studies 
suggest that lipids can also act as protein co-factors modulating their activity [14]. Under 
several pathophysiological conditions, an imbalance occurs between oxidative and anti-
oxidative species and lipids containing polyunsaturated chains are susceptible to oxidative 
damage caused by these species generated during oxidative stress. 
 
1.1.2. Overview on oxidants and oxidative stress 
Oxidative stress results from a redox imbalance and consequent increase in oxidative 
species such as partially reduced oxygen and nitrogen species (PROS and RNS). In normal 
conditions, these species have important roles in signaling, detoxification of xenobiotics and 
phagocytosis. However, in pathophysiological conditions an excess of these oxygen and 
nitrogen species can cause cellular damage and oxidative modifications of biomolecules 
such as lipids, proteins and DNA [15, 16]. Reactive oxygen species can be free radicals 
such as superoxide (O2•-) and the hydroxyl radical (•OH), which are the most unstable and 
reactive oxygen species and can cause significant damages. They can also be non-radical, 
such as hydrogen peroxide (H2O2), which is a selective oxidant that can form other, more 
reactive oxidant species [17]. One place where ROS can be generated is in mitochondria 
during oxidative phosphorylation. During this process, electrons can accumulate and be 
transferred to oxygen molecules resulting in the production of (O2-) [18]. This radical is polar 
and does not diffuse through cell membranes, so is generally less damaging than another 
ROS. However, it can generate H2O2 by spontaneous dismutation or enzymatically by 
superoxide dismutase (SOD). H2O2 is relatively non-polar and soluble so it does diffuse into 
the membrane and can cause damage outside the site of formation making it more toxic. 
Additionally, O2•- can generate the hydroxyl radical (•OH), peroxinitrite (ONOO-) and singlet 
oxygen (1O2) [19, 20]. In the presence of a transition metal, such as iron, H2O2 can give rise 
to the hydroxyl radical by the Fenton reaction, with oxidation of Fe2+ to Fe3+ [21]. •OH is the 
most reactive oxygen species of all those found in biological systems, since there are no 
enzymes capable of detoxifying this radical. There are two further mechanisms to generate 
•OH. These are the decomposition of water that generates •OH and •H and the reaction of 
O2- with H2O2 in the presence of transition metal such as iron (Fe2+) and copper (Cu2+), 
Haber-Weiss reaction. However, in vivo, it is mostly generated by the Fenton reaction [22]. 





Figure 1.5. Mechanisms of generation of reactive oxygen species. 
Free radicals can cause damage to important biomolecules, namely proteins, lipids, and 
DNA, changing their structure and thus being responsible for loss of function or even 
resulting in the formation of new deleterious species. Lipids are one of the major targets 
of oxidation in biological systems [23]. The development and progression of several 
diseases including age-related illnesses such as Alzheimer’s disease, Parkinson’s disease, 
multiple sclerosis, cardiovascular diseases, atherosclerosis, diabetes, liver and lung 
diseases have been associated with lipid peroxidation (LPO) [24-26]. Therefore, efforts 
have been made to understand the mechanism of lipid peroxidation and prevent its 
deleterious effects. 
 
1.1.3. Lipid peroxidation: mechanisms and products 
As previously mentioned, lipids are primary targets of the attack by PROS. Lipid 
peroxidation leads to the formation of a variety of oxidized products, produced by 
modification of polyunsaturated fatty acyl chains (PUFAs) [23]. While the enzymatic 
oxidation is regulated by receptors and intracellular signaling, the nonenzymatic oxidation 
results in new products with new bioactivities being formed, some of which may be 
deleterious to cells and tissues. In enzymatic lipid peroxidation, the oxidized products are 
generated by enzymes including lipoxygenases (LOX) and cyclooxygenases (COX), found 
in all mammalian species. In this case the lipid oxidation products often have a role in 
immunity and homeostasis. These biologically active oxidized phospholipids can initiate and 
modulate many cellular events [27]. For example, oxidized phospholipids (OxPL) can 
modulate the fate of an inflammatory response by intervening in the processes by removing 
apoptotic cells [28]. Nowadays, the importance of oxidized lipids as key players in the onset 
of cardiovascular diseases is well recognized and oxidized lipids, especially non-enzymatic 
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lipid peroxidation products, are considered as possible biomarkers for cardiovascular 
disease [29].  
On the other hand, non-enzymatic lipid peroxidation is a chain reaction by which lipids 
are modified by free radicals such as O2•- (superoxide radical), OH• (hydroxyl radical), 
HO2• (perhydroxyl radical) and RO• (alkoxy radicals) at carbon-carbon double bonds. Lipids 
can also be modified by non-radical forms of oxygen such as H2O2 (hydrogen peroxide) 
and 1O2 (singlet oxygen) as well as by hypochlorous acid (HOCl), product of the neutrophil 
enzyme myeloperoxidase. Figure 1.6 gives an example of the attack of OH• on a 
phosphatidylcholine, one of the main constituents of cell membranes. This process can be 
divided into two phases: first an hydrogen in abstracted from a carbon by the oxygen-based 
radical and then an oxygen is inserted in the lipidic chain resulting in a lipid peroxyl radical 
or hydroperoxide [20]. 
 
 
Figure 1.6. Lipid peroxidation mechanism. Hydrogen-atom abstraction by alkoxyl radical; oxygen 
addition to carbon radical; peroxyl radical rearrangement. 
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Lipid peroxidation starts with the attack of a free radical to generate a C-centred radical 
(L) (1), which then reacts with molecular oxygen to generate a lipidic peroxyl radical (LOO•) 
(2), which rearranges as shown above and the peroxyl radical is capable of propagating the 
chain reaction (3) [30]. It is also able to react internally to generate cyclic endo peroxidases 
as well as allowing other cleavage reaction that generate lipid peroxidation breakdown 
products which can also promote further oxidation [31]. To break the chain reaction, a 
reaction needs to occur between two radicals, or an antioxidant molecule intervenes [32]. 
 
1.1.4. Fatty acid free-radical oxidation products 
During lipid oxidation, new oxidised products are generated with different numbers of 
oxygen molecules bound to the acyl chain, therefore increasing the lipid molecular weight. 
These products are the so-called long chain oxidation products. However, the alkoxyl 
radicals can undergo β-cleavage generating short-chain oxidation products that can be 
either aldehydes or carboxylic acids (Figure 1.7) [33]. 
 
Figure 1.7. Schematic explanation of long and short chain lipid peroxidation products. 
Polyunsaturated fatty acids, either free or esterified, are particularly prone to undergo 
peroxidation, with linoleic and arachidonic acids as common examples of fatty acids that 
are oxidizable. The oxidation of these results in a great diversity of products that are 
structurally different from the non-modified lipid presenting a new shape, polarity and 
consequently biological activity. The oxidation of linoleic acid results in the formation of 9-, 
11- and 13-hydroperoxides due to the locations of the carbon radical (Figure 1.8). The 11-
HPODE is only formed in the presence of good H-donor such as alpha-tocopherol since the 
loss of oxygen at C11 is much faster than any other position [34]. Therefore, 9-HPODE and 
13-HPODE are the most common hydroperoxides resulting from linoleic acid peroxidation 
[35]. The main carbon chain of the fatty acid is preserved during the formation of the 
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hydroperoxides, the primary products, however prolonged peroxidation causes 
rearrangement or degradation and secondary oxidation products can be formed. 
 
Figure 1.8. Formation of hydroperoxides from linoleic acid. Following hydrogen abstraction, 
oxygen adds to all three reactive carbon positions (C9, C11 and C13). Other oxidative species can 
result from the rearrangement, further oxidation or breakdown of these hydroperoxides, including 
HNE. Adapted from [23]. 
Linoleic acid is the most abundant fatty acid in LDL and atherosclerotic plaques [36]. 
Oxidized linoleic acid products have been found in LDL and plasma of atherosclerotic 
patients [36] and the degree of oxidation was dependent on its severity [37]. These species 
are signaling molecules which recruit monocytes/neutrophils to atherosclerosis lesions [38].  
For example, 9-hydroxyoctadecadienoic acid (9-HODE) is pro-inflammatory and it has been 
reported in atherosclerosis [38], cardiac diseases such as infarction and coronary heart 
disease (CHD) [39], and it is known to induce PPARϒ-regulated apoptosis in monocytes, 
which LA itself cannot replicate the same effect [40]. Understanding the mechanisms behind 
the HODEs signaling may contribute to novel therapeutic approaches to these diseases. 
The arachidonic acid is another commonly oxidized ω-6 fatty acid. As mentioned above, 
AA is responsible for inflammatory processes by being the precursor of prostaglandins and 
leukotrienes. While these are products of enzymatic lipid oxidation, free radical 





Figure 1.9. Major pathways of free radical oxidation of arachidonic acid. The primary oxidation 
products are hydroperoxides. Only 11-HpETE shown here as example for simplicity, however there 
are six hydroperoxyl radicals generated from free radical oxidation of arachidonic acid. Secondary 
oxidation products are generated by further oxidation, decomposition or reduction of the 
hydroperoxides. Adapted from [23]. 
In comparison with LA, AA is more susceptible to oxidation due to a higher number of 
bisallylic positions and six major hydroperoxyeicosatetraenoates (HPETEs) can be formed, 
as well as their reduced analogues, the hydroxyeicosatetraenoates (HETEs). In Figure 1.9, 
only one of the six hydroperoxides is shown (11-HPETE) and its multiple reaction pathways 
which occur by cyclization [41, 42]. Arachidonic acid is substrate for prostaglandin 
generation by cyclooxygenase and lipoxygenase enzymes. Isoprostanes are prostaglandin-
like compounds generated from non-enzymatic free radical oxidation of arachidonic acid, 
and can be used as reliable markers for lipid peroxidation and oxidative stress in biological 
systems [43-45] due to their stability, specificity to lipid peroxidation and detection in free 
form or esterified in all biological fluids [46]. High levels of isoprostanes have been detected 
in urine from smokers [47], obese [48], diabetic [49], hypercholesterolemic [50] and 
Alzheimer’s disease patients [51]. 
Linoleic and arachidonic acid are both ω-6 fatty acids , however oxidation of ω-3 fatty 
acids, such as EPA and DHA, is also biologically important since these fatty acids have 
been associated with protective roles against inflammation. In fact, studies have shown that 
consumption of these lower the risk of cardiovascular diseases [52-54]. Nevertheless, 
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oxidation of ω-3 fatty acids generates a wide range of products and some of these have 
recently been reported as reactive against other biomolecules, therefore questioning the 
beneficial properties of ω-3 PUFAs [55, 56]. For example, DHA is an important source of 
PUFAs in tissues and has six double bonds making it highly susceptible to oxidation [57, 
58]. The wide range of oxidation products of these fatty acids include 4-hydroxy-hexenal 
(HHE) and 4-hydroxy-7-oxo-5-heptenoic acid (HOHA), both shown to be deleterious to 
proteins by generation of the adducts ethylpyrrole (EP) and 2-carboxyethylpyrrole (CEP), 
respectively [59] (Figure 1.10). The chemistry and analysis of the aldehydes formed by the 
oxidation of either ω-3 or ω-6 fatty acids are discussed in the next section of this introduction. 
 
Figure 1.10. Schematic representation of the formation of HHE and HOHA from DHA. 
Hydrolysis of DHA generates HOHA which in turn produces CEP-protein adduct. Oxidative cleavage 
of DHA also forms HHE which generates a similar protein modification, EP-protein adduct. Adapted 
from [59]. 
 
1.2. Aldehydes as short chain lipid peroxidation products 
Aldehydes are an example of PUFAs short-chain oxidation products [20, 23, 60]. As 
mentioned in the previous section, these can be generated by the decomposition of PUFAs 
through enzymatic or non-enzymatic mechanisms. Linoleic and arachidonic acids, both ω-
6-polyunsaturated fatty acyl chains, are good sources of aldehydes by cleavage of a C-C 
bond. The mechanisms by which a carbon-carbon bond can be cleaved are broadly 
classified into (i) reduction of hydroperoxide to an alkoxyl radical in the presence of a 
transition metal followed by β-scission; (ii) Hock rearrangement of a hydroperoxide and 
migration of a C-C to a C-O bond and cleavage; (iii) cyclization to form a dioxetane and 
subsequent cleavage (Figure 1.11). Similarly, ω-3-polyunsaturated fatty acyl chains, for 
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example docosahexaenoic acid, can also undergo fragmentation and give rise to many 
reactive aldehydes. The insertion of additional oxygen molecules can give rise to some 
variants of these mechanisms. If three O2 are added to the chain to form a 
hydroxyhydroperoxide, it can undergo β-scission or an  epoxyhydroperoxide can undergo 
Hock cleavage [23, 61-63]. 
 
 
Figure 1.11. Mechanisms of carbon-carbon bond cleavage. (i) reduction of hydroperoxide to an 
alkoxyl radical in the presence of a transition metal followed by β-scission; (ii) Hock rearrangement 
of a hydroperoxide and migration of a C-C to a C-O bond and cleavage; (iii) cyclization to form a 
dioxetane and subsequent cleavage. Adapted from [63]. 
These aldehydes have a carbonyl group or an α, β-unsaturated carbonyl, and may have 
other substitutions such as chlorination or hydroxylation, depending on the nature of the 
oxidant. Aldehydes can be classified on the basis of their chemical structure into alkanals, 
alkenals and γ-substituted-alkenals. This system of classification also focuses on their 
different reactivity towards biomolecules. 
 
1.2.1. Alkanals 
Alkanals are saturated carbon chains containing an aldehyde group. These are the 
simplest and least polar aldehydes. Several alkanals, varying in chain length from three to 
nine carbons, have been identified as lipid peroxidation products from linoleic and 
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arachidonic acid, both ω-6 fatty acids. Identification of these was performed by comparison 
of their retention time to aldehyde standards on a high-performance liquid chromatography. 
Butyraldehyde (butanal), hexenal and nonanal have been reported as the major alkanal 
generated by lipid peroxidation [64] (Figure 1.12).  
 
Figure 1.12. Structure of the three most common alkanals to occur as lipid peroxidation 
products. 
Hexanal was shown to be the most abundant aldehyde of all of the identified, even 
compared with 4-hydroxy-2-nonenal (HNE), a well-known aldehyde discussed later in this 
introduction in the substituted aldehydes section [64]. Still, there is a lack of studies on the 
biological reactions and effects of these aldehydes, which may be due to their lower 
reactivity and toxicity compared with other aldehydes. Their functional group, a single 
carbonyl group, only allows them to react with amine groups by Schiff base formation, for 
example with amino acids such as lysine. Even though alkanals have low reactivity, some 
studies have reported their role in disease. Hexanal, heptanal and nonanal were found in 
bronchoalveolar lavage fluid of animals after exposure to ozone [65]. The ozonation process 
in human samples was also studied and shown to produce aldehydes as lipid ozonation 
products in human lungs. Mostly hexanal and nonanal were identified, but the increase in 
these aldehydes was unrelated to airway inflammation [66]. Additionally, a study on 
oesophageal and gastric adenocarcinoma identified an increase in aldehydes such as 
butanal, pentanal, hexanal, heptanal, octanal and nonanal in cancer patients exhaled breath 
by selected ion flow tube mass spectrometry (SIFT-MS) [67]. POVPC, a 
phosphatidylcholine with a five carbon chain alkanal esterified at the sn-2 position, has been 
detected in atherosclerotic plaque by LC-MS/MS and can form adducts with ApoB100 on 
LDL [68, 69]. 
 
1.2.2. Alkenals 
Alkenals are aldehydes with a double bond in the carbon chain. Due to the structure of 
the PUFAs from which these are derived, alkenals from lipid peroxidation are often α,β-
unsaturated (double bond between carbons 2 and 3). Previous studies have listed some of 
these as products of ω-6 fatty acids peroxidation [24, 64]. Many unsaturated aldehydes with 
chain length from 3 to 9 carbon have been identified, with propenal (acrolein), 2-heptenal, 





Figure 1.13. Structure of the most common alkenals to occur as lipid peroxidation products. 
The shortest alkenal identified as an oxidation product is propenal, also known by the 
common name acrolein. With only three carbons, it is by far the strongest electrophile and 
therefore the most reactive, especially with thiol groups on proteins [70, 71]. Acrolein can 
be formed by combustion of organic matter, in tobacco smoke and from food processing 
[72, 73]. It can also be produced endogenously by the oxidation of non-lipids such as 
methionine, threonine, spermine, spermidine and glycerol [71]. In addition, there is evidence 
of lipid peroxidation of fatty acids as a source of acrolein in vivo [60, 71, 74], however the 
mechanisms still remain unclear. Previous reports proposed a mechanism for the formation 
of acrolein from the centre of the arachidonic aliphatic chain after it undergoes two β-
cleavages [60], even though this has been debated recently [60]. Supporting the hypothesis 
of acrolein being a lipid peroxidation product is a study where acrolein was detected by 
ELISA from arachidonic acid autoxidation samples [74]. Acrolein is known to be involved in 
pathophysiological processes. For example, acrolein is capable of modifying the p50 
subunit of NF-κB disrupting the regulation of gene expression. NF-κB is responsible for the 
expression of genes which regulate the antioxidant defence, apoptosis, and inflammatory 
and immunological responses, therefore its modification by acrolein may cause 
immunosuppression [75]. Some other signalling pathways have also been shown to be 
modified by acrolein, including nuclear erythroid-2 related factor 2 (Nrf2), ARE-dependent 
genes and PTP1B, which lead to increased oxidative stress and cellular damage. Exposure 
to acrolein can also cause membrane damage, increased membrane permeability and lead 
to functional defects or cell death [76, 77]. Acrolein accumulation creates an additional 
oxidative stress, increasing membrane permeability with time and eventually results in cell 
lysis [78]. It also impairs the mitochondrial respiratory function, increasing oxidative stress 
and stimulating PROS production and decreasing concentration of antioxidants such as 
GSH [79-82]. Tobacco smoke is a source of acrolein, which constitutes 50 to 60% of the 
total vapor phase electrophiles with a concentration in smoke ranged from 3 to 220 
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μg/cigarette [83]. Therefore, the mouth and respiratory tract are commonly exposed to 
acrolein and the estimated concentrations of it in the airway can be as high as 80 μM [84], 
which is increased in smokers in comparison with healthy subjects. Inhaled acrolein has 
been linked to lung injury [85] and cardiovascular diseases [86, 87]. A recent study reported 
that acrolein can harm the vocal fold epithelial barrier integrity and may lead to inflammation 
by the invasion of xenobiotics [88]. The popularity of e-cigarettes continues to grow as these 
have been sold as a safer alternative to tobacco. However, recent studies have detected 
the presence of acrolein in aerosols from e-cigarettes [89, 90]. The formation of aldehydes 
from vaping has been associated with the decomposition of propylene glycol and glycerol 
present in the e-liquid. Nevertheless, their quantity may also vary according to the power 
output or the composition of flavouring compounds [91]. Besides, these were reported to be 
4 to 6-fold lower than for tobacco [92] but long-term follow up studies are needed to confirm 
the effect of e-cigarettes in health. 
Crotonaldehyde (2-butenal) is a simple α,β-unsaturated aldehyde similar to acrolein. 
Although is it is much less toxic, it can still modify proteins and DNA in vivo [93]. 
Crotonaldehyde reacts with deoxy guanosine to form adducts with DNA which were showed 
to be involved in tumour formation. This modification was shown to generate unique 
epitopes that may trigger autoantibodies in cancer patients [94]. 2-Butenal, and the five 
carbon analogue 2-pentenal, come from the oxidative breakdown of ω-3 unsaturated fatty 
acids. In contrast, 2-heptenal, 2-octenal and 2-nonenal come from the breakdown oxidation 
of ω-6 unsaturated fatty acids. These longer alkenals are less reactive towards proteins 
than acrolein or crotonaldehyde perhaps due to their insolubility in water, which would 
favour the nucleophilic attack. However, immunoreactivity assays and liquid 
chromatography coupled to mass spectrometry (LC-MS) were used to detect protein 
modification by 2-nonenal, found preferentially on lysine residues [95]. 2-nonenal has a 
characteristically unpleasant greasy and grassy odour and is a major contributor to the 
unpleasant cardboard flavour in aged beer. Analysis of body odour components also 
showed 2-nonenal to be present in increasing amounts in the body odours of older people 
[96]. 2-nonenal is generally less reactive than other 2-alkenals and therefore has received 
less attention. Nevertheless, there is evidence of inhibition of enzymes such as platelet 
membrane-bound phosphotyrosine phosphatase [97] and liver microsomal glucose-6- 
phosphatase [98] by this aldehyde.  
 
1.2.3. Substituted aldehydes 
Lipid peroxidation can also form more complex aldehydes from the breakdown oxidation 
of unsaturated fatty acids. These species not only contain a carbonyl group (CHO) and an 
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α,β-unsaturation (C=C) but also contain an additional functional group at the C4 position, 
including  hydroperoxyl (-OOH), epoxy, hydroxyl (4-hydroxyakenals) or keto (4-oxo-
alkenals). Due to their highly reactivity and toxicity to biomolecules, α,β-substituted-alkenals 
have received the most attention in terms of their biological effects. The C3 position is 
especially susceptible to nucleophilic attack, allowing the formation of adducts with thiols 
and amines. Their bi-reactive nature is particularly important because it enables these 
compounds to crosslink proteins, which may contribute to the pathophysiology of diseases 
related to lipid peroxidation, such as Alzheimer’s disease [99, 100]. The 4-hydroxy-alkenals 
are a well-known type of lipid oxidation products and include 4-hydroxy-2-hexenal (HHE), 
4-hydroxy-2-nonenal (HNE) and 4-hydroxydodeca-2,6-dienal (HDDE) (Figure 1.14).  
 
Figure 1.14. Structure of the most common hydroxyalkenals to occur as lipid peroxidation 
products. 
HHE is a product of ω-3 PUFAs oxidation while HNE is a product of ω-6 PUFAs 
oxidation, via 15-hydroxyeicoatetraenoic acid (15-HpETE) or 13-hydroperoxylinoleic acid 
[101]. HDDE is a product of 12-HpETE, which if generated enzymatically by 12-
lipoxygenase [101]. HNE can also be an enzymatic product of ω-6 PUFAs by the action of 
15-lipoxygenase (15-LOX) on arachidonate [102]. Several reviews have detailed the non-
enzymatic processes of HNE generation by oxygen radical-dependent reactions [23, 62, 
63]. HNE was discovered in the 1960s [70] and nowadays is considered a useful biomarker 
of lipid peroxidation [100]. HNE is highly reactive, which translates into a higher number of 
studies regarding its biological effects. HNE is known to be involved in the pathophysiology 
of Alzheimer’s disease, cancer, cardiovascular diseases, diabetes, liver disease and 
Parkinson’s disease. It has been suggested as a signalling molecule. MAPK, JNK, p58, 
PKC β and δ, and Nrf2 are some of the signalling pathways found to be modulated by HNE 
[103], and a detailed review of the signalling pathways modulated by HNE has also been 
published previously [104]. Figure 1.15 summarises the key signalling pathways that can 
be modulated by HNE. These signalling processes probably involve HNE reaction with 
signalling proteins, altering their activity usually by its inhibition [103]. The severity of the 
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effect of HNE on these mechanisms is dependent on HNE concentrations, with higher levels 
of HNE leading to more deleterious outcomes, including cell death [105].  
 
Figure 1.15. Schematic summary of signaling proteins known to be modified by HNE. 
It has been demonstrated that Nrf2 binds to UPC3 (mitochondrial uncoupling protein 3) 
promoter in response to HNE, resulting in an important mechanism of protection of the heart 
under oxidative stress conditions. The Nrf2 pathway was shown to increase uncoupling 
proteins (UCP3) expression promoting cell survival [106]. However, HNE can also modulate 
mechanisms that lead to harmful consequences. For example, the modification of Src by 
HNE has been shown to be related to important cellular dysfunction. Src is the first proto-
oncogene involved in cellular proliferation and differentiation that is ubiquitously expressed 
non-receptor protein tyrosine kinase. It was reported that HNE can activate Src through 
three different mechanisms: i) EGFR is activated by HNE inducing activation of Src; ii) 
PTP1B is inhibited by HNE, increasing EGFR-induced Src activation; and iii) HNE directly 
activates Scr by modification of a cysteine residue [107]. The modification of Src by HNE 
leads to a constitutive activation of Src promoting survival, angiogenesis and proliferation 
which under cancer conditions helps a tumour to grow, demonstrating the connection 
between increased levels of HNE and cancer progression. Another protein involved in 
tumorigenesis that was shown to be regulated by HNE is the peroxisome proliferator-
activated receptor (PPAR). There is evidence that under high glucose, Nox activity is 
increased leading to an increase in ROS formation. This generates oxidative stress that 
induces lipid peroxidation and consequently HNE production. In turn, HNE activates PPARα 
and PPARβ/δ augmenting Nox expression and activity [108]. Hyperglycaemia can also 
activate PPAR through a different mechanism. It is known that high glucose accelerates 
atherosclerosis. This disease is characterised by monocytes being transformed into 
macrophages which them progress to become lipid-laden foam cells [109]. The foam cells 
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release HNE that activates PPARδ in endothelial cells leading to an increase in thioredoxin 
interacting protein (TXNIP) expression and consequent cellular senescence [110]. Some 
studies have reported specific amino acids that appear to be modified by HNE leading to 
dysfunction. His71 and Cys177 were identified as major sites for HNE modification in CDK2 
on colorectal cancer cells. These specific modifications inhibit the kinase activity, 
contributing to cell cycle arrest [111]. TRA DNA-binding protein (TDP-43) can also be 
modified by HNE, and it was reported to be directly modified on cys173, cys175 and cys198. 
This results in its solubilisation and mislocalization from nucleus to cytoplasm, consistent 
with what had been previously observed in sporadic amyotrophic lateral sclerosis (ALS) 
[112]. These findings show the importance of knowing the specific amino acid residues 
modified on each protein and relating those modifications to a specific function of the protein 
that could be used for the diagnostics or prognostics of diseases.  
The ω-3 essential fatty acids produce a different range of lipid oxidation products. The 
HHE is formed by decomposition of oxidized docosahexaenoic acid (DHA) [113, 114]. Only 
few studies have been reported on HHE, still there is evidence of it causing severe 
peritonitis, retinal or liver damage when injected [115] and causing apoptosis via modulation 
of NFkB signalling pathways [114]. However, lower levels of HHE have been shown to have 
protective effects against oxidative stress-induced cytotoxicity in vascular endothelial cells 
by stimulating the expression of antioxidants through the activation of Nrf2 [116, 117]. 
HDDE has also been found in human plasma although at lower concentrations that HHE or 
HNE, suggesting this aldehyde in produced in vivo [115, 118]. Previous studies on reactivity 
of 4-hydroxyalkenals comparing the reactivity of HHE, HNE and HDDE with 
phosphatidylethanolamine showed that HDDE was the most reactive [101], possibly due to 
a longer aliphatic chain which increased hydrophobicity, and suggests higher reactivity 
towards polar molecules such as phospholipids [101]. 
The same oxidation and cleavage mechanisms that generate 4-hydroxy-alkenals can 
also generate 4-oxo-alkenals such as 4-oxo-2-nonenal (ONE) and 4-oxo-2-hexenal (OHE) 
[119-122] (Figure 1.16). 
 
Figure 1.16. Structure of the most common oxoalkenals to occur as lipid peroxidation 
products. 
Studies on ONE concluded that it is an even more reactive protein modification and 
cross-linking agent than HNE [123], depending on the mechanism of adduct formation. 
While the rate of Michael addition with cysteine and histidine residues is higher, the rate of 
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Schiff base formation is slower [123]. There is increasing biological interest in studying ONE 
as an oxidative stress marker, since it was demonstrated to covalently link to human serum 
albumin, the main protein found in human blood [124], and histones [125]. Attention on OHE 
has also increased as its mutagenic properties were demonstrated by the ability to form 
adducts with nucleosides [120, 126]. 
The hydroxy-alkenals and oxo-alkenals discussed above can be further oxidized to the 
more stable carboxylic acid form by the action of aldehyde dehydrogenases, generating 
species such as 4-hydroxyhexenoic acid (HHA), 4-hydroxynonenoic acid (HNA) and 4-
hydroxydodecadienoic acid (HDDA). These products of the three aldehydes can be 
measured in human urine samples [118, 127]. Since HNE comes from ω-6 fatty acids, HHE 
from ω-3 fatty acids and HDDE is a lipoxygenase product, differential increases in their 
corresponding carboxylic acids in urine may be a marker of the type of mechanism of lipid 
peroxidation involved in a specific pathophysiological condition [127]. 
Bis-aldehydes are another significantly important short-chain oxidation product and, like 
4-hydroxy-alkenals, are bifunctional and can also be a source of cross-linking between 
proteins, lipids and DNA [128]. The best known is malondialdehyde (MDA), commonly used 
marker of oxidative stress in clinical samples due to its reactivity and toxicity [129, 130], 
although it has been much criticized in this respect (Figure 1.17).  
 
 
Figure 1.17. Structure of two bis-aldehydes known to occur as products of lipid peroxidation.  
MDA is generated by the decomposition of oxidised arachidonic acid through enzymatic 
or non-enzymatic mechanisms. Enzymatically, MDA can be generated as a side product of 
the synthesis of thromboxane A2, by a well stablished mechanism [131]. The nonenzymatic 
generation of MDA is less well studied. During cyclization of peroxyl radicals, a new free 
radical is formed which can cyclize again to form bicyclic endoperoxides and undergo 
cleavage to produce MDA [132]. The reactivity of MDA has been well-characterized 
previously [133]. MDA can be metabolized once formed, but it can also react with other 
biomolecules [129]. At physiological pH, MDA occurs in the enolate form with low reactivity, 
but when the pH drops, MDA reactivity increases. The main product of MDA reaction with 
DNA is pyrimido-[1,2-α]-purin-10(3H)-one deoxyribose (M1D), which has been shown to 
induce mutations on mammalian cells [129]. Due to the bis-aldehyde property, MDA can 
react further, creating an interstrand crosslink in DNA leading to potent biological effects 
[134]. There is also evidence of MDA being responsible for DNA-histones crosslinking but 
the biological importance of this is still to be shown [128]. Proteins can also be modified by 
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MDA, especially on nucleophilic amino acid residues, such as lysine, histidine and arginine. 
There is evidence that MDA-modified lysines in apoB from oxidised low density lipoproteins 
(oxLDL) are involved in atherosclerosis inflammatory processes [135, 136]. Apart from 
direct modification of proteins, MDA can also interfere with protein synthesis by modification 
of eElongation factor 2 (eEF2), which catalyses the movement of the ribosome along the 
mRNA in protein synthesis. Hence, MDA is more than just a product of lipid peroxidation; it 
has its own toxicity towards biomolecules and needs to be considered as an important 
molecule to study when looking for pathophysiological explanations of diseases. Glyoxal is 
another bis-aldehyde, analogous to MDA but with a two carbon chain (Figure 1.17). There 
is limited evidence of this aldehyde being a lipid peroxidation product, and the more 
common source of glyoxal is the oxidation of glucose, especially in diabetes mellitus  [60, 
137]. Other less well known bis-aldehyde lipid peroxidation products are 2,4-decadienal, a 
product of oxidized fatty acids and trans-2-butene-1,4-dial, a product of further oxidation of 
the former [119]. However, it is still not clear if these aldehydes are actually lipid peroxidation 
breakdown products in vivo. 
 
1.2.4. Chloroaldehydes 
Oxidizing compounds resulting from oxidative stress are most commonly derived from 
partially reduced oxygen species, as discussed previously in this report. These can react 
with other small molecules or ions such as halides generating, for example, reactive chloride 
species (RClS) by reaction with the biologically abundant chloride ion. The production of 
hypochlorous acid (HOCl) is catalysed by the enzyme myeloperoxidase (MPO) [138]. MPO 
is present in human neutrophils, monocytes and some macrophages [139-141]. In 
inflammation, MPO is activated and produces mainly HOCl, a strong oxidizing and 
chlorinating agent, from the oxidation of Cl- using H2O2 as a co-substract [138]. HOCl reacts 
with unsaturated lipids at the double bond by an electrophilic addition of chloronium ion (Cl+) 
to form chlorohydrins or α-chloro-β-hydroxy derivatives [142]. Additionally, phospholipids 
with an amino group in the polar head can also be chlorinated. Plasmenyl phospholipids, 
containing a vinyl ether bond, are the most susceptible to attack by HOCl [143], and this 





Figure 1.18. Plasmalogens are targets of HOCl at the alkene chain, at the amine polar head 
(highlighted in blue) and at the vinyl ether bond (highlighted in red). The latter is the responsible 
for the production of α-chloro-aldehydes. 
Although only a small amount of plasmalogens have been shown to be modified by 
chlorination, which is not enough to disrupt the membrane, alteration in plasmalogen 
content in specific membranes may have an effect on membrane protein function, making 
this modification worth studying [138]. As discussed before, plasmalogens are 
phospholipids with a vinyl ether-linked aliphatic chain at the sn-1 position. Hypochlorous 
acid attack leads to cleavage of the vinyl ether to yield an α-chlorofatty aldehyde and a 
lysolipid [143]. The free α-chloroaldehyde derived from the reaction of the vinyl ether with 
hypochlorous acid is the major halogenated lipid, and a precursor of other halogenated 
lipids [144]. An excess of HOCl can lead to a secondary oxidative modification of the 
lysolipid, leading to the complete degradation of the plasmalogen into a chlorohydrin 
derivative [145] or glycerophosphorylcholine with the release of the fatty acid at the sn-2 
position [146].  
Several studies have investigated the biological targets of α-chloroaldehydes. α-
chlorohexadecanal and α-chlorooctadecanal have both been detected as plasmalogen 
oxidation products in activated neutrophils [138] and have been found to be elevated 
significantly in atherosclerotic lesions in cardiovascular disease [147], and in mouse brain 
following systemic injection of endotoxin [148]. It was previously shown that 2-
chlorohexadecanal bound to LDL is able to reduce nitric oxide production through inhibition 
of endothelial nitric oxide synthase (eNOS) activity, decreasing eNOS mRNA stability [149].  
2-chlorohexadecanal is metabolized by oxidation to 2-chlorohexadecanoic acid or by 
reduction to 2-chlorohexadecanol [150]. These are also known to play biological roles, such 
as increase COX2 expression and prostacyclin production through increased NFkB 
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signaling in human coronary artery endothelial cells [151]. This study shown that α-
chloroaldehydes can be involved in pro-inflammatory pathways, therefore making it 
important to understand the mechanisms underlying such roles. α-chloroaldehydes have 
also been shown to be involved in cell death pathways as the apoptosis of microvascular 
endothelial cells is related to α-chloroaldehydes stimulating PROS production, caspase 3 
activation, ATP depletion and decreasing cell-cell barrier function [152]. A potential 
mechanism by which α-chloroaldehydes could cause these changes in cells is the adduction 
with amines in proteins and lipids. However, their reactivity is still not very well established 
compared to other lipid oxidation products. The reaction of α-chloroaldehydes with proteins 
is discussed in the next section 1.3. 
 
1.3. Post-translational protein modification by aldehydes 
Protein lipoxidation is described as the modification of proteins by lipid peroxidation 
products modifying the side chain of amino acids [153]. In fact, introduction of carbonyl 
groups into amino acids residues is a hallmark of oxidative damage to proteins. To note that 
direct oxidation proteins can also generate carbonyl groups, as this modification is not 
exclusive of lipoxidation. Lipoxidation occurs mainly on the nucleophilic residue cysteine, 
histidine, arginine and lysine [154]. This leads to the formation of a wide variety of adducts. 
Compounds containing aldehydes or ketones can react with amines (e.g. on lysine) to form 
Schiff base adducts by loss of water, whereas those containing an α, β-unsaturated moiety 
can also form Michael adducts by a nucleophilic addition reaction of the protein sidechain 
at the β-carbon. Bi-functional lipid oxidation products, such as dialdehydes or 
hydroxyalkenals, can react with proteins and still present free carbonyls, which can be 
exploited in some detection procedures or further react and give rise to intra or inter protein 
crosslinking.  
 
1.3.1. Mechanism of adduction 
Schiff bases, named after Hugo Schiff, are formed when a primary amine reacts with an 
aldehyde or a ketone [155]. A Schiff base is an analogue of an aldehyde where the carbonyl 
group (C=O) is exchanged by an imine (C=N). It can be synthesized from an amine and a 
carbonyl compound by nucleophilic addition forming a hemiaminals followed by dehydration 
to generate an imine (Figure 1.19A). In proteins, lysine residue side chain contains a NH2 
that reversibly reacts with aldehydes giving rise to aldehyde-protein adducts. Alkanals only 
react with proteins by forming a Schiff base, since their only reactive group is the carbonyl. 
Originally defined by Arthur Michael, Michael addition is a nucleophilic addition of a 
nucleophile to an α,β-unsaturated carbonyl [156]. The mechanism of this reaction is 
48 
 
displayed in Figure 1.19B. The nucleophile reacts with the electrophilic alkene in a 
conjugate addition reaction. Eventually, a proton is abstracted from the protonated base by 
the enolate to form the final adduct. In proteins, the thiol group of cysteines and the amine 
group of lysines can react reversibly with aldehydes, giving rise to aldehyde-protein 
adducts. Alkenal and α,β-unsaturated aldehydes having a C-C double bond react with 
proteins by Michael addition. 
 
Figure 1.19. Mechanism of adduction of short-chain aldehydes to proteins. (A) Schiff’s base 
formation mechanism. The example includes butanal as the electrophile and the amino acid lysine 
as the nucleophile. This reaction is a condensation and therefore loses water. (B) Michael addition 
mechanism. The example is acrolein as the electrophile and cysteine as the nucleophile. 
 
1.3.2. Aldehyde-protein adduction: Structure and Evidence 
As adducts can rearrange, to provide evidence for their formation requires good 
understanding of the multiple structures that these can form. The reaction of amino acids 




Figure 1.20. Products formed by reaction of acrolein with amino acid side chains. Where 
reactions occurred by Michael addition, only lysine adducts are shown but as indicated in the 
figure, these can also happen on a cystine, histidine or arginine residue. 
Acrolein has been shown to react with cysteine, lysine and histidine residues of proteins. 
It was previously shown that the primary product of acrolein reaction with proteins is a β-
substituted propanal by Michael addition. However, more than one molecule of acrolein can 
react with the same amino acid residue. For example, two acrolein molecules can attach to 
one lysine side chain, forming the piperidine, N-(3-formyl-3,4-dehydropiperidino)-lysine 
(FDP-lysine) [74]. Crotonaldehyde, 2-pentenal and 2-hexenal can generate a similar 
product, suggesting that this type of adduct is common between alkenals reacting with 
proteins. Another type of condensation adducts that can be generated after lysine adducts 
with 2-alkenals are the pyridinium adducts, N-(2-methylpyridinium)lysine (MP-lysine) for 
acrolein and N-(5-ethyl-2-methylpyridinium)lysine (EMP-lysine) for crotonaldehyde [157, 
158]. In the case of 2-nonenal, an analogous lysine-pyridinium adduct N-3-[(hept-1-enyl)-4-
hexylpyridinium]lysine (HHP-lysine) is formed [95]. Similar adducts have been reported for 
2-hexenal and 2-octenal [159, 160]. Protein amino acid residues can also react with more 
complex aldehydes such as 4-hydroxy-2-alkenals. The most studied of this aldehyde group 




Figure 1.21. Products formed by reaction of 4-hydroxy-nonenal with amino acid side chains. 
It is known that HNE as well as other 4-hydroxy-2-alkenals react with thiol groups on 
cysteines by Michael addition (a) [70, 161]. Moreover, HNE can also form Michael adducts 
with the imidazole group of histidine residues. In the first stage, the imidazole reacts with 
the unsaturation on 4-hydroxy-2-alkenals leaving the adduct with a free carbonyl group. 
This can afterwards undergo cyclization to form a cyclic hemiacetal [162] or crosslinking 
with other proteins or even inside the same protein [163]. For cyclization to occur, the 
hydroxyl at the aldehyde fourth carbon reacts with the carbonyl group to form the 
hemiacetal. Another amino acid residue that can be modified by HNE is lysine. Similar to 
the modification on histidine, HNE forms Michael adducts with lysine and generates a 
pyrrole adduct (b) [164]. The amino group of lysine reacts with the C3 of HNE by Michael 
addition. The free carbonyl group on the first carbon of HNE can further react with the same 
lysine reside forming a 1:2 HNE:amine. This can undergo oxidation and intermolecular 
cyclization to form the adduct 3-hydroxy-3-imino-1,2-dihydropyrrole-lysine (c).  
Another common aldehyde addition product occurs from adducts from saturated 





Figure 1.22. Products formed by reaction of glyoxal or malondialdehyde with amino acid side 
chains. 
Glyoxal is responsible for the formation of carboxymethyllysine (CML) as well as lysine-
lysine crosslinked dimers, resulting in intra or intermolecular crosslinking [165, 166]. A less 
common amino acid residue to form adducts is arginine. However, it was reported glyoxal 
reacts with arginine residues to form an imidazole [167]. Malondialdehyde (MDA) is known 
for specifically modifying lysine residues on proteins resulting in the Schiff base adduct N-
(2-propenal)lysine [168]. As explained for the other aldehyde adducts, the MDA adduct has 
a carbonyl group free to react with another amino acid residue again by Schiff base 
formation. Again, this results in intra or intermolecular protein crosslinking [169]. ONE is 
another bis-aldehyde capable of reaction with nucleophilic amino acid residues such as 
lysine, histidine, cysteine and arginine [170]. The first group to react is the double bond via 
Michael addition resulting in a 4-oxononanal adducts. Due to the lower stability of this 
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product, further reactions occur to more stable adducts. From the reaction with lysine the 
adducts are dihydrofuran, dihydropyrrole and 4-ketoamide derivatives [171], from reaction 
with arginine the adduct is a substituted imidazole [172] and from reaction with cysteine and 
histidine the adducts are furan derivatives [173, 174].  
 
1.3.3. Reversibility and detoxification of aldehyde-protein adducts 
Protein carbonylation by reaction with aldehydes, by Michael addition and Schiff-base 
formation, are not completely stable and can be reversible [175, 176]. In the presence of 
lower levels of short-chain aldehydes, these can modify a protein but readily be followed by 
its “decarbonylation”. This reversible protein damage may reflect a reversible signaling 
mechanism [177-179]. 
Abundant proteins like human serum albumin can protect other proteins from 
modification by aldehydes by acting as carbonyl scavengers using their surface and easily 
accessible nucleophilic residues [180]. Antioxidants can also quench carbonyl species 
preventing the formation of protein-aldehyde adducts and promoting their excretion [181]. 
Glutathione (GSH) and other thiol-containing proteins, such as thioredoxin (Trx) are 
effective in decreasing protein carbonyls and may be regulating this decarbonylation 
process [177, 179]. Previous in vitro studies have shown Michael adducts to be reversible 
in the presence GSH [180] which thiol residue conjugates with aldehydes not only protecting 
other residues from its modification but also enabling it excreted [181, 182] (Figure 1.23). 
Even though dialdehyde such as glyoxal and malondialdehyde cannot react by Michael 
addiction, it has been suggested that these can also be quenched by GSH as a cyclic adduct 
can be formed with the glutamate residue [183]. For α,β-unsaturated aldehydes, such as 
HNE, carnosine is another highly selective scavenger as it reacts by both Michael addition 
and Schiff-base formation involving both functional groups of these aldehydes [175]. To 
characterize and detect these scavenger-aldehyde adducts in biological samples is critical 
since scavengers of carbonyl species are being suggested as good therapeutic target for 
inflammatory diseases [184]. 
 
Figure 1.23.  Diagram illustrating the reversibility of protein modification by reactive carbonyl 
species and the detoxification of these by thiol-containing compounds such as glutathione. 
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1.4. Detection methods for aldehydic oxidation products 
To understand the biological significance of each lipid oxidation product, it is important 
to have reliable and sensitive methods to identify and quantify them. While some lipid 
oxidation products are stable, the aldehydes mentioned in the section above are highly 
reactive and therefore harder to detect. Aldehydes can be identified either in the free form 
or more likely as covalent adducts with proteins, DNA or aminophospholipids. 
Consequently, quantifying free aldehydes in complex clinical samples can represent a 
challenge and may not reflect the extent of their formation. However, the analysis of 
aldehydes as protein adducts also has its own challenges due to the number of possible 
products. To know the exact aldehydes formed, their targets and the masses of their 
modifications is usually required for the analysis. 
 
1.4.1. Analysis of free aldehydes and their metabolites 
Methods for the detection of free aldehydes and their quantification include 
spectrophotometric methods and gas or liquid chromatography coupled to mass 
spectrometry [185, 186]. The simplest approach is the direct spectrophotometric 
measurements; for example, HNE absorbs in the UV range at 220 nm [187]. However, a 
better approach would be to use aldehyde-reactive probes which allows their specific and 
sensitive detection and increase the stability of the aldehyde. The TBARS assay for 
malondialdehyde is extensively used due to its simplicity and low cost [188], but even when 
combined with other techniques such as HPLC, it has poor specificity among other 
limitations [129, 130]. 2,4-dinitrophenylhydrazine (DNPH), which gives a 
dinitrophenylhydrazone product with an absorbance at 380 nm [189], is often used to detect 
carbonyl groups on proteins by ELISA or western blotting.  
A disadvantage of the use of probes is the lack of specificity and consequently 
chromatographic separation is required pre-column or post-column derivatization by 
reverse phase HPLC [190]. Gas chromatography can also be used but requires the sample 
to be volatile and it is usually coupled to mass spectrometry. Free HNE can be converted 
to pentafluorobenzyl oximes (PFBO) by reaction with pentafluorobenzyl hydroxylamine, 
followed by formation of trimethylsilyl ethers and the PFBO-TMS derivatives of HNE 
analysed by GC coupled to electron-capture negative-ion ionization (NICI) MS. This method 
was previously used to detect HNE in patients with thyroid dysfunction or migraines [191], 
and a similar method was also used to analyse MDA and HNE in human serum samples 
[186]. GC coupled to NICI-MS and PBFO derivatization were also used to detect α-
chloroaldehydes [192, 193]. In contrast, LC-MS requires minimal samples manipulation 
prior to analysis[186]. Several approaches have been used for the analysis of aldehydes by 
54 
 
LC-MS usually following DNPH derivatization to stabilize them [194]. For example, this 
approach allowed the detection of MDA, crotonaldehyde (CRT), benzaldehyde (BNZ), 
hexanal (HXL), HHE, HNE, 2,4-nonadienal and 2,4-decadienal in animal feed [195]. 
It is known that free aldehydes are metabolized and detoxified, therefore the analysis of 
their metabolites may help get a better representation of the aldehyde in vivo. HNE can be 
detoxified by conjugation to glutathione [196], as previously mentioned, and metabolized to 
1,4-dihydrononane-mercapturic acid, which has been detected in urine [197]. 2,4-
decadienal (DDE) can be oxidized to 2,4-decadienoic acid and cysteine-conjugated 2,4-
decadien-1-ol, and both have been found in cell culture models and urine from mice by LC-
MS [198]. The carboxylic acids of HHE, HNE and HDDE were detected by NICI-MS in 
human urine for aging and diabetes [118]. Similarly, α-chloroaldehydes can be converted 
to the PFB ester form and analysed by GC coupled to NICI-MS [152] or can form adducts 
with GSH and be detected by LC-MS [199].  
 
1.4.2. Analysis of aldehydes as adducts with macromolecules 
The analysis of free aldehydes has several disadvantages as their high reactivity readily 
results in formation of adducts with a variety of biological molecules. Hence a large 
proportion of the aldehydes formed are likely to exist as adducts. Consequently, a full 
understanding of the roles of these aldehydes depend on analysis of the adducts formed 
through Schiff base reactions and Michael additions or rearrangement of these products, 
as described in 3.2. Although adducts with DNA bases are known to occur and are thought 
to contribute to the mutagenicity of acrolein and crotonaldehyde, most attention has focused 
on detecting the formation of adducts with proteins. The structures of a substantial number 
of protein adducts have been elucidated, and examples are shown in Figure 24-26. To this 
end, two main approaches exist: antibody-dependent techniques, and proteomic methods 
including protein identification and sequencing by mass spectrometry. These two 
approaches may also be combined. 
 
1.4.3. Antibody-based methods 
The development of antibodies against the adducts formed from MDA, HNE and others 
have increased in the past thirty years [200, 201]. These have been validated for ELISA, 
western blotting, immunocytochemistry and immunochemistry. The antibodies and antisera 
available for HNE have been previously reviewed [63]. A monoclonal antibody against 
acrolein adducts with proteins has also been developed [202, 203]. Another antibody 
against the same immunogen was shown to recognize acrolein-modified albumin with 
limited cross-reactivity with other albumin adducts [204]. A monoclonal antibody has been 
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raised against nonenal-modified keyhole limpet hemocyanin, and it was able to recognize 
the Nε-3-[(hept-1-enyl)-4-hexylpyridinium] lysine (HHP-lysine), a novel nonenal-lysine 
adduct [95]. Antibodies against aldehyde adducts with DNA bases have also been 
developed and have been developed and validated for FACS-based assay and ELISAs 
[205]. These antibodies have demonstrated the occurrence of adducts of aldehydes in 
tissues and, especially anti-HNE antibodies, have been applied to western blotting for 
lipoxidation identification [206]. Some antibodies such as anti-DNP have been broadly used 
for carbonyl-containing proteins [207], however carbonyls can arise from other modification 
than aldehydes, and even aldehydes only add a carbonyl group to the protein when reacted 
by Michael addition. Additionally, several of the antibodies available are polyclonal which 
decreases its specificity and increases cross-reactivity. Specificity is therefore the limitation 
of the antibody-based methods for aldehyde adducts detection. Antibody-based method 
have been recently reviewed by our group [31]. 
 
1.4.4. Protein analysis by mass spectrometry 
Mass spectrometry (MS) is a powerful analytical technique for protein research. MS is 
used for identification, quantification and characterization of proteins [208]. The advance in 
instrumentation and the coupling with separation techniques such as liquid chromatography 
has moved the proteomics field forward and allowed analysis of hundreds of proteins in 
parallel to be a common experiment. Mass spectrometry (MS) measures the mass-to-
charge ratio (m/z) of ionized analytes. The main methods for ionization are electrospray 
ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI). ESI generates 
ions from large and complex molecules in solution which makes MS a preferential ionization 
method to the analysis of molecules like proteins [209]. On the other hand, for MALDI the 
proteins are embedded within a matrix in a solid state and ions are generated by pulses of 
laser light [210]. The ions generated by ESI are more multiply-charged than MALDI, 
supporting the use of ESI over MALDI for large molecules analysis. Oxidative modifications 
of proteins alter their composition, and change their m/z ratio and potentially their ionization 
conditions [211]. Two different MS approaches can be applied to the analysis of proteins: 
top-down proteomics, which analyses intact proteins and their fragmentation within the 
mass spectrometer; and bottom-up proteomics, which analyses peptides from proteins 
digested with proteases prior to MS analysis.  
 
1.4.4.1. Sample preparation 
Bands or spots from western blotting or SDS-polyacrylamide gels stained with 
coomassie can be excised for protein analysis [212, 213]. Bottom-up approach requires the 
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proteins to be digested in-gel or in-solution, prior to MS analysis. Both protocols for protein 
digestion may cause artefacts to proteins such as oxidation of methionine and tryptophan 
or carboxymethylation of cysteine, which can interfere with interpretation of results [214]. 
The most commonly used protease is trypsin, which cleaves within the polypeptide chain 
on the carboxyl side of lysine or arginine residues, except when either is followed by proline, 
or an adjacent negatively charged residue that masks their positive charge [215, 216]. To 
increase the sequence coverage, alternative proteases can be used in combination with 
trypsin. Additionally, if the residues lysine and arginine are modified by lipoxidation as 
described above, the trypsin would miss these as cleavage sites, generating longer 
peptides that do not ionize as well and give low ion intensity, increasing the challenges with 
their detection [217]. Therefore, combination of different proteases could help overcome 
this limitation, including chymotrypsin (large hydrophobic), Asp-N (N-terminal to asp), Glu-
C (N-terminal to Asp and Glu) and others [218]. New digestion methods, such as SMART 
digestion (Thermo), a kit for in-solution digestion designed for fast and highly reproducible 
digestion of proteins, may help to minimize sample handling. In this protocol, there is no 
need to perform additional steps of denaturation, reduction and alkylation, decreasing the 
causes of artefacts. Addition of surfactant can also improve sample digestion and therefore 
sequence coverage, such as ProteaseMax (Promega) [219] and Rapigest (Waters) [220], 
which are MS-compatible additives.  
 
1.4.4.2. Enrichment and labelling approaches 
Label-free MS analysis of post-translational modification of proteins is challenging due 
to the low stoichiometric levels of modified protein in the complex mixture, and thus it is 
difficult to identify them among other more abundant signals. This limitation can be 
overcome by enrichment tools that can be applied to bottom-up approaches, increasing its 
sensitivity and specificity [221]. 
The most commonly used enrichment technique for carbonyl formations is the biotin 
hydrazide label, which is then enriched by avidin capture. Chavez et al. introduced a biotin-
tagged aldehyde reactive probe (ARP) that reacts with protein aldehydes forming a C=N 
bond on the carbonyl group resulting in a stable biotinylated oxime derivative followed by 
detection by western blotting or mass spectrometry [222]. This approach has been applied 
to enrich lipoxidation adducts of cardiac mitochondria, for which acrolein, HHE, HNE and 
ONE modifications among others were reported [223]. ARP-streptavidin for enrichment can 
either be used at the level of modified protein or modified peptides after proteolytic digestion 
[224]. The protein targets and modification sites identified in these enrichment studies can 
be useful to develop targeted assays. The same group also developed an alternative 
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method for relative quantification of site-specific carbonyl adducts, involving d0/d4-succinic 
anhydride labelling followed by enrichment using hydrazine-functionalized beads [225]. It 
was reported that HHE Michael adducts were the most abundant, but acrolein, HNE and 
ONE adducts to cystine, histidine and lysine were also reported. Comparison between 
carbonyl-labelling reagents indicated that 2,4-dinitrophenylhydrazine (DNPH), biotin 
hydrazide (BHZ) and O-(biotinylcarbazoylmethyl) hydroxylamine (ARP) were selective for 
aliphatic aldehydes and ketones and that better results are obtained from enrichment of 
peptides after digestion rather than labelling of the whole protein [226]. Therefore, biotin 
affinity with MS peptide analysis can provide information on a variety of protein 
modifications in clinical samples. However, this approach had limitations such as detection 
of carbonyls resulting from direct attack of free radicals on proteins instead of aldehydes 
from lipid peroxidation, and it would only enrich adducts generated by Michael addition 
bearing a carbonyl group and it will miss Schiff base adducts. 
A novel approach to determine targets of small reactive aldehydes involves the chemical 
synthesis of an aldehyde analogue with an alkyne or azido termini, which allows their 
adducts to be selectively extracted from biological samples [227]. For example, alkynyl 
analogues of HNE can form adducts with protein that can be label with azido-biotin tags by 
Cu+-catalysed cycloaddition (Click chemistry). Using this technique it was found that heat 
shock proteins 70 and 90, and the 78-kDa glucose-regulated protein, were selectively 
adducted by HNE [228].  
Yet, labelled methods also have disadvantages such as being expensive and an 
additional step in the analytical workflow. Additionally, most of the labelling probes rely on 
the detection of the carbonyl group which would not be present in the case of a Schiff-base 
formation resulting in non-detection of this type of modification on proteins. Other limitation 
of labels such as biotin is the low throughput and the difficulty in localising the modification 
by MS since the ionisation and peptide fragmentation can be compromised by the labelling 
[211]. Therefore, novel label-free methods with better sensitivity and specificity are needed 




Chromatography is a separation technique whereby molecules in a mixture applied onto 
a stationary phase are separated from each other by a mobile phase. Differences in 
adsorption, partition, affinity or molecular weight separate proteins/peptides in the mixture, 
since some remain longer in the stationary phase while others elute rapidly into the mobile 
phase [229]. Chromatographic methods coupled to mass spectrometry improve protein 
analysis by adding a separation step to reduce the diversity and complexity of proteins and 
peptides present in biological samples prior to MS analysis. The resolving power of the 
chromatography reduces the ion-suppression effect in MS and allows low abundance 
species such as post-translationally modified proteins and peptides to be detected [230]. 
Liquid chromatography coupled to mass spectrometry (LC-MS) is the most common 
analytical technique used in proteomics. LC has a broad selection of stationary and mobile 
phases that can be chosen and adapted to each study. The choice of appropriate LC 
method makes it possible to enrich low-abundance proteins presented in a complex sample. 
Reverse-phase, ion-exchange and size exclusion are the most commonly used liquid 
chromatography methods [231, 232] (detailed information on each method is available in 
the introduction of chapter 5). An advantage of LC is the ability to directly introduce the 
separated proteins or peptides into the mass spectrometer through electrospray ionization 
(ESI) for analysis [233]. The separation of peptides and proteins is key in both top-down 
and bottom-up MS approaches. 
 
1.4.4.4. Intact protein and top-down proteomics 
The analysis of intact protein by mass spectrometry is used to determine the mass of 
the protein, and changes in mass that can be indicative of post-translational modifications. 
Both ionization techniques mentioned above can be used, but ESI is more common as it is 
usually able to give better mass accuracies since it generates many different charges, giving 
rise to a higher number of peaks in the spectrum [234]. Nevertheless, multiple charging only 
works for a limited number of proteins in the mixture until the signals start to overlap and it 
becomes a challenge to deconvolute the data. This approach provides information on the 
total extent of modification on the whole protein and has been previously applied to detect 
several modifications on histones [235], glutathionylated haemoglobin [236], electrophilic 
modifications [237, 238] and characterization of monoclonal antibodies [239]. Top-down MS 
involves fragmentation of intact protein within the mass spectrometer and analysis of the 
fragment produced to determine the specific sites and nature of modification. Even though 
this approach has great potential for mapping lipoxidation modifications, it requires high-
resolution instrumentation and is limited by their sensitivity [240]. The combination of 
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different techniques is useful to understand the extent and better characterize lipoxidation, 
since these can complement each other and provide more and better information on protein 
modification. For example, a top-down approach was used to investigate the formation of 
adducts between ubiquitin and several aldehydes including MDA and HNE and to asses an 
order of reactivity of these, while a bottom-up analysis of the tryptic peptides of the same 
samples allowed mapping of the modification sites [241]. 
 
1.4.4.5. Bottom-up proteomics 
In contrast to top-down, bottom-up approach involves the digestion of protein to peptides 
as described in 4.2.2.1. This approach is routinely performed by LC-MS and is 
advantageous in complex protein mixtures as it has the potential to identify low abundance 
proteins. The presence of post-translational modification requires confirmation by tandem 
MS to sequence the peptide and localize the specific site and nature of modification [211] 
and this can be performed by various types of tandem MS experiments including untargeted 
or semi-targeted/targeted approaches [242] (Figure 1.24). Untargeted techniques have 
commonly been applied to individual proteins due to the challenges of implementation in 
complex samples. However, to develop targeted and semi-targeted approaches, the 
selection of peptides to be fragmented has to be carried out by preliminary untargeted MS 
scan [243].There have been significant efforts to develop new targeted and semi-targeted 
methods based on diagnostic ions for oxidative modification, but these require prior 
knowledge on the modified peptide and its fragmentation pattern. 
 
 
Figure 1.24. Schematic representation of various types of tandem mass spectrometry 
experiments. (A) Product ion scanning generates fragment ion spectra for the identification of the 
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amino acid sequence of specific peptides. The first analyzer (MS1) selects one precursor ion at a 
time, then the selected ion undergoes CID in the collision cell, and the fragments are analyzed by 
the second analyzer (MS2). This process is repeated for different precursors. (B) Precursor ion 
scanning sets the second analyzer (MS2) to transmit only one specific fragment. MS1 is scanned to 
detect all the precursor ions that generate this fragment. (C) Neutral loss scanning scans both 
analyzers to detect the mass difference of ions passing through MS1 and MS2, such difference 
corresponds to a neutral fragment lost in the collision cell. (D) MRM involves a series of one precursor 
ion and one specific fragment for that precursor being selected by MS1 and MS2, respectively. The 
instrument cycles through a series of transitions (precursor-fragment pair) which is particularly useful 
to detect specific analytes in complex samples. Adapted from [244]. 
1.4.4.6. Untargeted or Shotgun Mass Spectrometry Approach 
Untargeted approaches can also be referred to as shotgun or discovery approaches 
(Figure 1.24A). After digestion, the peptides are analysed by MS and the peptide mass 
fingerprint used to identify the proteins present by matching with theoretical masses of 
peptides in a database, since the large dataset generated would be too difficult to manually 
analyse [245]. The most common search engines and their advantages and disadvantages 
have been previously reviewed by our group [211]. These search engines have the option 
to include in the search the masses of specific post-translational modifications as variable 
modifications [246]. However, the number of modifications being search at once is limited 
due to the increase in false positive identifications [69, 243]. Even though these softwares 
are often able to detect the oxidative modifications, validation of the MS/MS data by de novo 
sequencing is essential to confirm the presence and location of the modification [247]. The 
fragmentation of peptide ions needs to be understood as this constitutes the basis for 
peptide identification and de novo sequencing validation [248]. The Roepstorff and Fohlman 
system [249] covers the cleavage of every single bond in a protonated peptide and the 
products are named A, B and C ions if the charge is retained on the N-terminal fragment or 
X, Y and Z if it is retained on the C-terminal fragment and the subscript numbers indicate 
the residues involved, counting from the relevant terminal (Figure 1.25). These 
nomenclature has been superseded by the Biemann system [250] which includes fragment 
ions generated by cleavage of side-chain groups. In this system the lettering is italicized 
lower case and the ion charge, and the hydrogens gained are implicit. More recently, 
another nomenclature system for peptide ion fragmentation was proposed to overcome 





Figure 1.25. Roepstorff and Fohlman nomenclature system for protonated peptide 
fragmentation. 
This approach allowed protein modification by HNE to be detected in Down syndrome 
cases in which 2D electrophoresis was carried out prior to MALDI-TOF peptide analysis 
and Mascot used for database search [252]. Using a similar approach, HNE modifications 
were found on complex I subunits in mitochondria from diabetic kidney, where two types of 
electrophoresis were used; the blue native polyacrylamide gel electrophoresis (BN-PAGE) 
and the denaturing SDS-PAGE, followed by protein digestion, separation by LC and peptide 
mapping by mass spectrometry [253]. Another study on ApoE by MALDI-TOF/TOF MS 
detected several acrolein adducts, for example the aldimine adduct with an increase in 
mass of 38 Da at Lys149 and Lys155, a propanal adduct with 56 Da at Lys135 and Lys138, 
MP-lysine adduct at Lys64, Lys67 and Lys254 and FDP-lysine at Lys68 [254]. Acrolein-
modified ApoE has impaired binding to LDL receptor and heparin, possibly due to changes 
in folding proving the biological importance of lipoxidation. A label-free LC-MS/MS approach 
was used to investigate the sites of modification of chymotrypsin, cytochrome c, β-
lactoglobulin and RNase A upon treatment with 2,4-dodecadienal [238]. A reporter ion at 
m/z 286 was detected and deduced to correspond to the presence of a lysyl-pyridinium 
adduct. Such diagnostic ions can be used to develop semi-targeted (precursor ion 
scanning) or targeted (single or multiple reaction monitoring) mass spectrometry 
approaches for the detection of these modifications.  
 
1.4.4.7. Targeted and semi-targeted approaches 
Reporter ions are diagnostic for a specific analyte of interest, usually products from the 
fragmentations of the peptide. These are discovered by untargeted MS data analysis and 
have been used in the development of label-free methods [255]. While for semi-targeted 
methods the fragmentation product is the report ion, but the precursors are unknown, for 
targeted methods both precursor and fragment ions are fixed and used as reporters. Both 
methods increase the specificity for oxidative post-translational modifications, including 
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aldehyde adduction to proteins, and relative quantification can be achieved using relevant 
reporter ions.  
Precursor ion scanning (PIS) (Figure 1.24B) and neutral loss scanning (NLS) (Figure 
1.24C) are tandem MS routines which enables molecules to be identified by characteristic 
fragmentation ions. These are both examples of semi-targeted approaches. In PIs the 
second analyser is fixed to detect a specific fragment ion and the first analyser is scanning 
for precursor ions that generate this ion upon fragmentation. Immonium ions are internal 
fragments generated by the combination of a and y type cleavage and are reporter ions for 
each amino acid residue. The modified amino acid residue gives rise to a modified 
immonium ion, which has been the most commonly used reporter ion for protein 
modification [256, 257]. In neutral loss scanning, the diagnostic fragment it is not charged 
so its generation is detected by scanning in both analysers a mass offset corresponding to 
the mass of that fragment. For example, protein adducts of HNE can be monitored by 
neutral losses of 138 Da and 156 Da, for Schiff base and Michael adducts respectively [258, 
259]. 
Targeted approaches include single reaction monitoring (SRM) and multiple reaction 
monitoring (MRM) (Figure 1.24D). For these, both precursor ion and product ion masses 
are fixed for analysis of an analyte of interest [260]. The peptides are filtered by the first 
quadrupole (Q1) based on the precursor ion m/z, followed by fragmentation of the peptides 
into product ions in a collision cell. The product ions are then filtered in Q3 based on the set 
product ion m/z value. The fragmentation from the m/z of  the precursor to the m/z of the 
product ion is referred to as a transition and the success of an MRM experiment depends 
on the selection of the most appropriate transitions. Therefore, to develop an MRM routine, 
prior knowledge of the analytes is required. As this is not a discovery technique, its most 
common application is as a MS-based quantification tool [261, 262]. For example, HNE-
modified HSA can now be quantified in plasma by a novel MRM routine that monitors two 
modified peptides each containing amino acid residues that were previously shown to be 
highly susceptible to HNE modification [263]. Another MRM method was developed to 
detect the presence of the enzyme CYP37A1 modified by isolevuglandin iso[4]LGE2 in 
human retinal samples, which was developed based on bottom-up MS data that identified 
three specific lysine residues for the adduction [264]. A similar approach was able to detect 
isoketallysine-lactam adducts in dendritic cells by stable isotope dilution MRM [265]. 
Methods for detection of isolevuglandins adducts in vivo is important since these cannot be 




1.4.5. Quantification of aldehydes in human plasma or serum 
The quantification of free aldehydes in serum may depend on their rate of production, 
breakdown, detoxification and adduction to macromolecules [267]. Additionally, adduct 
formation is a reversible reaction, unless reduction or cyclization happen, which may affect 
quantification. The concentration of free aldehydes has been measured in a number of 
diseases such as diabetes, rheumatoid arthritis and lung cancer. Different techniques result 
in different basal levels of aldehydes in health subjects, noting therefore a lack of consensus 
on these concentrations in plasma. HNE concentrations have been reported to be 80-960 
nM while MDA varies from 0.36 to 15 μM and ACR from 42 to 1260 nM in healthy subjects 
[31]. The quantification of these aldehydes has been previously reviewed [186] and it has 
been discussed that storage time can affect these concentrations by artefact formation 
[268]. Overall, a small increase in plasma aldehyde concentration is detected in case of 
disease, although larger increases have been reported in diabetics with an ACR and MDA 
concentrations of 6.35 μM and 25.6 μM, respectively [269]. Nevertheless, these 
concentrations should be interpreted carefully since aldehydes such as acrolein can have 
sources other than lipid peroxidation [71]. 
 
1.4.6.  Metabolomics by Nuclear Magnetic Resonance (NMR) 
During inflammatory diseases and cancer, cells change extensively their metabolism to 
meet the new metabolomic requirements [270]. Aldehydes can also cause alterations in 
metabolome by interaction with enzymes or metabolites themselves. Glycolytic enzymes 
are targets for reaction with lipid peroxidation aldehydic products. For example, HNE was 
reported to inactivate glyceraldehyde-3-phosphate dehydrogenase (GAPDH)  by covalent 
binding primarily to amino acid residues on the surface of the enzyme in a time-dependent 
manner [271]. Similarly, acrolein cellular toxicity has been related to inactivation of GAPDH 
[272]. Other glycolytic enzymes such as pyruvate kinase and phosphofructokinase are also 
sensitive to cellular redox balance and to inactivation by aldehydes [273].  
The proteomic studies reported above were performed by LC-MS/MS and reported 
specific sites of modification and mechanisms of inactivation. However, metabolomic 
studies can provide additional information on the mechanism of action. The study of the 
metabolomic state of a cell is important to understand the effect of protein modifications on 
metabolic pathways. Even though the most successful approaches for metabolomics are 
mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy [274], NMR 
offers many advantages over MS. These include the quantification of metabolites in 
biological samples or cell extracts without complex sample preparation and the ability to 
analyse compounds that would be difficult to ionize for MS analysis. Using stable isotope 
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labels, NMR is also able to elucidate metabolic mechanisms by tracer-based metabolism 
approach, which allows changes in metabolites to be assigned to particular pathways [275]. 
The most important nuclei in biomolecular NMR studies are 1H (proton), 13C, 15N, and 31P. 
Proton is the most sensitive and one-dimensional (1D) 1H NMR is the most widely used 
approach in metabolomics, but signal overlap might be a problem in metabolite 
identification. Two dimensional (2D) NMR, as well as the use of standards, can overcome 
ambiguous identification of metabolites in complex mixtures [276]. The combination of MS 
and NMR has been previously reviewed [277] and many improvements in metabolites 
characterization reported, both in their identification and quantitation. While MS quantifies 
isotopic labelling distribution, NMR gives the specific labelling position, information which is 
not always available from MS/MS data.  
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1.5. Aims and hypothesis of the work presented in this thesis 
Short-chain lipid peroxidation products such as aldehydes are highly reactive and able 
to modify proteins. Lipoxidation products occur in inflammatory pathologies, thus the 
importance of their study as potential diagnostic and prognostic markers of disease. Mass 
spectrometry based approaches are becoming increasingly important in lipidomic and 
proteomic research. However, there is still a need to improve the methods currently used, 
in particular the methods for detection of lipoxidation products. Subsequently, the biological 
implication of these products is still not completely understood. With this lack in knowledge 
in mind, the objectives of the thesis were as follows: 
• Detection of reporter fragmentation ions by MS of proteins and peptides modified by 
aldehydic short-chain lipid peroxidation products (chapter 2); 
• Development of targeted MS methods using reporter ions for the detection of 
lipoxidized proteins and peptides (chapter 2); 
• Alternatives to 2-chlorohexadecanal synthesis and comparison of their reactivity with 
the reactivity of other aldehydes towards proteins and peptides (chapter 3); 
• Test and comparison of chromatographic methods for native protein separation and 
lipoxidized proteins and peptides separation (chapter 4); 
•  Assessment of the effect of aldehyde adducts on the glycolytic enzyme pyruvate 
kinase activity and structure, determine the hotspots for modification by MS and 
analysis of the impact of the aldehydes in the cellular metabolism. The hypothesis 
was that the aldehydes were able to modify the enzymes altering its function and 
interfering with the normal cellular metabolism (chapter 5); 
• Assessment of the cellular structural changes by confocal microscopy monitoring of 
the Cys328-mediated effect of small aldehydes on vimentin network and monitoring 













Chapter 2. A mass spectrometry approach for the 





Oxidative stress results from a redox imbalance and consequently a relative increase in 
oxidative species [17]. Free radicals cause damage to biomolecules including proteins, 
lipids and DNA, changing their structure and possibly their function. Lipids are a major target 
of oxidation in biological systems [23]. Polyunsaturated fatty acids (PUFAs), for example 
present in membrane phospholipids, are highly susceptible to oxidation due to the multiple 
unsaturation in the carbon chain [23]. Lipid peroxidation leads to the formation of a variety 
of oxidized products. Oxidized lipids are known to be key players in the development and 
progression of inflammatory and age-related diseases such as Alzheimer, Parkinson, 
multiple sclerosis, cardiovascular diseases, atherosclerosis, diabetes, liver and lung 
diseases [29, 278, 279]. Oxidised lipids can undergo fragmentation and give rise to short-
chain oxidation products such as aldehydes [20, 23, 60]. Mechanism of formation and 
chemistry of these products are detailed in section 1.2. 
Acrolein (ACR) and 4-hydroxy-hexenal (HHE) are two short aldehyde that are models 
of alkenals and substituted alkenals respectively. Acrolein, with only three carbons, is the 
shortest alkenal identified as lipid peroxidation products. It is also the most reactive specially 
with thiol groups from proteins [70, 71], and besides being a product of lipid peroxidation, it 
is also present in tobacco smoke and processed foods [72, 73]. It has been linked with 
inhibition of cell proliferation, enhancement of apoptosis, and disruption of gene expression 
necessary to regulate inflammation and antioxidant defense [75, 76, 80, 280]. HHE is one 
of the major lipid peroxidation products of ω-3 PUFAs such as docosahexaenoic acid (DHA) 
[113] and it has been reported as the most prominent hydroxy-alkenal in human plasma 
[113, 114]. It has been linked with causing apoptosis via NFkB signalling pathways [114] 
and its reactivity has been compared with the reactivity of better known aldehydes such as 
HNE [101, 115]. However, lower levels of HHE have also been shown to protect against 
oxidative stress by stimulating the expression of antioxidants via Nrf2 activation [117].  
Lipoxidation is the modification of proteins and peptides by reactive lipid oxidation 
products, including short-chain aldehydes [281]. Typical reactions of aldehydes with 
nucleophilic amino acid residues is detailed in section 1.3. Lipoxidation adducts have been 
found in several inflammatory diseases such as atherosclerosis [282] and Alzheimer’s 
disease [283]. Human serum albumin has been identified as a major target of lipoxidation 
due to its abundance in plasma and nucleophilic residues such as Cys34, His146 and 
Lys199 [284]. This suggests that most of the reactive carbonyl species (RCS) such as 
aldehydes can be found as albumin adducts in plasma [285, 286]. A half-life in plasma of 3 
weeks makes albumin and its lipoxidation adducts a good biomarker of systemic oxidative 
stress since these adducts would have been formed in the weeks prior to measurement 
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[287, 288]. Aldehyde-albumin adducts have been detected in disease such as chronic renal 
failure [289]; HNE adducts have been reported in type 2 diabetes mellitus [290], while 
acrolein adducts have been found in brain infarction [291] and ischaemia-reperfusion 
damage [286]. Therefore, new methods for the detection of these adducts in plasma are 
needed to improve the diagnosis and monitoring the extent of diseases. 
The detection of free aldehydes is extremely challenging due to their short-life, high 
instability and high reactivity in plasma [285, 292]. Moreover, the detection of these as 
adducts in biological samples is as challenging due to their low abundance [281, 285]. 
Several techniques have been used, including antibodies, chemical probes and mass 
spectrometry, as described  more extensively in section 1.4 [23, 31, 285]. Mass 
spectrometry can detect these adducts by the change in the mass-to-charge ratio (m/z) of 
proteins and peptides and enables identification, characterization and localization of the 
modified amino acid [263, 293]. The fragmentation pattern of peptides depends on the 
excitation method used and low energy ionization, such as collision-induced dissociation 
(CID) and electron capture dissociation (ECD) [294], are the most commonly applied to 
proteins and peptides identification as these enable charge-induced cleavage of the peptide 
backbone and yield primarily b- and y-type fragment ions, as described in section 1.4.2., 
which allow for their de novo sequencing. However, in more complex samples the data 
output is much greater, making the identification of modifications difficult and time-
consuming. To help overcome this, the information on the lower mass range of the 
fragmentation spectra can be used to identify reporter ions specific for each modification.  
This region contains immonium and related ions which are fragments of a single amino acid 
and their characteristic mass indicates which amino acids are present in a sequence. In 
case of a modification on a specific amino acid, its respective immonium and related ions 
are also found to be modified and can be used as report ions which are modification and 
amino acid specific [257]. These reporter ions can therefore be used to develop semi-
targeted mass spectrometry approaches such as precursor ion scanning (PIS), neutral loss 
scanning (NLS) or multiple reaction monitoring (MRM), simplifying the analysis [31, 295-
297]. 
Multiple reaction monitoring (MRM) is a targeted high-resolution MS/MS method that 
can be used to quantify selected protein-aldehyde modification in complex biological 
samples such as plasma. MRM involves “bottom-up” analysis of proteins that have been 
enzymatically digested, usually by trypsin, into peptides [211] using a triple quadrupole 
mass spectrometer. During MRM, the peptide masses are filtered in two stages based on 
defined m/z values. Initially, the peptides filtered by the first quadrupole (Q1) based on the 
set precursor ion m/z values. Q2 fragments the peptides as a collision cell into fragments 
ions (product ions), which are then subsequently filtered by Q3 based on the set product 
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ion m/z values. The fragmentation from the precursor to the product ion m/z values makes 
a transition and the selection of the most appropriate transitions determines the success of 
an MRM experiment. A fully validated MRM method is a powerful tool for protein 
quantification with higher selectivity than the alternative shotgun MS/MS approach [261]. 
For example, Cys34 and Lys199 were found to be the most reactive residues in HNE-
modified human serum albumin and so a novel MRM approach was designed to quantify 
the levels of HNE-modified HSA in plasma using two modified peptides, each containing 
one of these most susceptible residues [263]. 
In this study, liquid chromatography coupled to tandem mass spectrometry was used to 
investigate protein modifications caused by acrolein and 4-hydroxy-hexenal, two short-
chain aldehydes which have been less studied. Two proteins were used as models for the 
study of small aldehyde lipoxidation: lysozyme (14,306 Da), rich in lysine and cysteine 
residues, and human serum albumin (66,437 Da), the most abundant human plasma 
protein. The first aim was to generate adducts in vitro and characterize them by LC-MS/MS 
in order to localize the modified amino acid residues and possibly identify reporter ions for 
these modifications. The second aim was to develop a targeted MRM approach using these 
report ions to selectively identify and quantify albumin-aldehyde adducts. Firstly the method 
was tested with in vitro modified HSA and later validated for its suitability to identify albumin-
aldehyde adducts in human plasma in vitro aldehyde-treated to determine whether the 
method is appropriate for use with biological samples.
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2.2. Material and Methods 
2.2.1. Chemicals 
All reagents were purchased from Sigma-Aldrich Chemical Co. (Dorset, UK) unless 
otherwise indicated. All solvents were of LC-MS grade and ultrapure water (Type 1) was used 
for buffers and reactions. Formic acid and dithiothreitol (DTT) were purchased from 
ThermoFisher Scientific (Runcorn, UK). 
 
2.2.2. Treatment of lysozyme or human serum albumin with aldehydes in vitro 
Lysozyme (1 mg/mL) was first reduced with 100 mM DTT. This step was omitted for HSA, 
which was used in its native form (1 mg/mL). Acrolein was added to the protein solution at 4, 
8 or 14 mM and allowed to react for 2 hours at room temperature. HHE was added at 8 or 16 
mM and allowed to react for 2 hours at 37 ⁰C. To stabilize adducts, 50 mM NaBH4 was added 
to the reaction and left for 1 hour at room temperature. For direct infusion mass spectrometry 
analysis, excess DTT was removed from the reduced lysozyme samples prior to the reaction 
with the aldehydes using Microcon Ultracel YM-10 centrifugal concentrators 10,000 MWCO 
(Millipore, Massachusetts, USA), according to the manufacturer’s protocol. 
 
2.2.3. Direct infusion MS analysis of modified lysozyme 
Modified lysozyme samples were dissolved in 50% acetonitrile, 0.5% formic acid in water 
and analysed by direct infusion into a 5600 TripleToF mass spectrometer (Sciex, Warrington, 
UK) using loop injection directly into a 2 μL/min flow rate of the same solvent and introduced 
into the source via a 20 μm i.d. steel capillary mounted on a standard nanospray source with 
a spray voltage of 2.4 kV, a source temperature of 150 ⁰C, declustering potential of 100 and a 
curtain gas setting of 25. Data was summed for 3-5 minutes and deconvoluted using the Bio 
Tool Kit plugin and PeakView 2.2 software (Sciex, Warrington, UK) with a step size of 0.5 Da 
at high (30,000) resolution and Gaussian smoothed with a 3 point window. 
 
2.2.4. Plasma collection and aldehyde treatment 
Ethical approval for the use of plasma from healthy volunteers was obtained from Aston 
University Ethics Committee (Project #954). Blood was collected by venepuncture from three 
healthy volunteers after overnight fasting and informed consent and collected into 50 mL tubes 
containing 0.1% EDTA. The blood was then centrifuged at 1,800 x g for 10 minutes at 5 ⁰C. 
The supernatant was removed and centrifuged again at 15,000 x g for 10 minutes to obtain 
clear plasma. The plasma from all three volunteers was pooled (as these were all control 
samples and the number of individuals limited) and diluted to 1:4 with 25 mM ammonium 
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bicarbonate, followed by treatment of acrolein with the same conditions used to treat HSA 
described above. Treatment with HHE was performed at a ratio of 1:10, at 37 C for 2 hours. 
 
2.2.5. Protein in-gel digestion 
The reaction products from above were separated by 15% SDS-polyacrylamide gel 
electrophoresis followed by staining with Coomassie blue to visualize the bands prior to further 
processing.  The separating gel (15 %) was prepared by adding 2.8 mL ddH2O, 3 mL of 40 % 
acrylamide/bis-acrylamide, 2 mL of 1.5 M Tris pH 8.8, 80 μL of 10 % SDS, 8 μL of TEMED and 
80 μL of 10 % APS. The stacking gel (4 %) was prepared by adding 3.1 mL ddH2O, 0.5 mL of 
40 % acrylamide/bis-acrylamide, 1.25 mL of 0.5 M Tris pH 6.8, 50 μL of 10 % SDS, 5 μL of 
TEMED and 50 μL of 10 % APS. The coomassie-stained bands present in the gel were excised 
and tryptic digestion was performed according to Verrastro et al., 2016 [298]. The gel pieces 
were washed with 500 µL of 100 mM NH4HCO3 and then with 100 mM NH4HCO3/50% 
acetonitrile. 10 µL of 45 mM DTT in 150 µL NH4HCO3 were added to the gel pieces and left 
incubating at 60 °C for 30 mins for reduction. Cysteine alkylation was performed by adding 10 
µL of 100 mM iodoacetamide and left to react at room temperature for 30 min in the dark. The 
gel pieces were then washed in 100 mM NH4HCO3/50% acetonitrile and incubated in 50 µL of 
100% acetonitrile for 10 min. The gel pieces were then dried completely using a vacuum 
centrifuge and resuspended in 25 µL of 0.1 µg/µL trypsin prepared in 25 mM ammonium 
bicarbonate. 25 µL of 25 mM ammonium bicarbonate was added to the trypsin digests and the 
digestions were incubated overnight at 37 °C. The gel pieces were pelleted by centrifugation 
and the supernatant was collected into a fresh tube. Further peptide extraction from the gel 
pieces was performed by adding 20 µL 5% formic acid and incubating at 37 °C for 20 mins, 
followed by addition of 40 µL acetonitrile and incubation for 20 mins at 37 °C. The gel pieces 
were pelleted by centrifugation, and the supernatant was removed and combined with the first 
supernatant. The peptide extracts were dried in a vacuum centrifuge for storage and 
resuspended in 30 µL H2O/acetonitrile (98:2, %) with 0.1% formic acid prior to MS analysis. 
 
2.2.6. Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Analysis 
Peptides were separated and analysed using an Ultimate 3000 system (Thermo Scientific, 
Hemel Hempstead, UK) coupled to a 5600 TripleTOF (ABSciex, Warrington, UK). The analysis 
was performed as previously described by Verrastro et al., 2016 [298]. Briefly, the peptide 
solution was loaded onto a C18 trap column (C18 PepMapTM, 5 μm, 0.5 x 5mm, Thermo 
Scientific, Hemel Hempstead, UK) before separation on a nano-HPLC column (C18 
PepMapTM, 5 μm, 0.075 x 150mm, Thermo Scientific, Hemel Hempstead, UK) at 300 μL/min 
using a gradient elution running from 2% to 45% aqueous acetonitrile, 0.1% formic acid over 
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45 minutes. Ionization of the peptides was achieved with spray voltage set at 2.4 kV, a source 
temperature of 150 ⁰C, declustering potential of 100V and a curtain gas setting of 25. Survey 
scans were collected in positive mode from 350 to 2000 Da using high-sensitivity TOF-MS 
mode. Information-dependent acquisition (IDA) was used to collect MS/MS data using the 
following criteria: the 10 most intense with +2 to +5 charge states and a minimum intensity of 
200 cps were chosen for analysis, using dynamic exclusion for 12 s and standard rolling 
collision energy settings. 
 
2.2.7. Multiple reaction monitoring (MRM) 
The acrolein-treated HSA and plasma peptides were resuspended in 50% acetonitrile, 
0.5% formic acid in water. Peptides were separated and analysed using an Ultimate 3000 
system (Thermo Scientific, Hemel Hempstead, UK) coupled to a 5500 triple quadrupole (Sciex, 
Warrington, UK). The peptide solution was loaded onto a C18 column (C18 PepMapTM 100, 5 
μm, 300 μm  x  25 cm, Thermo Scientific, Hemel Hempstead, UK) column at 5 μL/min using a 
gradient elution running from 2% to 45% aqueous acetonitrile, 0.1% formic acid over 45 
minutes. Ionization of the peptides was achieved with a spray voltage set at 5.5 kV, a source 
temperature of 150 ⁰C, declustering potential of 70 V. MS/MS analysis was carried out in MRM 
scanning mode, using the chosen transitions to fix the precursor ion and product ion m/z values 
at the first and third quadrupole, respectively. The total scan time was 0.7 seconds, dwell time 
ranged between 20 and 70 depending on the transitions and collision energy was set at 35 V 
at the second quadrupole for all transitions except  for the transitions using diagnostic ions, for 
which it was set as 41 V for m/z 509.3 → 168.1 and 55 V for m/z 566.3 → 159.1 and m/z 600.4 
→ 142.1. Method parameters such as collision energy and dwell time required optimization to 
improve the sensitivity of the method. Collision energy was firstly calculated as 𝐶𝐸 =
(𝑠𝑙𝑜𝑝𝑒) 𝑥 (𝑚 𝑧)⁄ + (𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡), where slope and intercept were dependent on the peptide 
charge. This shows how this parameter depends on the mass and charge of the peptide and 
that some peptides fragment more easily than others [299]. The dwell time is the duration in 
which each m/z ion signal is collected. Increasing the dwell time improved sensitivity, however 
resulting in fewer points collected across each peak [300]. The dwell time for each transition 
also depended on the number of transitions being monitored in the method at once, as 
increasing the number of transitions would mean decreasing each dwell time to get the same 
total scan time. Practical dwell-time settings range between 10 ms for good sensitivity and 100 




2.2.8. Database Searches 
The Mascot® probability based search engine (Matrix Science, London, version 2.4.0) was 
used to interrogate the SwissProt 2017-07 primary database. Mascot uses probability based 
scoring for protein identification using an adaptation of the MOWSE algorithm [301]. LC-MS 
.wiff files of each sample were searched for protein identification and oxidative post-
translational modifications (oxPTMs). For protein identification, variable modifications of 
methionine oxidation and carbamidomethyl cysteine were used. For the analysis of the 
lipoxidation products, the initial searches additionally used a variable modification list including 
reduced and unreduced ACR (mass changes of 56.06 Da, 58.08 Da, 40.06 Da, 94.11 Da, 
56.06 Da, 76.09 Da) or HHE (mass changes of 114.14 Da, 93.13 Da, 78.11 Da) adducts at 
cysteine, lysine and histidine residues. Other parameters for the searches were as follows: 
Enzyme: Trypsin; Peptide tolerance: ±0.6 Da; MS/MS tolerance: ±0.6 Da; Peptide charge 
state: +2, +3; Max Missed cleavages: 1; #13C: 0; Quantitation: None; Instrument: ESI-QUAD-
TOF; Data format: Mascot Generic; Experimental mass values: Monoisotopic; Taxonomy: 




2.3.1. Lysozyme as a model system to study lipid-protein adducts 
In the work reported in this section, the modifications of lysozyme by acrolein were 
evaluated as a model of lipid-protein adducts that may occur in inflammatory diseases. In 
order to increase the efficiency of the reaction between the protein and the aldehyde, the 
disulfide bonds on the lysozyme where reduced with dithiothreitol (DTT). Although lysozyme 
is known to have a single free cysteine residue, the reduction results in eight other cysteine 
residues available to react with the aldehyde from the reduction of 4 disulfide bonds. 
Therefore to increase the potential for reaction between the protein and the aldehyde, the 
disulphide bonds were first reduced with DTT and the results are shown in Figure 2.1. After 
deconvolution of the charge state envelope, the native lysozyme was observed at a mass 
of 14, 306 Da (Figure 2.1A). The incubation of lysozyme with 10 and 100 mM DTT resulted 
in the reduction of one (at m/z 14,308 Da) and three (at m/z 14,312 Da) disulfide bonds, 
respectively (Figure 2.1B and Figure 2.1C). A DTT concentration of 200 mM was required 
to reduce the protein completely, with a mass after deconvolution of 14,314 Da (4 disulfide 
bonds reduced and a mass increase of 8 Da over the native form) (Figure 2.1D). The 
charge state envelope shifts to lower m/z range with increasing DTT treatment 
concentrations as the protein unfolds and becomes more highly charged. All subsequent 
reactions for adduct formation were conducted on lysozyme reduction with 100 mM DTT 
which typically reduced 2-3 disulfide bonds, as the higher concentration required for full 




Figure 2.1. Reduction of intact lysozyme by DTT treatment. The left hand panels correspond to 
unprocessed (raw) MS data showing the charge state envelope for the protein, and the right hand 
panels show deconvoluted data giving the mass of the intact lysozyme. Lysozyme was treated for 
30 mins at room temperature with varying concentrations of DTT: (A) control treatment in the absence 




Peaks corresponding to reduced acrolein adducts of intact lysozyme were observed at 
mass increase of 58 Da, consistent with formation of a Michael adduct and subsequent 
stabilization by borohydride reduction. The optimal conditions for formation of acrolein-
protein adducts were investigated. The DTT-reduced lysozyme was reacted with acrolein 
for different time lengths and at a range of different concentrations. First, the time-
dependent effect was investigated with lysozyme incubated with 4 mM acrolein for 1 to 6 
hours. The formation of acrolein adducts was then analysed by direct infusion mass 
spectrometry (Figure 2.2). 
 
Figure 2.2. Deconvoluted ESI-MS spectra of lysozyme obtained after reaction with acrolein at 
4mM. Treatment for 1 h showing no adducts being formed (A). Treatment for 2 h (B), 4 h (C) or 6 h 
(D) showing the formation of several acrolein Michael adducts, each adding 58 Da (n=3). 
Reduced native lysozyme was identified at m/z 14,310 Da. The peak spacing between 
the acrolein adduct peaks was 58 Da, suggesting that lysozyme was modified by Michael 
addition of acrolein. Figure 2.2 shows that after one hour reaction, no adducts were formed 
(A), while after two (B), four (C) and six (D) hours reaction some adducts appeared to be 
formed in a time-dependent manner. Reaction with acrolein at 4 mM for 2 h (Figure 2.2B) 
gave rise to a maximum of 4 adducts while reaction for longer than 2 h (Figure 2.2C-D) 
resulted in more extensive modification with up to 8 adducts being formed. Both 4 and 6 
hour reactions resulted in the same number of modifications, so it seems that no more time 
is required beyond 4 h for 4 mM acrolein treatment. Therefore, the next step to evaluate the 




To evaluate the concentration-dependent effect of acrolein-treatment, lysozyme was 
reacted with acrolein at 8 mM and 14 mM and left to react for 2 or 4 hours, as explained 
above. Any adducts were then stabilized by reaction with sodium borohydride for one hour 
and the deconvoluted MS spectra obtained for each condition are shown in Figure 2.3. 
 
Figure 2.3. Deconvoluted ESI-MS spectra of lysozyme. Spectra obtained after reaction with 
acrolein for 2 hours at 8 mM (A) and 14 mM (B), and for 4 hours at 8 mM (C) and 14 mM (D). (n=3). 
The aldehyde concentration increases resulted in an increase of the ratio 
modified/unmodified lysozyme, as the native lysozyme peak intensity decreased. Since the 
number of adducts did not increase, these might suggest that other complex modifications 
are happening that are not being analysed, including protein cross-linking. It is also possible 
to see that 8 mM acrolein for 2 h (Figure 2.3A) provides the best conditions for the formation 
of the different adducts while higher concentration or time length resulted in a more 
complete modification of the protein where only 6 to 8 adducts can be seen (Figure 2.3B-
D). Leaving the protein and the aldehyde reacting for longer resulted in an extension of the 
reaction towards the modification increasing the number of adducts and the protein with 
lower modification is no longer present. From these optimization steps, 8 mM was chosen 
as the optimal aldehyde concentration and 2 hours as the optimal time of reaction for the 




To determine the specific amino acid residues modified, a bottom-up proteomic 
approach was carried out by tryptic digestion of the modified protein and LC-MS/MS 
analysis of the peptides. Lysozyme was modified by acrolein (4, 8 and 14 mM) for 2 hours 
before separation by 15% SDS-PAGE (Figure 2.4). 
 
Figure 2.4. SDS-PAGE (denaturing gel electrophoresis) results for lysozyme. Untreated and 
treated lysozyme with 4 mM, 8 mM or 14 mM acrolein for 2 hours. Gel stained with Coomassie blue 
staining. The highlighted sections boxed in white were cut for further analysis: (1) 15-20 kDa; (2) 25-
30 kDa; (3) 40-45 kDa. 
The molecular weight of lysozyme is 14 kDa, which means untreated and acrolein 
treated lysozyme should appear in the highlighted section 1 in Figure 2.4, around the 
markers 15 to 20 kDa. There are two bands within this region but due to the difficulty to 
separate them, these were studied together. The second and third sections contain a band 
at approximately double or triple the molecular weight of lysozyme and could represent 
protein cross-linking. However, this could also represent protein agglomerates that were not 
disrupted by the SDS. To confirm the nature of the band in highlighted section 2, another 
gel was run with the band from the first gel cut and placed in the sample well of the second 
gel. It was possible to see that the bands appear around the 26 kDa marker in the second 
gel and no bands corresponding to the monomer molecular mass appeared, confirming the 
protein cross-linking hypothesis and that the proteins present in those bands were 
covalently linked rather than just being a protein agglomerate. Further analysis is required 
in order to determine if acrolein was responsible for the cross-link. Interestingly, the fourth 
lane in the gel displayed in Figure 2.4 (2h, 14mM) shows bands in highlighted section 2 
and 3 but the band at the lysozyme molecular weight seemed to disappear. This can be 
correlated with spectrum in Figure 2.3B, where native lysozyme peak disappeared and a 
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new range of peaks appeared that do not correspond to simple acrolein adducts, which may 
also be related to the protein cross-linking. Gel bands from Figure 2.4 were excised from 
the gel, digested with trypsin and analysed by LC-MS/MS for characterization and 
localization of the acrolein modifications. Due to the difficulty in separating the two bands at 
15-20 kDa, these were cut and analysed together. Trypsin cleaved lysozyme at lysine (K) 
and arginine (R) amino acid residues and the digested peptides were then separated by 
liquid chromatography and analysed by MSMS. Initially MASCOT software [246] was used 
to identify peptides modified with acrolein, and each potential modification was also 
confirmed by manual analysis of the MS/MS spectrum (Figure 2.5). This bottom-up 
approach allowed the identification of 5 peptides from lysozyme modified by acrolein, based 
on the peptide molecular weight, mass/charge ratio and charge of the peptide ion, ion score, 
and LC retention time. The majority of acrolein adducts occurred at cysteine residues, 
although some lysine adducts were also identified (Table 2.1). 
 
Table 2.1. Modification of lysozyme by acrolein. 
Modified 
Residues 





























































































 1390.70 464.4 (3+) 30 31.08 
a (subscript) – amino acid position in the mature protein for the start and end residues. 





Figure 2.5. MS/MS spectra of lysozyme tryptic peptide. CELAAAMK modified on a cysteine 
residue by acrolein (58 Da). (A) The y and b ions indicated by the arrows confirm the peptide 
sequence and the modification on the cysteine residue. (B) x-axis adjusted to 50-150 Da for 
immonium ions identification: leucine (L) at m/z 72 Da and 86 Da, lysine (K) at m/z 84 Da and 129 
Da, glutamic acid (E) at m/z 102 Da, methionine (M) at m/z 104 Da and acrolein-modified cysteine 




Peptide fragmentation is not often a clean process and the spectrum may show peaks 
from side chain cleavages (generating y- and b-ions) and internal fragments. This makes 
the analysis more complex and increases the difficulty of reading the peptide sequence. In 
the example shown in Figure 2.5A it was possible to sequence the peptide and confirm the 
modification identified previously by MASCOT database search. This bottom-up proteomic 
approach allowed us to identify 8 amino acid residues modified by acrolein: Cys6, Cys30, 
Cys64, Cys76, Cys80, Lys96, Cys155 and Lys116. This information corroborates the intact 
protein analysis where up to 8 acrolein molecules adducted per protein were identified 
(Figure 2.3A). One lysozyme peptide (NLCNIPCSALLSSDITASVNCAK) was found to 
contain 3 acrolein adducts, at Cys76, Cys80 and Lys96. 
The immonium ion (breaking of two bonds in the peptide either side of the amino acid 
residue) of each amino acid residue can be seen in an MS/MS spectrum and these are 
helpful for their identification. In case of modification, the immonium ion is not seen in the 
spectrum due to the structure and mass change of the amino acid residue. Some amino 
acids, like tryptophan (W), proline (P) and histidine (H), give a strong immonium ion signal 
while others do not give much information. Figure 2.5B shows the same MS/MS spectrum 
with x-axis adjusted to 50-150 Da where the immonium ions can be identified. It was 
possible to identify the immonium ion for leucine (L) at m/z 72 Da and m/z 86 Da, for lysine 
(K) at m/z 84 Da and m/z 129 Da, for glutamic acid (E) at m/z 102 Da and finally for 
methionine (M) at m/z 104 Da, confirming the presence of these amino acid residues in the 
peptide and so corroborating the results from the analysis of b- and y-ions. Alanine (A) and 
cysteine (C) immonium ions do not give strong MS signals, hence they are not usually 
observed in the spectrum. Additionally, a peak at m/z 134 Da was identified as cysteine 
immonium ion (76 Da) plus the acrolein modification (58 Da), which can be used as a 
diagnostic fragmentation product of acrolein-cysteine adducts. The same approach was 
applied to the other modified peptides and two diagnostic fragments were consistently 
observed at m/z 134.06 Da and m/z 117.04 Da for acrolein-cysteine adducts, while acrolein-
lysine adducts gave diagnostic fragments at m/z 142.12 and m/z 159.15 (Figure 2.6). These 
fragment products are aldehyde- and amino acid residue-specific, which make them 
potential diagnostic ions to be used with targeted methods for the detection of these 





Figure 2.6. Proposed structures of the diagnostic ions found for the reduced acrolein 
modifications on lysine and cysteine. 
 
2.3.2. Human serum albumin lipoxidation analysis by LC-MS/MS 
As lysozyme had been used as a model system, once the protocols had been optimized 
the methodology developed was then tested on a biologically relevant protein, human 
serum albumin (HSA).This is most abundant protein in human blood, responsible for 
transportation of different molecules such as hormones and fatty acids and. therefore likely 
to be susceptible to adduct formation. 
 
2.3.2.1. Acrolein 
As previously described, to increase the efficiency of the reaction between the lysozyme 
and the aldehyde, the disulfide bonds on the protein were reduced with dithiothreitol (DTT). 
However, in these experiments the analysis was performed on unreduced HSA, which 
should better represent the protein in the organism. HSA was reacted with acrolein at 4, 8 
and 14 mM and for 2h, as these were the optimum conditions for the lysozyme experiments. 
Similarly, the reaction products were reduced by sodium borohydride to improve the 
adducts’ stability. 
The analysis of acrolein-HSA adducts by direct infusion mass spectrometry of the intact 
protein was not possible, probably due to the size of the protein. Hence to investigate the 
HSA modifications by acrolein, a bottom-up approach was applied, the same method as 
described for lysozyme. This allowed the identification of amino acid sequence and the 
acrolein modified amino acid residues. Acrolein-treated HSA as well as the native HSA were 





Figure 2.7. SDS-PAGE (denaturing gel electrophoresis) results for human serum albumin. 
Untreated and treated HSA with acrolein at 4 mM, 8 mM or 14 mM for 2 hours. Gel stained with 
Coomassie blue staining. The highlighted section boxed in white was cut out for further analysis. 
The molecular weight of Human serum albumin is 66,437 Da, according to the amino 
acid sequence. The protein appears on the gel between the markers 50 kDa and 75kDa. 
The gel run was followed by in-gel trypsin digestion of the main bands. The resulting 
peptides were then separated by liquid chromatography and analysed by MS/MS. MASCOT 
analysis identified 11 acrolein modifications on lysine (K), histidine (H) and cysteine (C) in 
11 different peptides (Table 2.2), based on peptide molecular wright, mass/charge ratio and 
charge of the peptide ion, ion score and LC retention time. These modifications were 
confirmed by manual analysis of the tandem mass spectrometry (MS/MS) data. De novo 
sequencing of each peptide confirmed the amino acid sequence as well as the location of 
the modification on specific amino acid residues. An example of this approach is given in 
Figure 2.8 for the amino acid sequence KQTALVELVK identified as modified by a reduced 
acrolein adduct on a lysine residue.  
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Table 2.2. Modifications of human serum albumin by acrolein. 
Modified 
Residues 











His67 S65LH+58TLFGDK73 1074.57 359.2 (3+) 43 28.51 
Lys137 K137+58YLYEIAR144 1112.62 557.3 (2+) 16 27.69 
His146 R145H+58PYFYAPELLFFAK159 1956.03 653.0 (3+) 66 41.35 
Lys262 A258DLAK+58YICENQDSISSK274 1998.96 667.3 (3+) 73 31.29 
Lys276 Y263ICENQDSISSKLK276+58 1741.86 581.6 (3+) 109 26.71 
His288 S287H+58CIAEVENDEMPADLPSLAADFVESK313 3031.38 1011.5 (3+) 61 42.41 
His338 R337H+58PDYSVVLLLR348 1524.88 509.3 (3+) 83 34.59 
Cys392 Q390NC+56ELFEQLGEYK402 1655.75 829.4 (2+) 42 41.14 
Lys414 K414+58VPQVSTPTLVEVSR428 1696.97 566.3 (3+) 59 30.89 
Lys525 K525+58QTALVELVK534 1185.73 396.3 (3+) 52 28.84 
Lys574 K574+58LVAASQAALG584 1198.73 600.4 (2+) 62 33.67 
a (subscript) – amino acid position in the mature protein for the start and end residues. 
b (superscript) – mass difference corresponding to the modification on the affected residue (shown in red). 
 
 
Figure 2.8. MS/MS spectra of human serum albumin tryptic peptide. KQTALVELVK modified on 
a lysine residue by acrolein (58 Da). The y and b ions indicated by the arrows confirm the peptide 
sequence and the modification on the cysteine residue. Immonium ions for acrolein-modified lysine 
found at m/z 142 Da. 
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It was possible to sequence the peptide and confirm the modification identified by 
database search. Mainly histidine and lysine residue were found to be modified and only 
one cysteine: His67, Lys137, His146, Lys262, Lys276, His288, His338, Cys392, Lys414, 
Lys525 and Lys574. This contrasts with  lysozyme, where mainly cysteine residues were 
found to be modified; this difference may be due to the DTT reduction which generates 
cysteines in the free thiol form, instead of being in disulfide bonds, and therefore these are 
available to react with the acrolein. In its native state HSA has 17 disulfide bonds and only 
one free cysteine, which is not the cysteine that was found to be modified, suggesting that 
this cysteine was made available for reaction possibly by rearrangement of albumin after 
lysine modification and the only free cysteine residue is well buried and protected in the 
protein’s structure. Figure 2.8 shows an example of an HSA peptide modified by acrolein 
on Lys525, where the peptide could be sequenced using the b and y fragment ions. The 
modified lysine immonium ion was also detected at m/z 142.12, which is an additional 
diagnostic fragmentation product of acrolein-lysine adduct not observed in section 2.3.1. 
HSA peptide analysis provided information on acrolein-histidine modifications and a 
diagnostic fragmentation product was found at m/z 168.11 Da. The structure of these two 
ions is in Figure 2.9, which is an update on all the diagnostic ions found for acrolein 
modifications.  
 
Figure 2.9. Proposed structures of the diagnostic ions found for the reduced acrolein 
modifications on lysine, cysteine and histidine. 
These fragment products are aldehyde- and amino acid residue-specific, which makes 
then potential diagnostic ions to be used with targeted methods for the detection of these 
modifications in more complex mixtures such as biological samples. Section 2.3.3 describes 




The lipoxidation of human serum albumin by another short-chain aldehyde was also 
performed. 4-hydroxy-hexenal (HHE), the 6-carbon analogue of the well-studied HNE was 
used to treat HSA for 2 hours at 8 and 16 mM. The same mass spectrometry approach was 
used and the HHE-modified HSA, as well as the untreated protein, were separated by 15% 
SDS-PAGE. HSA ran in the gel between the markers for 55 kDa and 72 kDa according to 
its expected molecular weight of 66.4 kDa, and this region is highlighted in Figure 2.10. 
 
 
Figure 2.10. SDS-PAGE (denaturing gel electrophoresis) results for human serum albumin. 
Untreated and treated HSA with HHE at 8 mM or 16 mM for 2 hours. Gel stained with Coomassie 
blue staining. The highlighted section boxed in white was cut out for further analysis. Arrows identify 
possible protein crosslinking. 
Following the same proteomic approach previously described, including in-gel tryptic 
digestion and analysis of the peptides by LC-MS/MS. MASCOT analysis identified 12 HHE 
modifications on lysine (K), histidine (H), cysteine (C) and arginine (R) residues distributed 
in 14 different peptides (Table 2.3), based on peptide molecular wright, mass/charge ratio 




Table 2.3. Modifications of human serum albumin by 4-hydroxyl-hexenal (HHE). 
Modified 
Residues 











Cys75 74LC+96TVATLR81 971.55 486.76 (2+) 27 35.62 
Cys124 115LVRPEVDVMC+114TAFHDNEETFLK136 2706.30 677.59 (4+) 29 31.91 
Cys124 115LVRPEVDVMC+114TAFHDNEETFLKK137 2834.39 709.61 (4+) 32 29.62 
Lys137 137K+78YLYEIAR144 1132.63 567.32 (2+) 15 29.21 
Cys245 241VHTEC+114CHGDLLECADDR257 2085.86 522.46 (4+) 44 23.89 
Cys245 241VHTEC+114CHGDLLEC*ADDRADLAK262 2584.14 647.04 (4+) 47 26.26 
His247 241VHTECCH+114GDLLEC*ADDRADLAK262 2584.14 647.04 (4+) 33 26.47 
Cys265 263YIC+114ENQDSISSK274 1499.68 750.85 (2+) 29 22.82 
Cys279 275LKEC*C+114EKPLLEK286 1602.84 535.28 (3+) 40 20.46 
His288 287SHC+114IAEVENDEMPADLPSLAADFVESK313 3030.38 758.61 (4+) 25 39.59 
Cys360 360C+114CAAADPHEC*YAK372 1551.62 776.80 (2+) 45 22.83 
Arg410 403FQNALLVR+96YTK413 1447.82 483.62 (3+) 22 32.98 
His464 446MPC*AEDYLSVVLNQLCVLH+114EK466 2574.25 859.10 (3+) 40 46.30 
Cys477 473VTKCC+114TESLVNR484 1465.73 489.59 (3+) 39 24.61 
Cys477 476CC+114TESLVNR484 1137.52 569.75 (2+) 59 28.67 
a (subscript) – amino acid position in the mature protein for the start and end residues. 




These modifications were confirmed by manual analysis of the tandem mass 
spectrometry (MS/MS) data and de novo sequencing of each peptide confirmed the amino 
acid sequence, as well as the location of the modification. Mainly cysteine and histidine 
residues were found to be modified and only one lysine and one arginine: Cys75, Cys124, 
Lys137, Cys245, His247, Cys265, Cys279, His288, Cys360, Arg410, His464 and Cys477. 
The HHE-modified immonium ions of these residues were also detected and as 
previously described, these were hypothesized to be reporter ions for these modifications. 
Diagnostic fragments were observed at m/z 215.18 and 243.17 Da for HHE-lysine adducts 
generated by Michael addition, at m/z 197.16, 180.14 and 179.15for HHE-lysine adducts 
generated by Schiff base, at m/z 224.14 Da for HHE-histidine adducts and at m/z 226.16 
Da for HHE-arginine adducts generated by Michael addition at m/z 208.14 Da for HHE-
arginine adducts generated by Schiff base. Figure 2.11 shows the proposed structures for 
these aldehyde- and amino acid residue-specific reporter ions. These could be used to 
develop targeted label free mass spectrometry approaches such as MRM (multiple reaction 
monitoring). 
 
Figure 2.11. Proposed structures of the diagnostic ions found for 4-hydroxy-hexenal (HHE) 
modifications on lysine (A), histidine (H) and arginine (R).  
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2.3.3. Developing an MRM approach as a potential diagnostic tool for acrolein-HSA 
modifications 
The detection and analysis of lipoxidation adducts in biological samples is challenging 
due to their low abundance. Even though mass spectrometry is a good technique to detect 
the mass shift caused by the adducts, the data output is much greater in complex samples. 
To overcome this issue, new targeted methods are needed to simplify the detection of 
adducts in biological samples such as human plasma. Therefore, a multiple reaction 
monitoring (MRM) approach was developed to detect acrolein modifications on human 
serum albumin (Table 2.4).  
 
Table 2.4. MRM transitions for human serum albumin peptides unmodified or modified by acrolein.  









337RHPDYSVVLLLR348 509.3 (3+) 
564.3 B4 35.0 40 
885.4 B7 35.0 40 
168.1 RI 41.0 35 
337RHPDYSVVLLLR348 489.9 (3+) 
756.3 B6 35.0 60 
613.4 Y5 35.0 60 
414KVPQVSTPTLVEVSR428 566.3 (3+) 
511.3 B4 35.0 70 
798.5 B7 35.0 70 
159.1 RI 55.0 60 
414KVPQVSTPTLVEVSR428 547.3 (3+) 
589.3 Y5 35.0 10 
740.4 B7 35.0 25 
574KLVAASQAALG584 600.4 (2+) 
541.4 B5 35.0 20 
898.5 B9 35.0 20 
142.1 RI 55.0 25 
574KLVAASQAALG584 507.3 (2+) 
712.4 B8 35.0 25 




Transitions were designed based on the MS/MS data on acrolein-treated HSA tryptic 
digests obtained in Section 3.2. The m/z of the modified peptides was set as the parent ion. 
Ions from the b or y fragmentation series were used as the product ions for each chosen 
peptide, generally selecting the ions with highest intensity. The reporter ions previously 
described in 3.2 were also selected for each modified peptide with respect to its modified 
residue. The collision energy (CE) and dwell time of each transition were optimized by trial 
and error. 
Three peptides were shown to be selective for the identification of acrolein adducts on 
HSA: KLVAASQAALG modified on the lysine residue (Lys574), RHPDYSVVLLLR modified 
on the histidine residue (His338) and KVPQVSTPTLVEVSR modified on the lysine residue 
(Lys414). For each, three transitions were selected for the modified and two transitions for 
the corresponding unmodified peptide. Specifically, the transitions using the reporter ions 
were of most interest as these are novel and have never been reported for identification of 
acrolein adducts. The reporter ions used were two lysine modifications specific (m/z 142.1 
and m/z 159.1) and one histidine modification specific (m/z 168.1). Figure 2.12 shows the 
XICs for the three transitions selected for the modified peptide in untreated and in vitro 
acrolein-treated human serum albumin. 
The first two transitions studied for each peptide were chosen here as peptide-specific 
ion transitions. These were only detected in the acrolein treated sample, not in the untreated 
control sample, except for the peptide in Figure 2.12C (KVPQVSTPTLVEVSR). Regarding 
the transitions including the reporter ions, m/z 600.4→142.1 and m/z 509.3→168 proved to 
be excellent at detecting lysine and histidine modified peptides, respectively. These 
generated high intensity signal peaks for the treated samples while not being detected in 
the untreated sample. Additionally, these ions eluted at the same retention time as the 
peptide-specific ions, supporting the hypothesis of these being selective of their acrolein-
modified residue. However, the transition m/z 566.3→159.1 gave a relatively low intensity 





Figure 2.12. Multiple reaction monitoring (MRM) for the identification of three human serum 
albumin peptides modified by acrolein. Untreated and treated HSA with ACR at 8 mM for 2 hours. 
KLAASQAALG modified on lysine residue (A), RHPDYSVVLLLR modified on histidine residue (B) 
and KVPQVSTPTLVEVSR modified on the lysine (C).  
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The same MRM method was used to study the effect of different acrolein concentration 
treatments in amount of modified-peptide detected. Figure 2.13 shows a plot of the area 
under the curve as the signal intensity for the peaks detected of each of the modified-peptide 
transitions after acrolein treatment at 4, 8 and 14 mM. Transitions for KLVAASQAALG 
(Figure 2.13A) showed an interesting pattern not observed for the other peptides. The 4 
mM treatment resulted in the lowest amount of modified peptide while 8 mM appeared to 
be producing the highest, instead of 14 mM as for the other two peptides, confirmed by the 
three transitions tested. Once more, treatment of HSA with 4 mM acrolein produced fewer 
RHPDYSVVLLR modified peptides when compared to higher concentration treatments. 
Interestingly, these showed very similar intensities for this peptide and the transition 509.3 
→ 168.1 presented the highest signal intensity of all three transitions for this modified 
peptide (Figure 2.13B). The product ion m/z 511.3 for KVPQVSTPTLVEVSR was detected 
at higher intensity than m/z 789.5 for all the concentrations studied. For both transitions, 4 
and 8 mM resulted in similar levels of modification and thus similar signal intensity. The 
highest concentration treatment at 14 mM resulted in higher levels of this modified peptide 
in comparison with the lower concentration treatments mainly detected by the ion m/z 511.3. 
The reporter ion m/z 159.1 was detected with the highest intensity at 4 and 14 mM while at 





Figure 2.13. MS/MS signal intensities produced by three human serum albumin peptides 
treated with different concentrations of acrolein (0 mM, 4 mM, 8 mM and 14 mM). Two 
transitions for peptide-specific product ions (green and blue) and one transition for residue and 
modification-specific report ion (yellow). KLAASQAALG modified on lysine residue (A), 
RHPDYSVVLLLR modified on histidine residue (B) and KVPQVSTPTLVEVSR modified on the lysine 
(C). (n=1).  
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2.3.4.  Testing the developed MRM approach for acrolein-HSA modifications on 
pooled human plasma 
The next step was to test these transitions on an acrolein-treated human plasma pool 
with the goal of detecting acrolein-modified HSA within a complex mixture of proteins. 
Plasma pooled from healthy volunteers was diluted to 1:4 to give a human serum albumin 
concentration of roughly 10 mg/mL [302] and treated with acrolein as described for HSA 
previously. Figure 2.14 shows the XICs for the MRM analysis of the untreated plasma and 
acrolein-treated plasma at 8 mM. The MRM method used was the same as described in 
Table 2.4. 
All 14 transitions (for treated and untreated peptides) were successfully detected in 
plasma, although only the XICs for the transitions for the modified peptides are shown in 
Figure 2.14, for both treated and untreated plasma. These transitions eluted at the same 
retention time as observed for HSA supporting the hypothesis that these are selective for 
acrolein-albumin modifications. Here it is evident that the MRM method developed can be 
applied to complex biological samples of human plasma, without the need for much sample 
preparation as it was used as whole and no proteins were precipitated from the plasma. 
Just as observed for HSA, all the three transitions tested for KLAASQAALG were 
detected in the acrolein-treated plasma while not being detected in the untreated plasma 
showing their power to detect this lysine modification not only in HSA but also in human 
plasma (Figure 2.14A). Once more, the diagnostic ion m/z 142.1 proved to be a reporter 
ion for lysine modification even in a complex sample. In the XIC for RHPDYSVVLLLR, the 
peptide-specific transitions 509.3 → 885.4 and 509.3 → 564.3 gave rise to two peaks 
instead of one as observed for HSA (Figure 2.14B), suggesting that in plasma there are 
two precursors sharing the same mass and producing the same fragmentation product, 
varying only on retention time. When compared with the untreated plasma, this peptide 
showed a small increase in the signal intensity for the peptide-specific product ions while 
the reporter ion clearly shows an increase in intensity upon acrolein treatment. The 
transitions 509.3 → 168.1, using the report ion, was the best at detecting this histidine 
modification in the plasma. On the other hand, the peptide KVPQVSTPTLVEVSR showed 
that the reporter ion for lysine modification at m/z 159.1 was detected in the treated and the 
untreated plasma samples at roughly the same intensity (Figure 2.14C). This pattern was 
also observed on the analysis of HSA, evidently showing that this ion is not selective for 
lysine modification on this particular peptide. Nevertheless, the transitions 509.3 →168.1 
and 600.4→142.1, for RHPDYSVVLLLR modified on the histidine and KLVAASQAALG 
modified on the lysine residues respectively, were detected at high intensities in the 
acrolein-treated plasma and at very low intensities in the untreated plasma, as described 
above. The detection of these in the control sample might be expected at low intensities 
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due to in vivo albumin-acrolein modifications that could already be present in the plasma at 
the time of collection. 
 
Figure 2.14. Multiple reaction monitoring (MRM) for the identification of three human serum 
albumin peptides modified by acrolein in human plasma. Untreated and treated human plasma 
with ACR at 8 mM for 2 hours. KLAASQAALG modified on lysine residue (A), RHPDYSVVLLLR 
modified on histidine residue (B) and KVPQVSTPTLVEVSR modified on the lysine residue (C).  
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The same MRM method was tested to detected acrolein-modified human serum albumin 
peptides in plasma after different acrolein concentration treatments. Figure 2.15 shows a 
plot of the area under the curve as the signal intensity for the peaks detected of each 
modified-peptide transition after plasma being treated with acrolein at 4, 8 or 14 mM. The 
transitions studied were sensitive to changes in the acrolein concentration treatment and 
different amounts of the modified peptides were detected in the plasma. Transitions for 
KLVAASQAALG were detected with the lowest intensity for 4 mM while 8 and 14 mM 
produced the highest intensity signals and at very similar levels (Figure 2.15A). The 
transitions 600.4 → 898.5 and m/z 600.4 →142.1 showed the best signal intensity out of 
the three tested for this peptide. Interestingly for RHPDYSVVLLLR, the transitions 509.3 → 
885.4 and 509.3 → 564.3 were detected at the same levels for both 4 and 8 mM (Figure 
2.15B). Only the transition 509.3 → 168.1 detected the increase of this modified peptide 
between these treatments. The lowest signal intensity detected for all of this peptide 
transitions were detected after the 14 mM treatment. The transition 566.3 → 511.3 for 
KVPQVSTPTLVEVSR detected an increase in this modified peptide at 8 and 14 mM in 
comparison with the control, however the signal for 14 mM was lower than for 8 mM (Figure 
2.15C). The other two transitions showed lower intensity signals overall. The transition 
566.3 → 159.1 was detected at roughly the same intensity at all concentration treatment 





Figure 2.15. MS/MS signal intensities produced by three human serum albumin peptides 
identified in human plasma after treatment with different concentrations of acrolein (0 mM, 4 
mM, 8 mM and 14 mM). Two transitions for peptide-specific product ions (green and blue) and one 
transition for residue and modification-specific report ion (yellow). KLAASQAALG modified on lysine 
residue (A), RHPDYSVVLLLR modified on histidine residue (B) and KVPQVSTPTLVEVSR modified 




In this study, the modification of proteins by two aldehydes, acrolein and 4-hydroxy-
hexenal, was evaluated as a model of lipoxidation adducts that may occur in inflammatory 
diseases. The first aim was to map the sites of modification using LC-MS/MS and identify 
potential diagnostic ions for adducts with different amino acid residues. To ensure extensive 
adduct formation and to allow a better MS characterisation of the adducts formed, high and 
non-physiological concentrations of the aldehydes were used, even though it has been 
suggested that local levels of aldehydes can be higher than plasma levels [303]. Acrolein 
modifications were found in 5 lysozyme and 11 HSA peptides and were predominantly 
formed by Michael addition reactions with cysteine, histidine and lysine amino acid residues, 
based on the mass increases of 56 Da or 58 Da for unreduced or reduced forms 
respectively, despite the potential for this aldehyde also to form Schiff’s base adducts. 
Additionally, 5 diagnostic ions for acrolein adducts with cysteine, histidine and lysine were 
consistently observed in the MS/MS spectra of modified peptides. HHE modifications were 
found in 14 HSA peptides, with adducts identified on cysteine, lysine, histidine and arginine 
residues, based on the mass increase of 114 Da or 96 Da for Michael addition and Schiff 
base, respectively. In addition, 8 potential diagnostic ions for HHE adducts with lysine, 
arginine and histidine were observed. 
The bottom-up proteomic approach allowed identification of 8 lysozyme residues 
modified by acrolein: Cys6, Cys30, Cys64, Cys76, Cys80, Lys96, Cys155 and Lys116, 
which fitted well with the 8 acrolein molecules found covalently bound per lysozyme by intact 
protein analysis. For HSA, mainly histidine and lysine residues were found to be modified: 
His67, Lys137, His146, Lys262, Lys276, His288, His338, Lys414, Lys525 and lys574. The 
high number of cysteines modified in lysozyme is likely to result from the reduction prior to 
reaction with the acrolein. This also confirms that free cysteine residues are highly 
susceptible to acrolein modification. For HSA the reduction was omitted and since only one 
single cysteine (Cys34) is in the free thiol form, modifications of lysine and histidine were 
consequently more prevalent. The tryptic peptide containing the HSA free cysteine was 
challenging to detect, as it is a long peptide that gives low ion intensity. Some of the peptides 
identified contained missed cleavages owing to modification of lysine residues, which could 
complicate relative quantification against untreated samples due to generation of different 
peptides. A number of the lysines and histidines observed to be modified have been 
reported to be susceptible to electrophilic attach, and the occurrence of acrolein-protein 
adducts has previously been reported both in vitro and in vivo [74], including studies of 
acrolein modification of albumin [304]. The same bottom-up proteomic approach was used 
to identify 12 HSA residues modified by HHE: Cys75, Cys124, Lys137, Cys245, His247, 
Cys265, Cys279, His288, Cys360, Arg410, His464 and Cys477. Two residues were found 
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to be modified by both aldehydes (Lys137 and His288), suggesting highly susceptibility of 
these to lipoxidation.  
HSA is highly abundant, and its modification might be seen as a defence mechanism to 
prevent the damage of other critical and less abundant proteins. However, it is still important 
to consider the potential physiological consequences of lipoxidation, as human serum 
albumin has many biological functions that could as well be affected by modification. For 
example, His67 was readily modified by acrolein, and is one of the residues contributing to 
the zinc binding site on albumin [20, 305, 306]. Zinc is required for essential intra and 
extracellular enzymes function. The zinc site on albumin is formed by the side chains of 
His67 and Asn99 from domain I, and His247 and Asp249 from domain II [305]. So 
modification on any of these residues could disrupt zinc binding to and transport by albumin. 
As decreased binding of zinc can affect fatty acid binding to albumin [307], this modification 
could result in increased levels of fatty acids in the blood and contribute to plasma lipid 
changes in cardiovascular diseases and diabetes. While acrolein was found to modify many 
relevant residues, under physiological conditions the profile of the modifications could be 
different. The data presented here, and previous literature suggest that the cysteine 
residues would be major sites of modification [285, 308, 309]. Furthermore, the sequence 
coverage obtained was incomplete (typically 80-85%) and some potential modification sites, 
such as the N-terminal, were not covered; hence no conclusions can be drawn about these 
sites. Nevertheless, this shows the importance of identifying the correct location of protein 
modifications and understand their relevance to disease. 
A major aim of the study was to identify the diagnostic ions for the aldehyde adducts 
that could subsequently be used in targeted mass spectrometry approaches such as 
multiple reaction monitoring (MRM), or to confirm peptide identifications. At lower m/z range 
of the MS/MS spectra, immonium and related internal fragmentation ions specific to amino 
acids present in the peptides can be observed; these ions are potential MS/MS reporter 
ions for modified amino acid residues. From the MS/MS spectra of the modified tryptic 
peptides, several potential diagnostic ions for the acrolein (Figure 2.9) and for HHE (Figure 
2.11) modifications were identified. While protein-acrolein adducts have been extensively 
studied previously [308, 310, 311], the focus was on finding these reporter ions since it 
appears that there are no specific studies of this kind aiming to improve the detection of 
these modifications. The success of the application of these reporter ions on novel detection 
methods corresponds to the second aim of this chapter and it is discussed in detail below. 
In summary, the first aim has provided new data on the sites of modification in two model 
proteins by acrolein and HHE. It has also identified novel diagnostic fragment ions for 
acrolein and HHE adducts of cysteine, lysine, histidine and arginine. This study shows the 
power of combined use of direct infusion and LC-MS/MS to identify the type, the number 
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and the location of protein adducts. The MS approaches described here could also be 
applied to study other types of adducts as biomarkers of lipoxidation in cells and tissues 
under pathophysiological conditions. The acrolein diagnostic ions were used in targeted 
mass spectrometry approaches, such as multiple reaction monitoring, to identify and 
quantify aldehyde adducts. 
For the second aim of the study in this chapter, an MRM approach was developed to 
detect albumin-acrolein adducts in human plasma. The success of developing any MRM 
method depends upon selection of the most appropriate peptides and their respective 
transitions. Transitions were designed based on MS/MS data resulting from bottom-up 
analysis of acrolein-treated HSA. To ensure that the MRM method could be applied to 
biological samples, multiple transitions were established per peptide owing to the 
complexity of human plasma [211]. The m/z of the modified peptide was set as the precursor 
ion. Ions from the b and y type fragmentation chosen based on the highest intensity 
fragmentation ions present in the MS/MS spectra [312], as well as the report ions for 
acrolein modification, were used as the product ions. The bottom-up data used to choose 
these ions was acquired on a Q-TOF while the MRM data was acquired on a triple 
quadrupole, which could explain why some of the transitions did not work as well to detect 
the modifications with the MRM method [300, 312]. No peptide containing modified cysteine 
was used in the MRM method, as cysteine gives weak immonium ion signals and 
consequently its corresponding report ion did not work well in this method development. 
Two of the three peptides used in the method (RHPDYSVVLLLR and 
KVPQVSTPTLVEVSR) contained at least one proline residue and it has been suggested 
that peptides containing this residue are able to produce higher intensity MS/MS signals 
facilitating their detection [313]. The three peptides used were shown to be selective and 
provided good intensity peaks indicating highly sensitive detection of HSA-acrolein 
modifications. 
After the method development performed on in vitro modified HSA, this was tested on 
in vitro acrolein-treated plasma. Previous studies reported that due to the large variety of 
proteins present in plasma, the MRM approach detected a large amount of noise and 
interference, and better results were obtained when the MRM method was run on plasma-
extracted albumin instead of the whole plasma [314]. However, for our method, no sample 
preparation was used apart from plasma dilution before treatment and the method proved 
to be sensitive with minimal background noise. 
One issue detected in the plasma but not in the HSA data was the double peak detected 
by the transitions 509.3 → 885.4 and 509.3 → 564.3 for RHPDYSVVLLLR. This might mean 
that another precursor ion with the same mass m/z 509.3 is also producing the same 
product ions. However, this does not interfere with the identification of the modified peptide 
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because another transition was used in parallel using the reporter ion m/z 168.1, which has 
previously been shown to be selective for acrolein-histidine modification. This confirmed the 
retention time consequently identifying which of the two peaks correspond to our peptide of 
interest. 
One hypothesis tested with this method was that increasing the concentration of acrolein 
treatment on HSA, would consequently increase the level of acrolein modifications. 
However, this hypothesis was not confirmed. This could be due to the level of acrolein-
induced albumin crosslinking that occurs during the different treatments. Unfortunately, 
crosslinking was not studied, and this could not be confirmed. Acrolein protein-protein 
cross-linking has been previously studied [315, 316], including in proteins such as Hsp90 
which has a role in the response to oxidative stress [317], but none of these were studied 
using mass spectrometry, as opposed to the interchain cross-linking of DNA mediated by 
acrolein which has been studied by MALDI-TOF [318, 319]. The same hypothesis could 
possibly explain why at 8 mM acrolein treatment similar or slightly higher intensity peaks 
were detected than at 14 mM treatment for the peptides RHPDYSVVLLLR and 
KLAASQAALG. This could be because acrolein modifications at His338 and Lys574 are 
more likely to induce crosslinks than modifications at Lys414, and therefore there would be 
fewer of these modified peptides resulting from enzymatic digestion. However, without 
further studies, it is not possible to confirm this hypothesis, and the evidence supporting the 
formation of acrolein-induced albumin crosslinking is a limitation of this work. 
A thorough validation process of the transitions used in this method would be desirable 
to be able to accurately quantify the level of acrolein-albumin adducts. For example, the 
samples would need to be spiked with a known concentration peptide to serve as an internal 
standard [300]. Once the transitions are accurately validated using in vitro acrolein-treated 
plasma from healthy volunteers, it would be ideal to test it with plasma from patients with a 
pathophysiological conditions known to result in increased acrolein-albumin adducts such 
as cardiovascular disease, type 2 diabetes mellitus, Alzheimer’s disease and brain 
infarction [314, 320] to fully validate the method. Unfortunately, there was not enough time 
to source such samples and carry out further investigation. 
In conclusion, it is evident that an MRM approach for acrolein-albumin adducts has the 
potential to become a robust method with further validation. Many pathophysiological 
conditions result in increased levels of oxidative stress, and other RCS-albumin adducts as 
biomarkers for oxidative stress have repeatedly been suggested in recent years [302, 314]. 
The lack of sensitive, specific and validated analytical assays has held back progress in the 
use of these adducts as biomarkers of oxidative stress. LC-MS/MS analysis, specially 
targeted methods as MRM, provide a promising solution to this need for sensitive and highly 
specific measurements of RCS-albumin adducts. The method developed in this chapter has 
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identified successful and promising MRM transitions, specially the novel transitions using 
report ions which proved to be highly selective for acrolein modification. This provided an 
approach that could potentially be used in the future for detection of acrolein-albumin 
adducts in human plasma, for example from diabetic patients or lung cancer since acrolein 














Chapter 3. Synthesis of 2-chlorohexadecanal and its 





In inflammation, neutrophils are activated and release numerous bioactive and anti-
microbial molecules, including partially reactive oxygen species such as hydrogen peroxide. 
Hydrogen peroxide is a substrate of the enzyme myeloperoxidase (MPO), which in the 
presence of chloride ion produces hypochlorous acid (HOCl) [139, 321], a strong oxidizing 
and chlorinating agent. HOCl is primarily responsible for the microbicidal action of 
neutrophils but during chronic inflammation it is able to react with host proteins, nucleic 
acids and lipids [322]. Plasmalogens, which contain a vinyl ether bond, are particularly 
susceptible to reaction with HOCl, resulting in the production of free α-chloroaldehydes 
[142, 143]. Plasmalogens are a subclass of phospholipids found in many cells but are 
particularly enriched in phagocytes such as neutrophils [323]. α-chloroaldehydes have 
previously been reported to accumulate in activated human neutrophils and monocytes 
[138, 324] and to be elevated in human aortic atherosclerotic plaques [147]. Although α-
chloroaldehydes are produced during neutrophil activation, the mechanism by which they 
have an impact on cell function remains to be resolved. The biological activity attributed to 
α-chloroaldehydes may be mediated through metabolism to α-chloro carboxylic acids, 
which have been reported to induce apoptosis [325]. However, α-chloro aldehydes are likely 
to cause direct cellular effects due to their reactive aldehyde group and α-chlorinated 
carbon. A potential mechanism by which α-chloroaldehydes could cause impact in cell 
function is by forming reversible Schiff base adducts with amines in proteins [326]. 
The HOCl oxidation of plasmenylcholine (16:0/18:1) results in formation of 
lysophosphatidylcholine (0:0/18:1) and 2-chlorohexadecanal (2-ClHDA), by far the most 
studied α-chloroaldehyde [138, 146]. 2-ClHDA is known to be involved in pro-inflammatory 
and cell death pathways, making it important to understand the mechanisms underlying 
such roles [151, 152]. Therefore, it is important to understand its metabolism and cellular 
impact. 2-ClHDA has been reported to contribute to atherosclerosis and cardiac dysfunction 
[147, 327] suggesting that this chloroaldehyde in particular is relevant in inflammatory 
diseases. Additionally, it has been reported to activate cyclooxygenase-2 (COX-2), which 
is highly expressed in atherosclerotic lesions, via an NF-kB mediated pathway [151]. MPO 
is also highly expressed in neuroinflammatory diseases, such as Parkinson’s and 
Alzheimer’s diseases, in comparison with normal brain [328, 329], and 2-ClHDA has been 
reported to affect brain function by induction of blood-brain barrier dysfunction (BBB). This 
was shown in primary brain microvascular endothelial cells (BMVEC) on treatment with 
MPO-H2O2-Cl, and in a mouse model, neutrophils released MPO into the 
cerebrovasculature, induced decrease of brain plasmalogen content, formation of 2-ClHDA, 
increased BBB permeability and activated the MAPK cascade in response to systemic 
lipopolysaccharide (LPS) administration [148, 330]. Previous studies suggest that 2-ClHDA 
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causes brain damage by covalent modification of proteins, which impairs function and 
triggers responses associated with oxidative stress [331]. PARK7 (DJ-1), which protect cells 
from oxidative stress, has been identified as a prime target of 2-ClHDA in brain [331]. 
Additionally, DJ-1 has also been reported to form adducts with other electrophilic aldehydes, 
such as HNE and these adducts were found increased in blood from Parkinson’s disease 
patients when compared with healthy controls [332].  
2-ClHDA undergoes redox metabolism via the fatty acid-fatty alcohol cycle, resulting in 
the corresponding alcohol or carboxylic acid [333]. The oxidation to 2-chlorohexadecanoic 
acid (2-ClHA) from 2-ClHDA is dependent on fatty aldehyde dehydrogenase (FALDH) and 
has been demonstrated both in isolated human neutrophils and in vivo systems [150, 333]. 
2-ClHA does not show the neutrophil chemoattractant properties of 2-ClHDA [138] and its 
generation from 2-ClHDA might be considered as a protective pathway. However, 2-HDA 
was found to accumulate in activated monocytes and to induce apoptosis through 
mechanisms involving H2O2 release and ER stress, in monocytic and macrophagic cell 
lines, as well as primary human monocytes [325]. 
Pre-treatment of monocytes with glutathione (GSH) shown to ameliorate the production 
of H2O2 induced by 2-ClHA and reduce the caspase 3 activity, PARP cleavage and CHOP 
expression [325]. GSH is responsible for detoxification of endogenous and exogenous 
potentially toxic electrophiles due to its nucleophilic thiol, which can react with unsaturated 
and halogenated carbons [334, 335]. The α-chlorinated carbon of 2-ClHDA was shown to 
react with the nucleophilic thiol of GSH, resulting in a peptidoaldehyde (FALD-GSH) which 
has been found in activated neutrophils and in plasma of a mouse arthritis model [199]. LC-
MS/MS [336] confirmed the structure of the adduct, which is formed from nucleophilic attack 
at the α-chlorinated carbon by the thiol with loss of chlorine [199]. The dihydrochalcone-
type polyphenol phloretin has also been shown to be able to attenuate the cellular effect of 
2-ClHDA, providing protection against BBB dysfunction, apoptosis and ATP depletion [152]. 
The structure of the adduct of phloretin and 2-ClHDA was confirmed by NMR, and biological 
experiments demonstrated that the adduct did not alter cell function, so this can therefore, 
be considered a detoxification pathway [337].  
2-chlorohexadecanal is not commercially available, thus its synthesis is necessary prior 
to any study on its effect on proteins. Recent studies have used the for reaction of 1-O-
hexadec-enyl-glycerol-3-phosphocholine with HOCl followed by lipid extraction and HPLC 
purification to obtain 2-chlorohexadecanal [151]. This approach proved to be time 
consuming and relatively expensive. In this study, two alternative approaches were tested. 
First, a multi-step reaction was evaluated, consisting of: 1) synthesis of hexadecanal from 
hexadecanol by Corey-Suggs oxidation [338]; 2) acetal protection of the hexadecanal using 
trimethylorthoformate to protect the aldehyde from nucleophilic attack during chlorination; 
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3) chlorination via manganese catalysed chlorination with trimethylsilylchloride; 4) 
deprotection the 2-chloro-methylacetal hexadecanal by mild acid hydrolysis. This was also 
time consuming, although it would allow synthesis of reasonable quantities of the 
chloroaldehyde, and so an alternative one-pot method was investigated using 
trichloroisocyanuric acid (TCCA) as the oxidizing and chlorinating agent with TEMPO 
(2,2,6,6-tetramethylpiperidine 1-oxyl) as a catalyst [339]. All reaction products were 
characterized by 1H NMR. 
Liquid chromatography coupled to tandem mass spectrometry was used to investigate 
protein modifications by 2-chlorohexadecanal. As for chapter 2, lysozyme (14,306 Da), 
which is rich in lysine and cysteine residues, and human serum albumin (66,437 Da), the 
most abundant human plasma protein were used as model proteins. Non-physiologically 
high concentrations of 2-chlorohexadecanl were used to ensure adduct formation as the 
aim was to generate adducts in reasonable abundance in order to characterize the modified 
amino acids and identify potential reporter ions for these modifications which are preferably 
amino acid- and modification-specific and, which could be used to develop targeted 




3.2. Material and Methods 
 
3.2.1. Multi-step synthesis of hexadecanal from hexadecanol 
3.2.1.1. Synthesis of hexadecanal (Corey-Suggs oxidation) 
Into a three-necked round bottom flask, under positive pressure of nitrogen gas, 123.63 
mmol (17.9 g) of pyridinium chlorochromate (PCC) dissolved in 150 mL of dry 
dichloromethane (DCM) was added. The mixture was stirred for 15 min at room 
temperature, then 82.49 mmol (13.4 g) of hexadecanol dissolved in 50 mL of dry DCM was 
added in one portion. The mixture immediately turned black. It was left to stir for 1.5 hours 
at room temperature after which 150 mL of dry diethyl ether was added, and a black tarry 
precipitate formed [338]. The solution was filtered under gravity and the black precipitate 
was washed with dry diethyl ether and wash filtered. The filtrate was then filtered for a 
second time using a sintered funnel loaded with 30g of Florisil® to remove fine particulates. 
The Florisil® was then washed 2 x 30 mL with petroleum ether 60-80/diethyl ether (90:10). 
The organic extracts were evaporated under vacuum and the resulting off-white powder 
was dried in a desiccator. The reaction was monitored by TLC (silica gel 60 F254, Merck, 
Darmstadt, Germany) using pet ether 60-80/ether (90:10) as solvent and the retention factor 
(Rf) for the starting material was 0.1 and for the final product was 0.37. 
 
3.2.1.2. Synthesis of dimethylacetal hexadecanal (protection) 
4.19 mmol of hexadecanal (1 g) from the previous reaction and 8.21 mmol (900 μL) of  
trimethylorthoformate (TMOF) were dissolved in 20 mL of dry methanol. 4.65 mmol of p-
toluene sulfonic acid (0.8 g) was then added. The mixture was stirred under reflux for 4 h at 
70 °C. The reaction was then diluted with 20 mL of pentane, washed with 10 mL of 0.5% 
NaOH solution and the aqueous phase extracted with 3 x 10 mL of pentane. The organic 
phases were combined and dried over MgSO4. The solvent was evaporated under vacuum 
to obtain the hexadecanal methyl acetal as a white solid. The reaction was monitored by 
TLC using n-hexane/ethyl acetate (95:5) as solvent and the Rf of the final product was 0.56. 
 
3.2.1.3. Synthesis of 2-chloro-methylacetal hexadecanal (chlorination) 
MnCl2 (1.5 mmoles, 0.339 g) was weighed into a flask with 10 mL of acetonitrile and 
methanol (50:50) and the mixture stirred until the MnCl2 was completely dissolved. MnO2 
(3.1 mmoles, 0.527 g) and the methyl acetal (3.5 mmoles, 1.14 g) from the reaction above 
were added and the mixture immediately turned black. The stirred mixture was refluxed at 
40 °C for 15 minutes before trimethylsilylchloride (TMSCl) (14.4 mmoles, 3.1 g) was poured 
into the mixture in one portion. The reaction was left to reflux for 42 hours and then it was 
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diluted with 20 mL of hexane. The mixture was diluted with 20 mL of CH2Cl2 and the 
precipitated removed by filtration. The organic phase was washed with 10 mL of 1.5 % 
NaOH solution. The aqueous layer was then extracted with 2 x 10 mL of hexane, and the 
organic phases were combined, dried over MgSO4 and then evaporated under vacuum. 
The reaction was monitored by TLC using pet ether 60-80/dichloromethane (70:30) as 
solvent and the Rf of the final product was 0.28. 
 
3.2.1.4. Acid hydrolysis of 2-chloro-methylacetal hexadecanal (deprotection) 
To 1.25 mmol (400 mg) of 2-chloro-methylacetal hexadecanal dissolved in 5 mL of 
anhydrous CH2Cl2 were added 2.5 mL of 50:50 trifluoroacetic acid (TFA) and water (v/v). 
The reaction was stirred at 37 °C for 48 hours, after which it was diluted with 20 mL of 
CH2Cl2 and washed three times with 20 mL of an aqueous 5% NaHCO3 solution. The 
aqueous phase was re-extracted with CH2Cl2 (3 x 20 mL) and the combined organic phases 
were dried over MgSO4 evaporated in vacuum. The reaction was monitored by TLC using 
hexane/dichloromethane (50:50) as solvent and the Rf of the final product was 0.59. 
 
3.2.2. Direct conversion of alcohol into chloroaldehyde 
3.2.2.1. First attempt 
Hexadecanol (4.12 mmol, 1 g) was dissolved in 20 mL of dichloromethane. 3.3 mmol 
(0.78 g) of trichloroisocyanuric acid (TCCA) and 0.3 mmol (0.0415 g) of TEMPO (catalyst) 
were added to the reaction which was left stirring for one hour at room temperature. The 
product was filtered twice, and a white powder was formed. Reaction was monitored by TLC 
using hexane/dichloromethane (50:50) as solvent. The Rf of the starting material was 0.32 
and for the final product was 0.79. Product was characterized by 1H NMR. 
3.2.2.2. Second attempt 
Hexadecanol (0.5 mmol, 121.2 mg) and TEMPO (0.03 mmol, 4.69 mg) were dissolved 
in 5 mL dichloromethane. The mixture was cooled to 0 °C. TCCA (0.5 mmol, 116.2 mg) was 
added in small portions while stirring. The reaction was left to stir for 10 minutes at 0 °C. 
The reaction was then stirred for additional 30 minutes at room temperature while being 
monitored by TLC using hexane/dichloromethane (50:50) as solvent. The retention factor 
(Rf) for the starting material was 0.25 and for the final product was 0.68. Pentane was added 
and the mixture filtered. The filtrate was then washed three times with 20 mL of water, dried 
over MgSO4 and concentrated under vacuum. The product obtained was a yellow oil that 




3.2.3. 1H NMR analysis 
1H NMR experiments were performed at room temperature on a Bruker spectrometer 
operating at 400 MHz with a 5mm PABBO probe. Spectra were acquired with an 8012.82 
Hz spectral width, 296.6 K data points, a 1s relaxation delay (d1) and 16 scans. Data 
processing was performed using MestReNova (Mnova NMR) programme, version 8.1 
(Mestrelab Research, California, USA). Chemical shifts are given in ppm. The chemical 
shifts were referenced internally to the TMS signal at 0.00ppm. Splitting pattern 
abbreviations are s, singlet; d, doublet; t, triplet; m, multiplet. 
 
3.2.4. GC-FID analysis 
GC-FID analysis was performed using an Agilent HP-5 column (30m, 0.32mm i.d., 
0.25um) with an Agilent Technologies 7829A gas chromatograph. The analysis of the 
multistep reaction was performed with the injector at 250 °C and an isothermal analysis with 
the oven kept at 260 °C with an analysis time of 2 minutes. The analysis of the direct 
conversion products was performed as previously described by Wacker, B.K. et al [336]. 
The injector and the transfer lines were kept at 250 °C. The GC oven was kept at 150 °C 
for 3.5 minutes and increase the temperature at a rate of 25 °C /min to 300 °C. This 
temperature was held for an additional 5 minutes. 
 
3.2.5. Treatment of model proteins with 2-chlorohexadecanal in vitro 
Lysozyme and human serum albumin (1 mg/mL) were first reduced with 100 mM DTT 
for 30 minutes as described in Section 2.2.2. Synthesized 2-chlorohexadecanal was added 
to the protein at treatment concentrations of 8 and 16 mM and allowed to react for 2 hours 
at room temperature. To stabilize adducts, NaBH4 was added to the reaction to a final 
concentration of 5 mM and left for 1 hour at room temperature. 
 
3.2.6. Liquid Chromatography-Mass Spectrometry (LC-MS) Analysis 
Peptides were separated and analysed using an Ultimate 3000 system (Thermo 
Scientific, Hempstead, UK) coupled to a 5600 TripleTOF (ABSciex, Warrington, UK). The 
analysis was performed as previously described by Verrastro et al., 2016 [298] and as 
detailed in section 2.2.6.  
 
3.2.7. Database Search 
The Mascot® probability-based search engine (Matrix Science, London, version 2.4.0) 
was used to interrogate the SwissProt 2017-07 primary database. LC-MS .wiff files of each 
sample were searched for protein identification and oxidative post-translational 
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modifications (oxPTMs). For protein identification, variable modifications of methionine 
oxidation and carbamidomethyl cysteine were used. For the analysis of the lipoxidation 
products, the initial searches additionally used a variable modification list including 2-chloro-
hexadecanal reduced adducts at 258.9 Da and 222.4 Da for arginine, lysine and histidine 
amino acid residues and at 240.4 Da for cysteine amino acid residue. Other parameters for 
the searches were as follows: Enzyme: Trypsin; Peptide tolerance: ±0.6 Da; MS/MS 
tolerance: ±0.6 Da; Peptide charge state: +2, +3; Max Missed cleavages: 1; #13C: 0; 
Quantitation: None; Instrument: ESI-QUAD-TOF; Data format: Mascot Generic; 
Experimental mass values: Monoisotopic; Taxonomy: Chordata. All data identifying 




3.3.1. Multi-step reaction synthesis of 2-chlorohexadecanal 
While the aim was to characterize the modification by chloroaldehydes of proteins using 
the proteomic approach described in chapter 2, α-chloroaldehydes are not commercially 
available and its synthesis was required prior all the other experiments. 2-
chlorohexadecanal has been the most studied α-chloroaldehyde as it is a biological product 
of the reaction of HOCl with plasmenylcholine (16:1/18:0). The first approach to the 
synthesis of 2-chlorohexadecanal was a multi-step reaction that started with the oxidation 
of hexadecanol to hexadecanal following the Corey-Suggs protocol [338] using pyridinium 
chlorochromate (PCC), a readily available, stable reagent, that oxidizes a wide variety of 
alcohols to carbonyl compounds with high efficiency (Figure 3.1). 
 
 
Figure 3.1. Corey-Suggs oxidation of hexadecanol to hexadecanal using pyridinium 
chlorochromate as catalyst. 
 
The reaction was monitored by thin-layer chromatography (TLC) and the retention factor 
(Rf) for the starting material was 0.1 while for the product was 0.37. The reaction yield was 
97.7%. A proton nuclear magnetic resonance (1H NMR) spectrum was also obtained in 






Figure 3.2. 1H NMR spectrum of the starting material hexadecanol (A) and the product of its 
oxidation, hexadecanal (B). A- 1H NMR: 3.63 ppm (2H, t, CH2); 1.56 ppm (2H, m, CH2); 1.28 ppm 
(26H, m, CH2); 0.88 ppm (3H, t, CH3). B-1H NMR: 9.77 ppm (1H, t, C(=O)H); 2.40 ppm (2H, m, 
CH2); 1.63 ppm (2H, m, CH2); 1.28pm (24H, m, CH2); 0.88 ppm (3H, t, CH3). Internal reference 
(TMS) at 0.0 ppm.  
The 1H NMR analysis confirmed that the product obtained was hexadecanal. The peak 
at 7.3 ppm corresponds to chloroform, the solvent used. The peak lower in the field (higher 
frequency), observed at 9.7 ppm was only observed in Figure 3.2B has a singlet and 
corresponds to the proton in the aldehydic group (RC(=O)H). This confirms that the 
oxidation from the alcohol to aldehyde occurred. The protons identified as b are closer to 
the electronegativity of the oxygen than the remaining protons and therefore appear at lower 
field (2.3 ppm) that the remaining protons. The protons identified as e appear as a triplet at 
0.9 ppm and correspond to the terminal methyl group. The area of the multiplet peak 
identified as c confirms that it corresponds to the remaining 22 protons in the structure. 
While the next step could be chlorination of hexadecanal, the carbonyl group would be 
vulnerable, so it needs to be protected. This is most easily achieved through formation of 
the dimethylacetal. This was formed by reaction of hexadecanal with trimethyl orthoformate 
(TMOF) in methanol and using p-toluenesulfonic acid (pTSA) as organic acid catalyst. The 




Figure 3.3. Introduction of a protective group to hexadecanal by trimethyl orthoformate 
(TMOF) in methanol and using p-toluenesulfonic acid (pTSA) as catalyst, resulting in 
hexadecanal dimethyl acetal. 
The reaction was monitored by thin-layer chromatography (TLC) and the retention factor 
(Rf) for the product was 0.56, and the reaction yield was 94.7%. A proton nuclear magnetic 
resonance (1H NMR) spectrum was also obtained in order to confirm the structure of the 
final product (Figure 3.4).  
 
 
Figure 3.4. 1H NMR spectrum of hexadecanal dimethyl acetal, product of the reaction of 
hexadecanal with TMOF in the presence of pTSA. 1H NMR: 4.36 ppm (1H, t, (OR’)CH(OR’’)); 3.31 
ppm (6H, s, OCH3); 2.30 ppm (2H, td, CH2); 1.59 ppm (2H, tt, CH2); 1.26 ppm (24H, m, CH2); 0.88 
ppm (3H, t, CH3). Internal reference (TMS) at 0.0 ppm.  
The main differences between starting material and final product were the 
disappearance of the proton in the aldehydic group (the peak previously observed at 
approximately 9 ppm), and appearance of the protons from the methyl groups of the acetal 
identified as a in Figure 3.4. The area of the peak at 3.3 ppm corresponds to 6 protons and 
confirms the formation of the protecting group. The peak at lower field that appeared at 4.4 
ppm as a triplet (b) corresponds to the proton on the carbon adjacent to the two oxygen  
atoms increasing the electronegativity. The remaining protons in the structure were 
explained above since these did not change during this reaction. Again, the peak at 7.3 ppm 
corresponds to deuterated chloroform. 
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With the aldehyde group protected, the next step was the alpha chlorination of the 
dimethylacetal. The chlorinating agents used were manganese chloride (MnCl2) and 
manganese oxide (MnO2), in a mixture of acetonitrile and methanol. Trimethylsilyl chloride 
(TMSCl) was used as catalyst. The final product was 2-chloro-hexadecanal dimethyl acetal 
(Figure 3.5). 
 
Figure 3.5. Chlorination reaction of hexadecanal dimethyl acetal to a 2-chloro-aldehyde dimethyl 
acetal, using manganese chloride (MnCl2) and manganese oxide (MnO2), in a mixture of acetonitrile 
and methanol, and trimethylsilyl chloride (TMSC) as catalyst. 
The reaction was monitored by thin-layer chromatography (TLC) and the retention factor 
(Rf) for the product was 0.28. It was not possible to determine the reaction yield as the 
required product was obtained in low amount and in a mixture with other components. A 
proton nuclear magnetic resonance (1H NMR) spectrum was also obtained in order to 
confirm the structure of the different products Figure 3.6. 
 
Figure 3.6. 1H NMR spectrum of 2-chlorohexadecanal dimethyl acetal, the product of the 
chlorinating of hexadecanal dimethyl acetal. 1H NMR: a- 3.61 ppm (6H, s, OCH3); b- 5.23 ppm 
(1H, d, (OR’)CH(OR’’); c- 3.82 ppm (1H, m, CHCl); d- 1.55 ppm (2H, m, CH2); e- 1.20 ppm (24H, m, 
CH2); f- 0.82 ppm (3H, t, CH3); A- 3.38 ppm (6H, s, OCH3); B- 4.25 ppm (1H, t, (OR’)CH(OR’’); C- 
2.25 ppm (2H, m, CH2). Internal reference (TMS) at 0.0 ppm. 
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The main difference between starting material and final product was the insertion of a 
chloro group on the α-carbon of hexadecanal dimethyl acetal. The identification of the 
protons identified as  a to c was crucial to confirm that the chlorination had occurred. The 
peaks at 3.6 ppm (a) and 3.3 ppm (A) were identified as the protons from the methyl groups 
from the final product and the starting material, respectively. The peak at lower field was 
identified as b at 4.2 ppm due to the combined electronegative effect of the oxygen and 
chlorine atoms. The same reason justifies the identification of protons the peak at 4.1 ppm 
as c. Protons identified as B and C, triplet at 4.3 ppm and multiplet at 2.3 ppm respectively, 
appear at higher field from b and c because the starting material does not contain the 
chlorine and therefore only oxygens affected the electronegativity. The remaining structure 
has been discussed previously and did not change during the course of this reaction. Peaks 
from the starting material were identified, which means that the chlorination was incomplete 
and by the integration of their peaks it was possible to relatively quantify these and obtained 
a product/starting material ratio of 0.927. 
The final step to obtain 2-chlorohexadecanal was the deprotection of the 2-
chlorohexadecanal dimethyl acetal, which was achieved by acid hydrolysis using 
trifluoroacetic acid (TFA) (Figure 3.7).  
 
 
Figure 3.7. Acid hydrolysis of 2-chlorohexadecanal dimethyl acetal with TFA to obtain 2-
chlorohexadecanal. The last step of the multi-step synthesis. 
The reaction was monitored by thin-layer chromatography (TLC) and the retention factor 
(Rf) for the product was 0.59. A proton nuclear magnetic resonance (1H NMR) spectrum 




Figure 3.8. 1H NMR spectrum of 2-chlorohexadecanal, the product of TFA acid hydrolysis 
reaction. 1H NMR: a- 9.28 ppm (1H, d, C(=O)H); b- 4.89 ppm (1H, m, CHCl); c- 1.45 ppm (2H, m, 
CH2); d- 1.06 ppm (24H, m, CH2); e- 0.68 ppm (3H, t, CH3). 1- 3.49 ppm (6H, s, CH3); 2- 5.10 ppm 
(1H, d, OCH); 3- 3.96 ppm (1H, m, CHCl). I- 3.36 ppm (6H, s, CH3); II- 3.77 ppm (1H, t, OCH); III- 
2.19 ppm (2H, m, CH2). Internal reference (TMS) at 0.0 ppm. 
The acid hydrolysis deprotects the aldehydic groups and the appearance of a doublet 
at 9.3 ppm (a) confirm this. Similarly to the previous reaction, the identification of the peaks 
a and b was crucial for the product identification, the latter being identified at 4.8 ppm. Many 
other peaks appeared in the spectra and these were identified as starting material, 2-
chlorohexadecanal dimethyl acetal and hexadecanal dimethyl acetal, the two products from 
the previous reaction and already described above. This confirms that the acid hydrolysis, 
similarly to the chlorination, was not complete.  
GC-FID analysis of hexadecanol and hexadecanal separately allowed their retention 
time to be determined as 6.3 min and 5.9 min, respectively (Figure 3.9A and Figure 3.9B). 
GC-FID analysis of the acid hydrolysis product confirmed the presence of 7.4 % of 
hexadecanol, 1.8 % of hexadecanal, 60.7 % of 2-chlorohexadecanal, and 30 % of unknown 






Figure 3.9. GC-FID spectra of 2-chlorohexadecanal as a product of acid hydrolysis, the last 
step of a multi-step reaction. GC data acquired with an isothermal analysis at 260 ⁰C for 2 minutes. 
A – hexadecanol (1.06 min, 99.9%); B – hexadecanal (0.99 min, 37.9%; 1.02 min, 58.5%); C – 




3.3.2. Direct conversion of hexadecanol to hexadecanal and 2-chloro-hexadecanal 
Although the α-chloroaldehyde was obtained in reasonable overall yield using the 
approach above, the synthesis was time-consuming due to the number of steps required, 
and the product was impure and obtained in low overall yield. Other approaches were 
evaluated for the synthesis of the aldehyde by the direct conversion of the primary alcohol 
to the corresponding α-chloroaldehyde [339-341]. The method developed by Jing et al [339] 
for the direct conversion of primary and secondary alcohols into the corresponding 
aldehydes using trichloroisocyanuric acid, serving both as stoichiometric oxidant and α-
halogenating reagent was used to produce α-chlorohexadecanal from hexadecanol and two 
different attempts were made as described below. 
 
3.3.2.1. First Attempt at Direct Synthesis of 2-chloro-hexadecanal  
The first attempt to the direct conversion of hexadecanol to 2-chlorohexadecanal used 
trichloroisocyanuric acid (TCAA) as the oxidizing and chlorinating agent and TEMPO as 
catalyst (Figure 3.10). Hexadecanol was dissolved in CH2Cl2, TCCA and TEMPO were 
added at room temperature, and the reaction was left stirring for one hour. The reaction was 
initially orange, and after 45 minutes became yellow and after one hour was white. By 
filtration, an off-white powder was removed to obtain a colorless solution. 
 
Figure 3.10. First attempt at the direct conversion of hexadecanol to α-chlorohexadecanal and 
hexadecanal. 
The reaction was monitored by thin-layer chromatography (TLC) and the retention factor 
(Rf) for the starting material was 0.32 and for the final product was 0.79. A proton nuclear 
magnetic resonance (1H NMR) spectrum was also obtained in order to confirm the structure 




Figure 3.11. 1H NMR spectrum of 2-chlorohexadecanal, the product of direct conversion from 
hexadecanol (1st approach). 1H NMR: a- 9.5 ppm (1H, d, C(=O)H); b- 4.2 ppm (1H, m, CHCl); c- 
1.8 ppm (2H, m, CH2); d- 1.3 ppm (24H, m, CH2); e- 0.9 ppm (3H, t, CH3). A- 9.7 ppm (1H, t, 
C(=O)H); B- 2.4 ppm (2H, m, CH2); C- 1.6 ppm (2H, m, CH2). Internal reference (TMS) at 0.0 ppm. 
The direct conversion comprises of two simultaneous reactions, oxidation of the alcohol 
and chlorination of the alpha carbon. The oxidation alone produces hexadecanal, for which 
the protons were identified from A to E in Figure 3.11, and from the oxidation and 
chlorination results in 2-chlorohexadecanal, protons from which were identified form a to e. 
The main difference between both products and the starting material is the appearance of 
peak at around 9 ppm corresponding to the protons from the aldehydic group. The protons 
from the aldehyde appear as a triplet at 9.7 ppm, while the protons from the α-
chloroaldehyde appear as a doublet at 9.5 ppm. The protons in the α-carbon of the 2-
chlorohexadecanal (b) appear at higher field to the protons in the α-carbon of the 
hexadecanal (B) due to electronegativity of the chlorine. GC-FID analysis (Figure 3.12) 





Figure 3.12. GC-FID spectra of 2-chlorohexadecanal as a product of direct conversion from 
hexadecanol. GC data acquired with a gradient starting from 150 ⁰C to 300 ⁰C at a rate of 25 ⁰C/min, 
total run time of 14.5 minutes. A – hexadecanol (6.3 min, 99.7 %); B – hexadecanal (5.9 min, 93.9 





3.3.2.2. Second Attempt at Direct Synthesis of 2-chloro-hexadecanal 
The second approach to the direct conversion of hexadecanol to hexadecanal and 2-
chlorohexadecanal still used trichloroisocyanuric acid (TCAA) as the oxidizing and 
chlorinating agent and TEMPO as catalyst (Figure 3.13). Hexadecanol and TEMPO were 
dissolved in CH2Cl2 and cooled to 0 ⁰C prior to addition of TCCA, and the mixture was stirred 
for 10 minutes at 0 ⁰C. The reaction was then allowed to warm to room temperature and 
stirred for another 30 minutes. After filtration, a yellow oil was obtained. 
 
Figure 3.13. Second attempt at the direct conversion of hexadecanol to α-chlorohexadecanal 
and hexadecanal. 
The reaction was monitored by thin-layer chromatography (TLC) and the retention factor 
(Rf) for the starting material was 0.25 and for the final product was 0.68. The reaction yield 
was 64%. A proton nuclear magnetic resonance (1H NMR) spectrum was also obtained in 





Figure 3.14. 1H NMR spectrum of 2-chlorohexadecanal, the product of direct conversion from 
hexadecanol (2nd approach). 1H NMR: a- 9.5 ppm (1H, d, C(=O)H); b- 4.2 ppm (1H, m, CHCl); c- 
1.8 ppm (2H, m, CH2); d- 1.3 ppm (24H, m, CH2); e- 0.9 ppm (3H, t, CH3). A- 9.7 ppm (1H, t, 
C(=O)H); B- 2.4 ppm (2H, m, CH2); C- 1.6 ppm (2H, m, CH2). Internal reference (TMS) at 0.0 ppm. 
The analysis of this spectra was the same described previously for Figure 3.11 since 
the expected final products were the same. Hexadecanal protons were identified from A to 
E and 2-chlorohexadecanal protons from a to e. The protons from the aldehyde appear as 
a triplet at 9.7 ppm while the protons from the α-chloroaldehyde appear as a doublet at 9.5 
ppm. The protons in the α-carbon of the 2-chlorohexadecanal (b) appear upfield due to the 
combination of oxygen and chlorine electronegativity. The remaining protons upfield were 
not affected during this reaction and were less affected by the electronegativity thus 
appearing at lower frequency. GC-FID analysis (Figure 3.15) confirmed the presence of 1.7 
% of hexadecanol, 5.7 % of hexadecanal and 60.9 % of 2-chlorohexadecanal. 
 
Figure 3.15. GC-FID spectra of 2-chlorohexadecanal as a product of direct conversion from 
hexadecanol. GC data acquired with a gradient starting from 150 ⁰C to 300 ⁰C at a rate of 25 ⁰C/min, 
total run time of 14.5 minutes. Three peaks were identified: hexadecanal at 5.9 min, 5.7%; 
hexadecanol at 6.3 min, 1.7%, 2-chlorohexadecanal at 6.7 min, 60.9%. Other three peaks at around 
6.9 min with a total of 12.3% were identified as unknown impurities.  
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3.3.3. Lipoxidation of lysozyme by 2-chloro-hexadecanal 
Biomolecules exposed to reactive chlorine species and the chlorination of plasmenyl 
phospholipids results, among other reaction products, in α-chloroaldehydes. These 
aldehydes are known to be involved in cellular process such as apoptosis [342]. Therefore, 
it is important to study the modification of proteins by α-chloroaldehydes. A recent study 
demonstrated using LC-MS/MS the 2-chlorohexadecanal modification of glutathione, 
indicating that the field is slowly starting to move forward [199]. Consequently, the next step 
of the study was to react the synthesized α-chloroaldehyde with two model proteins, 
lysozyme and human serum albumin, and characterize its modifications. 
Lysozyme was incubated with 8 or 16 mM of 2-chlorohexadecanal for 2, 4 or 24 hours, 
after which the products were reduced and stabilised by the addition of sodium borohydride 
(NaBH4) at 5 mM final concentration. A bottom-up proteomic approach was carried out as 
described in chapter 3. The native and the aldehyde-treated lysozyme were separated by 
15% SDS-PAGE (Figure 3.16), before the gel bands were cut for tryptic digestion and the 
peptides analysed by LC-MS/MS. 
 
Figure 3.16. SDS-PAGE (denaturing gel electrophoresis) results for lysozyme untreated and treated 
with 8 mM or 16 mM 2-chloro-hexadecanal (2-ClHDA) for 2, 4 or 24 hours. Gel stained with 
Coomassie blue staining. The highlighted sections boxed in white were cut for further analysis. 
This approach allowed the identification of 2 peptides from lysozyme modified by 2-
chlorohexadecanal, based on the peptides’ molecular weight, mass/charge ratio and charge 
of the peptide ion, ion score and LC retention time (.Table 3.1). The mass of the adduct 
suggested that 2-chlorohexadecanal reacted by Schiff base formation with additional loss 
of HCl (Appendix1). Both arginine (Arg, R) and lysine (Lys, K) residues were also found to 
be modified, with the modified residues being identified as Arg5 and Lys13.
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+222CELAAAMK13 1516.89 1517.15 506.7 (3+) 52 29.17 
Lys13 C*6ELAAAM*K





+222CELAAAMK13 1516.89 1517.13 506.7 (3+) 58 30.82 
Lys13 C*6ELAAAM*K





+222CELAAAMK13 1516.89 1517.16 506.7 (3+) 63 29.01 
Lys13 C*6ELAAAM*K
+222R13 1286.75 1286.80 644.4 (2+) 65 50.94 
4 hours 
16 mM 
82 % Lys13 C*6ELAAAM*K
+222R13 1286.75 1286.80 644.4 (2+) 64 51.14 
24 hours 
16 mM 
82 % Lys13 C*6ELAAAM*K
+222R13 1285.75 1286.80 644.4 (2+) 52 50.86 
a (subscript) – amino acid position in the mature protein for the start and end residues. 




Initially MASCOT software was used to identify peptides modified by 2-chlorohexadecanal, 
and each potential modification was confirmed by manual analysis of MS/MS spectrum as in 
the example shown in Figure 3.17 for the peptide CELAAAMKR modified on Lys13. Similarly 
to the work described in section 2.3.1, the MS/MS spectra were analysed in the search for 
diagnostic ions of these modifications. It was possible to identify the modified lysine immonium 
ion at m/z 323 Da when this amino acid residue was found modified and the proposed structure 
is shown in Figure 3.18. This ion, being amino acid- and aldehyde-specific, is a good candidate 
for a diagnostic fragmentation ion for 2-ClHDA-lysine modifications and could be used for the 
development of targeted methods, such as MRM and precursor ion scanning. 
 
 
Figure 3.17. MS/MS spectra of lysozyme tryptic peptide. CELAAAMKR modified on a lysine residue 
by 2-chlorohexadecanal by Schiff base formation with loss of HCl followed by NaBH4 reduction (+ 222 
Da). The y and b ions indicated by the arrows confirm the peptide sequence and the modification on the 
cysteine residue. Immonium ions for hexadecanal-modified lysine found at m/z 323 Da. 
 
 
Figure 3.18.  Proposed structure for the reporter ion observed at m/z 323 Da. A) structure of the 




3.3.4. Lipoxidation of human serum albumin by 2-chloro-hexadecanal 
Human serum albumin is the most abundant protein in human blood and therefore is 
subject to constant post translational modifications (PTMs), so the effect of 2-
chlorohexadecanal on this protein was assessed. HSA was incubated with 8 or 16 mM of 2-
ClHDA for 2, 4 or 24 hours before these samples were separated by 15% SDS-PAGE (Figure 
3.19) and the bands highlighted were cut out, digested with trypsin and the tryptic peptides 
analysed by LC-MS/MS.  
 
 
Figure 3.19. SDS-PAGE (denaturing gel electrophoresis) results for human serum albumin 
untreated and treated with 8 mM or 16 mM 2-chloro-hexadecanal for 2, 4 or 24 hours. Gel stained 
with Coomassie blue staining. The highlighted sections boxed in white were cut for further analysis. 
 
This approach allowed the identification of 3 peptides from HSA modified by 2-
chlorohexadecanal (Table 3.2). The mass of the adducts suggest that 2-chlorohexadecanal 
reacted by Schiff base formation with additional loss of HCl, the same as was observed for 
lysozyme in 3.3 (Appendix 1). Only lysine (Lys, K) residues were found to be modified: these 
were Lys257, Lys499 and Lys549. Initially MASCOT software was used to identify peptides 
modified by 2-chlorohexadecanal, and each potential modification was confirmed by manual 



















m/z (charge) Ion score Rt (min) 
2 hours 
8 mM 
82 % Lys257 250AEFAEVSK+222LVTDLTK264 1872.12 1872.03 625.1 (3+) 30 51.33 
4 hours 
8 mM 
73 % Lys499 497VTK+222CCTESLVNR508 1573.89 1574.20 525.7 (3+) 34 35.23 
24 hours 
8 mM 
81 % Lys549 549K+222QTALVELVK558 1349.93 1349.82 675.9 (2+) 53 43.25 
4 hours 
16 mM 
81 % Lys549 549K+222QTALVELVK558 1329.93 1349.82 675.9 (2+) 48 43.23 
a (subscript) – amino acid position in the mature protein for the start and end residues. 




The work described in this chapter had two main aims, firstly to test different synthesis 
protocols for α-chloroaldehydes, and find alternatives to the methods currently used, and 
secondly to characterize the adducts of the synthetic aldehyde with proteins by LC-MS/MS. 
Previous studies have assessed the biological effects of 2-chlorohexadecanal for which the 
synthesis of the aldehyde was required. The mostly used methods included the reaction of 
1-O-hexadec-enyl-glycerol-3-phosphocholine with HOCl and HPLC purification [151]. This 
method is time consuming and expensive. Therefore, less time-consuming alternatives 
were tried.  
In this study, two other approaches were tested. First, a multi-step reaction, which 
included hexadecanol oxidation to hexadecanal followed by acetal derivatisation, 
chlorination and finally deprotection to obtain 2-chlorohexadecanal. This chain of reactions 
took one week of work overall, therefore also being time consuming and not showing an 
improvement to the other method mentioned above. Additionally, these reactions require 
the use of harmful chemicals such as TFA and pTSA, both corrosive and irritant, TMOF and 
TMSC, both flammable, and PCC which is carcinogenic. This chain of reaction allowed us 
to obtain in the end 60.7 % of 2-chlorohexadecanal, with 7.4 % of hexadecanol and 1.8 % 
of hexadecanal still present as well as 30 % of unknown impurities. As a result of the poor 
yield, presence of impurities that were hard to remove and the use of PCC, two attempts 
were made to use an alternative method to directly convert hexadecanol into hexadecanal 
and 2-chlorohexadecanal, according to the method  of Jing et al. [339]. This reaction used 
TCCA as an oxidizing and chlorinating agent and TEMPO as a catalyst. In the first attempt, 
all reaction components were dissolved in CH2Cl2 and left stirring for one hour at room 
temperature. The 1H NMR analysis confirmed the presence of hexadecanal and 2-
chlorohexadecanal and the GC-FID analysis confirmed the presence of 9.5% of 
hexadecanol, 8% of hexadecanal, 59.1% of 2-chlorohexadecanal, and 23.4% of unknown 
impurities. This reaction was already a good alternative, taking only one hour and 
decreasing the amount of unknown impurities in comparison with the multi-step reaction. 
However, a second attempt was made to try to improve the hexadecanal/2-
chlorohexadecanal ratio and decrease the percentage of impurities. In the second attempt, 
hexadecanol and TEMPO were firstly dissolved in CH2Cl2 and cooled to 0 ⁰C, then TCCA 
was added and left stirring for 10 minutes, after which the reaction was warmed to 37 ⁰C 
and left stirring for another 30 minutes. In this attempt, pentane was added to the reaction 
before filtration, which being a non-polar solvent promoted the precipitation of pentane 
insoluble compounds, removing some of the impurity as 2-ClHDA due to the long carbon 
chain is non-polar and therefore soluble. The resulting oil was characterized by 1H NMR 
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and although the product yield was not greatly increased, the amount of unidentified 
impurities was lower. According to the GC-FID data, the changes made for the second 
attempt decreased the amount of hexadecanol, hexadecanal and unknown impurities in the 
final product, while slightly increasing the amount of 2-chlorohexadecanal. Nevertheless, 
both attempts at the direct conversion of hexadecanol to 2-chlorohexadecanal represent a 
good alternative to current methods used, as they are less time consuming and use fewer 
harmful chemicals, improving time spent with the synthesis as well as health and safety of 
the experiments. This finding will help the research on this particular aldehyde move forward 
since its synthesis can be quicker and still with satisfactory quality. Another methods that 
could have been tested to synthesize 2-chlorohexadecanal was the direct organocatalytic 
asymmetric α-chlorination of aldehydes from Halland et al. which  has also been reported 
to be a quick method that synthesizes α-chloroaldehydes with good yield within one hour 
reaction [343]. 
The modification of two proteins by 2-chlorohexadecanal was evaluated as a model of 
lipoxidation adducts that may occur in inflammatory disease. The aim was to characterize 
these modifications using LC-MS/MS and identify potential diagnostic ions for adducts of 2-
chlorohexadecanal with different amino acid residues. While the physiological concentration 
of 2-ClHDA ranges between 25 to 30 μM [148, 330], higher concentrations were used to 
ensure adducts were formed. 2-ClHDA modifications were identified on 2 lysozyme and 3 
human serum albumin peptides, all with a mass increase of 222.2 Da corresponding a 
Schiff’s base formation between the carbonyl from the aldehyde and the amine form lysine, 
followed by reduction of imine by sodium borohydride(Figure 3.20A). This is a mild reducing 
agent therefore the unsaturation on the carbon chain was not reduced. Duerr et al  
previously reported the 2-ClHDA-thiol adduct to occur by nucleophilic attack to the α-
chlorinated carbon with the adduct formed retaining the carbonyl group [199] and 
corresponding to a mass shift of 240.25 Da in its reduced form (Figure 3.20B), however no 
modifications were detected on cysteine residues. Condensation of thioamides with α-
halocarbonyl compounds confirms that the thiol group reacts with the α-halogenated carbon 
while the amine group reacts with the carbonyl group [344]. Similarly, 2-chloroaldehydes 
react differently with the thiol group in cysteines and the amine group in lysines. This justifies 
the different mechanism of adduction reported in this thesis and the mechanism reported 
by Duerr et al [199]. While the adduct resulting in a same mass shift of 22.2 Da can also be 
achieved by hexadecanal-lysine modification (Figure 3.20C), the samples were reduced 
and therefore there is a higher probability of this mass difference being a result of a reduced 






Figure 3.20. Structure of unreduced and reduced hexadecanal and 2-chlorohexadecanal 
adducts. (A) 2-Chlorohexadecanal adducts with amines by Schiff base formation followed by imine 
reduction but not the carbon chain unsaturation; (B) 2-Chlorohexadecanal adducts with thiol 
(cysteine residue) by nucleophilic attack of C-Cl followed by reduction of the remaining carbonyl; (C) 
Hexadecanal adduct with amine by Schiff base formation followed by imine reduction. 
The bottom-up proteomic approach allowed the identification of 2 modified lysozyme 
residues: Arg5 and Lys13. For HSA only lysine residues were found to be modified: Lys257, 
Lys499 and Lys549. The proteins were not reduced prior to the 2-ClHDA treatment as 
explained in chapter 3, meaning that the cysteine residues were in disulphide bonds and 
therefore not available for modification. This might explain why no 2-ClHDA-cysteine 
adducts were detected, even though these have been previously reported by another group 
in work using glutathione [199]. A major aim of the study was to identify diagnostic ions for 
the 2-ClHDA adducts that could later be used in targeted mass spectrometry approaches, 
multiple reaction monitoring (MRM) or precursor ion scanning (PIS). MS/MS spectra contain 
immonium ions that are specific to amino acid residues present in the peptide and these 
ions are potential MS/MS reporter ions for modified amino acid residues. One diagnostic 
ion was detected for 2-ClHDA-lysine modification at m/z 323. While protein-acrolein adducts 
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have been previously reported, it appears that there aren’t any specific studies of reporter 
ions that could be used for this type of modifications. None of the HSA amino acid residue 
positions found modified have been previously reported modified by lipoxidation. 
Nevertheless, this approach allowed us to identify some protein modifications by 2-ClHDA 
and mostly important to provide reporter ions that could be relevant in disease diagnostic 
method development.  
In summary, this study has provided a novel approach to 2-chlorohexadecanal synthesis 
able to obtain the product in an hour saving time and consumables in research. It also 
provided novel data on modification in two model proteins by 2-ClHDA and has identified a 
novel diagnostic ion for 2-ClHDA-lysine adduct that can be used in targeted mass 















Chapter 4. Chromatography methods for separation of 





The analysis of the proteome of an organism is a difficult challenge due to the dynamic 
range of protein concentrations [345, 346]. Genetic information processing increases 
protein variation through mutations, polymorphisms and alternative splicing. Protein 
isoforms have high sequence similarity and arise either from the same gene family or from 
polymorphisms [347]. A single gene can code for multiple proteins due to alternative mRNA 
splicing, resulting in multiple protein forms with different peptide sequences [348]. However, 
protein isoforms can also be generated from separate genes such as actin and pyruvate 
kinase isoforms [349, 350]. Each protein isoform can be expressed in different tissues being 
therefore associated with different roles. However, for some isoforms their roles are still not 
completely understood and post translational modification (PTMs) can add extra differences 
to the complexity of the cellular proteome, which itself can change in response to different 
stimuli. Therefore, a comprehensive characterization of all of these isoforms is important to 
improve diagnosis and treatment of diseases such different types of cancer where protein 
biomarkers are important [351, 352]. 
A wide variety of methods can be used for protein study, yet mass spectrometry 
approaches are distinctively suited to handle the complexity of proteomics [248]. There are 
two strategies for protein analysis by MS: bottom-up and top-down approaches. The 
bottom-up proteomics approach involves proteins being chemically or enzymatically 
digested prior to peptide analysis by MS [353]. The identification of the peptides is 
performed by analysis of their fragmentation pattern, which identifies the protein and 
characterizes and localizes possible PTMs, usually by comparison to databases [353, 354]. 
However, different isoforms may produce peptides with the same sequence, making this 
approach a disadvantage for isoform investigation. Other disadvantages of the bottom-up 
approach are the limited dynamic range of MS analysis, which only allows peptides present 
at higher relative abundance to be analysed but  misses information regarding low abundant 
proteins, as several peptides might not be specific to a single protein and regions of the 
protein sequence might not be covered so information on possible PTMs is unavailable. 
The top-down approach corresponds to intact protein analysis by MS in which intact protein 
ion masses are measured followed by fragmentation without prior digestion [355]. This 
approach facilitates a complete characterization of protein isoforms, as well as PTMs by the 
shift caused to the protein mass. Several applications have been reported for this proteomic 
approach, including the interpretation of the “histone code” by characterizing the 
combination of multiple modifications such as acetylation, methylation and phosphorylation 
[235, 356, 357] and the  characterization of biotherapeutic molecules such as monoclonal 
antibodies [239, 358]. Even though top-down analysis has been shown to be a powerful 
tool, the throughput for proteome analysis still needs improvement. Recent advances in the 
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chromatographic methods, MS instrumentation, dissociation methods and data processing 
software have greatly improved intact protein analysis [359, 360]. The development of soft 
ionization techniques such as electrospray ionization (ESI) revolutionized protein and 
peptide analysis using MS [209], particularly by the ability to couple MS with liquid 
chromatography (LC). 
The separation of peptides and proteins is a key step in both top-down and bottom-up 
MS approaches. Liquid chromatography is one of the most common methods for small 
molecule separation, which consists of differential partitioning of analytes between a liquid 
mobile phase and a stationary phase. Intact protein analysis using LC coupled to MS 
provides information on the accurate mass of the protein, relative abundance of its isoforms, 
PTMs localization and combination of any other modifications on the protein [361, 362]. 
Each of these applications requires upfront separation. Reverse-phase chromatography 
(RPLC) has been widely used for intact protein analysis due to its compatibility with ESI-
MS. The aqueous solvent mixtures used in RPLC are compatible with ESI-MS and the 
additives such as formic acid or triflouroacetic acid improve not only the chromatographic 
peak shape but also provides a source of protons. Nevertheless, other separation methods 
can separate proteins based on their structure, mass, charge or presence of modifications 
such as size exclusion chromatography (SEC) and ion exchange chromatography (IEX).  
RPLC uses non-polar stationary phase and polar mobile phase and therefore 
hydrophilic analytes elute first. Several stationary phases can be used, with alkyl chains 
linked to porous silica particles being the most common, where shorter chains such as C4 
are generally used since proteins show strong retention on long chains (e.g. C8, C18) [361]. 
However, derivatized nonporous silica (NPS) particles and superficially porous particles 
containing a nonporous silica core and a porous shell have also been reported to be suitable 
for protein work [233, 363, 364]. For this study, a polymeric reversed-phase material (resin 
based on a hydrophobic supermacroporous polymer) was used, which offered high-
resolution separation of intact proteins with increased mechanical strength (stable at 
extreme pH and high temperature), high efficiency with low carry-over and high throughput. 
In RPLC the retention of proteins is also affected by the size of the particles, the pressure, 
the temperature and the composition of the mobile phase [365-367].  
Ion exchange chromatography (IEC) is a non-denaturing separation technique which 
separation relies on the differences in the charge of the analytes. Changes in protein charge 
cause by modifications may affect the separation. Protein separation by IEC depends on 
the protein interaction with the charged stationary phase and a salt-gradient is usually 
applied for elution [232, 368]. Proteins are eluted in order of increasing binding charge, 
which closely correlates with their isoelectric point (pI). Employing a pH gradient instead of 
a salt-gradient can be a useful alternative to separate proteins with small changes in pI. In 
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this method, proteins’ net charges are modified during the gradient and proteins elute at 
their pI. The proteins suitable to be separated using this technique would depend on the pH 
range of the gradient. The choice of the eluent to be used is also important, so usually a 
mixture of amine buffering species and weak acids are chosen to create the gradient [369, 
370]. The advantage of a pH gradient is the low concentration of salt used, which allows 
on-line coupling to mass spectrometry [371]. This method has been mainly applied to 
separation and charcaterization of biopharmaceuticals like monoclonal antibodies [372]. In 
addition, it has also been used to separate protein isoforms. The use of both cation 
exchange chromatography (CEC) and anion exchange chromatography (AEC) have been 
reported for intact protein analysis when coupled to RPLC, which not only increases the 
fractionation but also desalts the samples prior to MS analysis. For example, the 
Escherichia coli proteome was studied by two-dimensional separation using CEC coupled 
to on-line RPLC [373] and AEC coupled to RPLC-MS [374]. A few years later, a similar 
method using AEC-RPLC was applied to top-down analysis of human leukocytes proteome 
in order to implement this technique in clinical studies [375]. IEC can also be applied to 
separation of HSA isoforms, which are known to be a biomarker of age [376]. The analysis 
of HSA isoforms started with a mixed-mode anion exchange-hydrophobic interaction 
chromatography, which is commonly used to assess the redox state of HSA [377]. However, 
this technique was not coupled to mass spectrometry, thus limiting the information provided 
by the method. Later, different HSA isoforms were separated by their pI using a pH gradient 
method and an anion exchange column, and fractions were collected for further analysis by 
RPLC-MS [378]. More recently, non-denaturing ion exchange chromatography methods 
coupled on-line to native mass spectrometry were developed for monoclonal antibodies 
[379], interferon-β [380] and HSA isoforms characterization [381]. The use of MS-
compatible salts allows the direct detection and characterization by MS, which could easily 
be applied for clinical diagnosis purposes.  
The separation methods described above have been used to separate protein isoforms 
resulting from post-translational modifications such as deamidation, glycation and 
phosphorylation but as yet have not been applied for separation of lipoxidation products. 
Lipoxidation is more commonly analysed by bottom-up approaches that allow the 
modifications to be localized and characterized by mass spectrometry [217]. RPLC is 
usually used for separation of lipoxidized proteins since the oxidized lipid modification 
increases the hydrophobicity of the proteins. The same modifications can also change the 
protein net charge and therefore IEC could also be applied for lipoxidized protein 
separation. 
The aim of the work reported in this chapter was to test different chromatographic 
methods for protein isoform and oxPTM  separations and ion exchange chromatography by 
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pH gradient and reverse-phase chromatography were the methods used. Additionally, the 
same modified proteins were analysed by bottom-up approach to localize and characterize 
these modifications. Comparison between trypsin digestion protocols and data processing 
software for peptide analysis was also performed.  
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4.2. Material and Methods 
4.2.1. Materials 
Water (Optima LC-MS grade) and ammonium formate (LC-MS grade) were obtained 
from Fisher Scientific (Schwerte, Germany). Formic acid (LC-MS grade), ammonium 
acetate, acetic acid, human serum albumin and human serum plasma were purchased from 
Sigma-Aldrich (Sigma-Aldrich, Munich, Germany). 4-Hydroxy-2-trans-nonenal (HNE) and 
4-Hydroxy-2-trans-hexenal (HHE) were purchased from Cayman Chemicals. 
 
4.2.2. Treatment of proteins with aldehydes in vitro 
Ubiquitin, insulin and human serum albumin (100μM) were modified by two different 
aldehydes. 4-hydroxy-hexenal (HHE) and 4-hydroxy-nonenal (HNE) were added to the 
protein solution at a 1:10 (protein: aldehyde) molar ratio and allowed to react for 2 hours at 
room temperature. To stabilize adducts, NaBH4 was added to a final concentration of 25 
mM and left to react for 1 hour at room temperature. 
 
4.2.3. Ion Exchange Chromatography (IEC) 
UHPLC separation was performed on Thermo Scientific Vanquish UHPLC System 
equipped with a binary pump, an autosampler and a column compartment. A binary solvent 
system was used, in which eluent A consisted of 10 mM ammonium acetate and 10 mM 
ammonium formate and eluent B of 10 mM acetic acid and 10 mM formic acid. Proteins 
(25 μL; each sample in technical triplicate) were loaded onto an anion exchange column 
(ProPac SAX-10, 2 x 50 mm) at 0% B and eluted using a gradient: ramp from 0% to 60% B 
during 10 minutes followed by an isocratic gradient at 100% for 1 min. Together with an 
equilibration time of 9 min, the samples were injected every 20 min. The pH range of the 
gradient was 2.9-6.5. Proteins (25 μL; each sample in technical triplicate) were loaded onto 
a cation exchange column (MabPac SCX-10 RS 5 μm, 2.1 x 50 mm) at 0% B and eluted 
using a gradient: ramp from 0% to 75% B for 10 min followed by an isocratic gradient at 
100% for 4 min. Together with an equilibration time of 11 min, the samples were injected 
every 25 min. The pH range of the gradient was 5.3-10.9. For both methods, the column 
temperature was set to 25 °C and the flow rate to 400 μL/min. 
 
4.2.4. Reverse Phase Chromatography 
UHPLC separation was performed on Thermo Scientific Vanquish UHPLC System 
equipped with a binary pump, an autosampler and a column compartment. A binary solvent 
system was used, in which eluent A consisted of 0.1% of formic acid in water and eluent B 
of 0.1% of formic acid in acetonitrile. Proteins (5 μL; each sample in technical triplicate) were 
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loaded onto a reverse phase column (MabPac RP 4 μm, 2.1 x 50 mm) at 0% B and eluted 
using a gradient: ramp from 0% to 40% B for 4 min, then isocratic gradient at 40% B for 2 
min followed by 1 minute at 100% B. Together with an equilibration time of 3 min, the 
samples were injected every 10 min. Column temperature was set to 50 °C and the flow 
rate to 600 μL/min. Peptides (5 μL from 20 μM solution; each sample in technical triplicate) 
were loaded onto a reverse phase column (Acclaim VANQUISH C18 2.2μ, 2.1 x 250 mm) 
at 10% B and eluted using a gradient: ramp from 10% to 45% B for 13 min followed by an 
isocratic gradient at 90% B for 2 min. Together with an equilibration time of 5 min, the 
samples were injected every 20 min. Column temperature was set to 35 °C and the flow 
rate to 250 μL/min. 
 
4.2.5.  Mass Spectrometry for intact protein analysis 
 A Q Exactive HF mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) 
using a HESI source was operated in Full MS HMR mode for HSA and in Protein mode for 
the other two proteins. Every sample was measured in technical triplicates in positive ion 
mode. Ion source parameters were the following: Source Voltage: 3.6 kV; Ion transfer tube 
temperature: 320°C; Sheath Gas: 30 arbitrary units; Aux Gas: 15 arbitrary units; vaporizer 
temperature: 100°C. The Orbitrap mass analyser was operated in high mass resolution 
(HMR) mode at a resolution setting of 15,000 and in Protein mode at a resolution setting of 
60,000 for m/z 200 in full-scan mode (scan range: 2000–6000 m/z automatic gain control 
target: 3e6; max. injection time: auto (needed to be changed in at least 500 ms, 10 
microscans). The S-Lens RF level was set to 150%.  
 
4.2.6. Mass Spectrometry for peptide analysis 
A Q Exactive HF mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) 
using a HESI source was operated in data-dependent acquisition (DDA) mode. Every 
sample was measured in technical triplicates in positive ion mode. Ion source parameters 
were the following: Source Voltage: 3.6 kV; Ion transfer tube temperature: 320°C; Sheath 
Gas: 30 arbitrary units; Aux Gas: 15 arbitrary units; vaporizer temperature: 100°C. The 
Orbitrap mass analyser was operated at a resolution setting of 120,000 for m/z 200 in full-
scan mode (scan range: 350–2000 m/z automatic gain control target: 3e6; max. injection 
time: auto (needed to be changed in at least 500 ms, 10 microscans) and at a resolution 
setting of 30,000 for m/z 200 in the Top10 DDA MS/MS mode (HCD, Stepped Normalized 
Collision Energy: 30 ± 10 eV; Isolation Width: 1.0 Da; Activation Q: 0.2; Activation Time: 
10 ms; automatic gain control target: 1e5; max. injection time: 100 ms; Intensity threshold: 
5e4 counts) with dynamic exclusion for 10 s and in profile mode. 
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4.2.7. In-gel digestion 
The reaction products from 4.2.2. were separated by 12.5 % SDS-polyacrylamide gel 
electrophoresis (section 2.2.5) followed by staining with Coomassie blue to visualize the 
bands prior to further processing. Bands present in the gel were then excised and tryptic 
digestion was performed according to Verrastro et al., 2016 [298]. The peptide extracts were 
dried for storage and resuspended in 0.1% formic acid in water prior to MS analysis. 
 
4.2.8. SMART Digestion 
Samples were diluted to 2 mg/mL (protein). Then 150 μL SMART Trypsin Buffer was 
added to the SMART digest vials, followed by 50 μL of sample (100 μg). Samples were 
incubated at 70 ⁰C with mixing at 1400 rpm. The tubes were incubated for different digestion 
times according to the protein size. Following trypsin digestion, samples were centrifuged 
for 2 minutes at 4600 g and the supernatants placed in a fresh tube. Reduction of disulphide 
bonds was carried out with DTT, final concentration 10 mM, for 30 minutes in the dark.  
 
4.2.9. Data processing 
The software BioPharma Finder 3.1 (Thermo Fisher Scientific) was used for peptide 
mapping analysis and to match them to the primary sequence of each protein (Uniprot 
entries: Insulin, P01315; Ubiquitin, P0CG48; HSA, P02768). Allowed variable modifications 
were methionine oxidation, Cys carbamidomethylation and HNE- or HHE-carbonylation on 
Cys, Lys, Arg and His to form Michael addition or on Lys and Arg to form base Schiff base 
adducts (respectively characterized by an isotopic delta mass equal to 114.14 Da, 93.13 
Da and 78.11 Da for HHE, and 156 and 138 for HNE). Furthermore, the following key 
processing parameters were set such as mass tolerance ± 10 ppm, relative abundance 




4.3.1. Protein separation by ion exchange chromatography 
An anion exchange chromatography method was used to separate protein within a pH 
range of 2.9 to 6.5. It was important to know the isoelectric point (pI) of each protein being 
separated with this method, since it should fit within this pH range. The pI corresponds to 
the pH at which the net charge on the protein is zero, meaning that the protein is no longer 
interacting with the column and elutes. The proteins used were insulin (pI 5.35), ubiquitin 
(pI 6.79) and human serum albumin (pI 4.7) and their AEC base peak chromatograms are 
shown in Figure 4.1. 
 
Figure 4.1. Base peak chromatograms resulting from anion exchange chromatography 
separation of different protein isoforms. Retention time 0.0 to 10.0 minutes. Protein used were 
insulin, ubiquitin and human serum albumin 
This chromatographic method was able to separate different isoforms for insulin as well 
as for human serum albumin, since the base peak chromatograms above show multiple 
peaks corresponding to different protein isoforms. The same was not observed for ubiquitin, 
for which only one peak eluted. Insulin and ubiquitin both started eluting early reflecting 
higher PIs whereas HAS did not elute until later. These proteins were then treated with 4-
hydroxy-hexenal (HHE) or 4-hydroxy-nonenal (HNE) and the same chromatographic 




Figure 4.2. Base peak chromatograms from anion exchange chromatography separation of 
untreated and HHE or HNE treated protein. A-insulin; B-ubiquitin; C-human serum albumin. 
Retention times varying from 0.0 to 14.0 minutes. Untreated samples data in black, HHE treatment 
data in red and HNE treatment in blue. Each peak was assigned a number for later identification. 
Treated and untreated forms of the same protein were not separated by the AEC 
method used, since no new peaks were detected upon treatment or a change in retention 
time detected. However, in Figure 4.2A it was possible to observe a tailing of the peaks for 
the treated samples. In fact, the isoform eluting between 2 and 4 minutes showed what 
seems to be two peaks with low resolution. This effect was not observed for ubiquitin 
(Figure 4.2B) which continue to correspond to only one peak even upon aldehyde 
treatment. In turn, human serum albumin showed a quite complex chromatogram upon 
treatment possibly due to the high amount of modifications and distinct peaks were no 
longer observed (Figure 4.2C). Nevertheless, the analysis of the MS data confirmed the 
presence of the HHE and HNE modifications on the proteins by the increase in the protein 
mass corresponding to the insertion of these aldehydes either by Michael addition or by 




Figure 4.3. MS spectra of untreated or HHE/HNE-treated intact protein separated by AEC. The 
spectra correspond to the peaks in Figure 4.2 and these are labelled with the same number as the 
corresponding chromatographic peak. (A) Insulin (z=4+), isoform in peaks 3 and 4 from Figure 2 are 
shown; (B) Ubiquitin (z=6+), MS data from single peak in chromatogram.; (C) HSA, MS data from 
peak at highest relative abundance and for aldehyde-treated samples, the same retention time was 
selected. Untreated samples data in black, HHE treatment data in red and HNE treatment in blue. 
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The untreated insulin was identified at m/z 1445.17 (charge 4+). The covalent adducts 
with the aldehydes were confirmed by the insertion of one (m/z 1473.689), two (m/z 
1502.207) or three (m/z 1530.725) HHE molecules or one (m/z 1484.202), two (m/z 
1523.231) or three (m/z 1562.514) HNE molecules (Figure 4.3A). Comparison between the 
two spectra for the same treatment showed an increase in the extension of modification by 
an increase in the relative abundance of the modified species in the second spectrum 
(higher retention time). This demonstrated that the method was able to separate slightly 
insulin with different extent of aldehyde modification. The untreated ubiquitin was identified 
at m/z 1428.44 (charge 6+). Upon treatment, a total of up to 5 covalent adducts were 
confirmed for HHE and up to 4 were confirmed for HNE, including Michael addition and 
Schiff base formation, corresponding to a mass increase of 114.07 Da and 96.06 Da for 
HHE and 156.12 Da and 138.10 Da for HNE respectively. The highest covalent modification 
corresponded to the insertion of four HHE molecules by Michael addition and one by Schiff 
base resulting in the m/z 1520.344, or the insertion of three HNE molecules by Michael 
addition and one by Schiff base resulting in the m/z 1529.519. For HSA, due to the larger 
protein size, it was not possible to determine the charge envelop and therefore no specific 
modifications could be reported from this data.  
In order to separate protein isoforms with higher pI, a cation exchange chromatographic 
(CEC) method was tested with a pH range of 5.3 to 10.9. The proteins tested were the same 
as for AEC and the base peak chromatograms for insulin (pI 5.35), ubiquitin (pI 6.79) and 
human serum albumin (pI 4.7) are shown in Figure 4.4. 
 
Figure 4.4. Base peak chromatograms resulting from cation exchange chromatography 
separation of different protein isoforms. Retention time was 0.0 to 10.0 minutes. Protein used 
were insulin, ubiquitin and human serum albumin. 
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CEC was not able to separate insulin isoforms, in contrast to what was previously 
observed for AEC; however, the retention of this protein in this chromatography was 5 
minutes,  which was longer than with AEC. On the other hand, CEC was found to be more 
suitable for ubiquitin separation than AEC; two peaks were observed confirming the 
separation of different isoforms with retention times of 4.5 and 4.9 minutes. Human serum 
albumin, with a lower pI than the other proteins tested, was not separated by CEC, since 
no clear peaks were observed in the chromatogram. Similarly to the experiment described 
above, these proteins were treated with 4-hydroxy-hexenal (HHE) or 4-hydroxy-nonenal 
(HNE) and the modified proteins were then separated by CEC (Figure 4.5). 
 
Figure 4.5. Base peak chromatograms from cation exchange chromatography separation of 
untreated and HHE or HNE treated protein. A-insulin; B-ubiquitin. Retention times varied from 1.0 
to 9.0 minutes. Untreated samples data in black, HHE treatment data in red and HNE treatment in 
blue. Each peak was assigned a number for later identification. 
The aldehyde treatment did not change the retention time of insulin; upon HHE 
treatment, it still only one peak was present in the chromatogram, while HNE treatment 
resulted in the detection of two peaks showing some separation. In case of ubiquitin, HHE 
treatment changed the retention time of the protein resulting in earlier elution. In contrast, 
HNE treatment of ubiquitin resulted in four peaks in the chromatogram with increasing 
retention time in comparison with the untreated ubiquitin. HSA results are not shown since 
the untreated samples did not present good separation with this method. Figure 4.6 shows 
the MS spectra of each peak identified in the chromatograms above, which are identified 




Figure 4.6. MS spectra of untreated or HHE/HNE-treated intact protein separated by CEC.  The spectra correspond to the peaks in Figure 4.5 and these 
are labelled with the same number as the corresponding chromatographic peak. (A) Insulin (z=3+), MS data for single chromatogram peak for untreated and 
HHE-treated and for the two peaks for HNE-treated; (B) Ubiquitin (z=6+), MS data from the single peak 1 for untreated protein, peaks 1 and 2 for HHE-treated 
protein and peaks 1, 2, 3 and 5 for HNE-treated protein. Untreated samples data in black, HHE treatment data in  red and HNE treatment in blue. 
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The untreated insulin was identified at m/z 1926.5657 (charge state 3+). In Figure 4.6A, 
the MS data for HHE-modified insulin corresponds to the single peak in Figure 4.5A and the 
HHE covalent adducts were confirmed by the insertion of one (m/z 1964.5916), two (m/z 
2002.6157) or three (m/z 2040.6393) HHE molecules by Michael addition. Also in Figure 4.5A 
two peaks were observed after HNE-treatment and therefore in Figure 4.6A two spectra are 
shown corresponding to each chromatographic peak. The HNE covalent adducts were 
confirmed by the insertion of one (m/z 1978.9421) or two (m/z 2024.9862) HNE molecules by 
Michael addition and one (m/z 1972.9353) or two (m/z 2018.9811) HNE molecules by Schiff-
base reaction. Additionally m/z 2077.0281 was also observed with the highest retention time 
peak and was identified as the insertion of 3 HNE molecules, two by Michael addition and one 
by Schiff-base reaction. The MS data confirmed the separation by CEC of insulin with different 
extent of aldehyde modification. The peak with the highest retention time was shown to 
correspond to higher amount of insulin HNE-modification. In Figure 4.6B, the untreated 
ubiquitin was identified at m/z 1428.4528 (charge 6+), and these MS data correspond to peak 
1 in Figure 4.5B. Up to 4 HHE molecules and 3 HNE molecules were found to be covalently 
linked to ubiquitin, identified by the masses described above for Figure 4.3B. For HHE-treated 
ubiquitin, two peaks were observed in the chromatogram and comparison of the MS data of 
each peak did not shown differences in the amount of protein modification. On the other hand, 
comparison of the spectra for each HNE-treated ubiquitin chromatographic peak showed a 
decrease in untreated protein relative abundance and an increase in the extent of HNE 
modification with the increase in retention time. This observation is in accordance to the results 
from insulin, showing the ability to separate proteins with different degrees of modification by 
cation exchange chromatography, as the aldehyde modification alters the protein’s pI, resulting 
in later elution from the column. HSA data was not shown since no conclusions could be 
obtained from it.  
 
4.3.2. Intact protein separation by reverse phase chromatography 
In order to assess which chromatography method would better suit the separation of 
lipoxidized proteins, a reverse phase (RP) chromatography method was used to separate 
untreated as well as HHE or HNE-treated insulin, ubiquitin and human serum albumin (the 
same samples used for ion exchange chromatography described in 4.3.1). This separates 
proteins according to their hydrophobicity, starting as hydrophilic followed by a gradient 
increasing in hydrophobicity. Due to the solvents used, intact protein analysis by RP 
corresponds to the denatured forms of the proteins, in contrast to the native non-denaturing 
ion exchange chromatography. Figure 4.7 shows the base peak chromatograms obtained for 




Figure 4.7. Base peak chromatograms from reverse phase chromatography separation of 
untreated and HHE or HNE treated protein. A-insulin; B-ubiquitin; C-HSA. Retention times varying 
from 2.5 to 5.5 minutes Untreated samples data in black, HHE treatment data in  red and HNE treatment 
in blue. More than one peak was observed in each chromatogram; therefore a number was assigned 
for later identification. 
For all the proteins tested, it was observed that the aldehyde modification changed their 
retention time, reflecting increased hydrophobicity. For insulin, 3 peaks were detected after 
HHE treatment and 6 after HNE treatment. The same effect was observed for ubiquitin with 
three peaks and five peaks detected upon HHE and HNE respectively. For HSA, no distinct 
and resolved peaks were observed but it was still possible to observe the shift in retention time 
after aldehyde modification. The MS shown in Figure 4.8 helped with the identification and 
characterization of the species in each of these peaks. HSA data are not shown for the same 




Figure 4.8. MS spectra of untreated or HHE/HNE-treated intact protein separated by reverse phase chromatography. The spectra correspond to the 
peaks in Figure 4.7 and these are labelled with the same number as the corresponding chromatographic peak. A-Insulin (z=4+), MS data shown for peak 1 for 
untreated, peaks 1 and 3 for HHE-treated and peaks 1, 3 and 5 for HNE-treated; B-Ubiquitin (z=6+), MS data shown for peak 1 for untreated, peaks 1 and 2 for 
HHE-treated and peaks 1, 2, 3 and 5 for HNE-treated. Untreated samples data in black, HHE treatment data in  red and HNE treatment in blue. 
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Compared to the native peak at m/z 1445.1696 (charge 4+) for insulin and at m/z 
1428.4484 (charge 6+) for ubiquitin, increased m/z for the modifications were observed. MS 
data analysis showed that the distinct peaks separated by RPLC demonstrated in Figure 
4.7 correspond to different degree of modification of the protein with the highly modified 
proteins eluting later. This observation was confirmed for both HHE and HNE. These results 
shown reverse phase chromatography to be able to separate unmodified from modified 
protein as well as separation of proteins by the extent of modification, thus being a better 
choice than the ion exchange chromatography methods described in 4.3.1. for lipoxidized 
proteins separation. 
 
4.3.3. Comparison between protein digestion methods 
A bottom-up approach was also used to localize and characterize the HHE and HNE 
modifications to insulin, ubiquitin and human serum albumin. The same samples were 
digested into peptides by two different protocols for comparison. The first method tested 
was the commonly used in-gel digestion method where an SDS polyacrylamide gel was run 
and the band of interest cut and digested with trypsin to obtain peptides. The second method 
used was the SMART Digest™ Trypsin Kit from Thermo, which has been reported to be a 
significant improvement over in-solution digestion methods requiring less than 60 minutes 
to achieve full digestion, whereas usually it would take up to 24 hours and the reduction in 
the number of chemicals used resulted in cleaner samples [382]. After MS data was 
acquired, the analysis was performed using Biopharma Finder. The protein sequence 
coverage obtained was dependent on the digestion method used (Table 4.1).  
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Table 4.1. Sequence coverage of insulin, ubiquitin and human serum albumin. Proteins were 
digested by in-gel or SMART trypsin digestion, and peptide MS analysis performed using Biopharma 
Finder. 
 
The percentage of protein sequence coverage was shown to be dependent on the 
digestion method and on the aldehyde treatment. Using biopharma finder, the sequence 
coverage for proteins digested by in-gel trypsin digestion was slightly higher than by SMART 
digest for three proteins tested. Additionally, both aldehyde treatments decreased the 
percentage of sequence coverage when samples were digested by SMART digest but the 
same was not observed for in-gel digestion samples, for which the percentage of sequence 
coverage showed a 20% increase upon treatment. This bottom-up approach allowed for the 
localization and characterization of the HHE and HNE modifications on ubiquitin and human 
serum albumin and the results are reported in Table 4.2 and Table 4.3, respectively. The 
peptides were identified based on their molecular weight, mass/charge ratio and charge of 
the peptide ion and LC retention time. Results for insulin are not shown in the tables below, 
because data was only acquired for SMART digestion.  
Sequence Coverage (%) 
Proteins 
Untreated HHE-treated HNE-treated 
In-Gel SMART In-Gel SMART In-Gel SMART 
Insulin - 7.4 - 6.5 - 6.5 
Ubiquitin 72.4 51.3 94.7 60.5 94.7 40.8 
HSA 79.3 59.7 90.6 78.1 92.5 70.8 
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Table 4.2. Modification of ubiquitin by HHE or HNE. Peptides obtained by in-gel (G) or SMART 
(S) trypsin digestion and MS data was analysed by Biopharma Finder. 
Modified 
Residues 










4-hydroxy-hexenal (HHE)  
His68 E64STLH+114LVLR72 1180.6825 394.568 (3+) 8.39 G S 
His68 E64STLH+96LVLR72 1162.6708 582.343 (2+) 9.98 G S 
His68 E64STLH+78LVLR72 1144.6608 573.338 (2+) 10.40 G 
4-hydroxy-nonenal (HNE)  
His68 E64STLH+156LVLR72 1222.7278 612.371 (2+) 10.48 G 
His68 E64STLH+138LVLR72 1204.7179 603.366 (2+) 11.88 G S 
 
 
Table 4.3. Modification of human serum albumin by HHE or HNE. Peptides obtained by in-gel 
(G) or SMART (S) trypsin digestion and MS data was analysed by Biopharma Finder. 
Modified 
Residues 









4-hydroxy-hexenal (HHE)  
His3 DAH+114KSEVAHR 1262.6368 421.887 (3+) 3.23 S 
Lys4 DAHK+114SEVAHR 1262.6368 421.886 (3+) 3.12 S 
His9 SEVAH+114R 811.4183 406.716 (2+) 3.25 S 
Lys12 FK+114DLGEENFK 1339.6661 670.840 (2+) 6.80 S 
Lys12 FK+96DLGEENFK 1321.6554 441.559 (3+) 6.80 S 
His67 SLH+114TLFGDK 1130.5974 377.873 (3+) 8.37 G S 
Cys75 LC+96TVATLR 971.5478 486.781 (2+) 7.88 G S 
Cys101 NEC+114FLQHK 1131.5392 566.777 (2+) 6.35 G S 
Cys101 NEC+114FLQHKDDNPNLPR 2052.9702 685.665 (3+) 6.58 G S 
Cys124 LVRPEVDVMC+96TAFHDNEETFLKK 2816.3889 568.087 (5+) 9.45 S 
His128 LVRPEVDVMCTAFH+114DNEETFLKK 2834.3984 710.108 (4+) 9.45 S 
His146 RH+114PYFYAPELLFFAK 2012.0592 672.028 (3+) 11.70 S 
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Cys177 AAC+96LLPK 810.4671 406.241 (2+) 7.79 G 
Arg186 LDELR+114DEGK 1187.6028 396.875 (3+) 4.89 G 
Lys190 LDELRDEGK+114ASSAK 1631.8389 544.954 (3+) 4.05 S 
Cys200 C+96ASLQK 744.3839 373.199 (2+) 5.86 S 
Lys212 AFK+96AWAVAR 1114.6284 372.550 (3+) 7.50 S 
Arg218 AWAVAR+114LSQR 1270.7145 636.365 (2+) 7.38 S 
Cys265 YIC+114ENQDSISSK 1499.6815 750.848 (2+) 6.24 G S 
Cys265 YIC+96ENQDSISSK 1481.6710 741.843 (2+) 6.24 G S 
Cys289 SHC+114IAEVENDEMPADLPSLAADFVESK 3030.3918 1011.472 (3+) 11.54 G S 
Arg338 RH+114PDYSVVLLLR 1580.9049 791.460 (3+) 9.49 S 
Lys378 VFDEFK+114PLVEEPQNLIK 2158.1587 720.728 (3+) 10.46 S 
Cys392 QNC+114ELFEQLGEYK 1713.7913 857.903 (2+) 10.14 S 
Cys392 QNC+96ELFEQLGEYK 1695.7797 848.897 (2+) 10.14 S 
Arg410 FQNALLVR+114YTK 1465.8291 489.617 (3+) 8.33 S 
Arg410 FQNALLVR+96YTK 1447.8217 483.614 (3+) 8.83 S 
Lys414 K+114VPQVSTPTLVEVSR 1752.9985 878.008 (2+) 7.62 S 
Lys432 NLGK+114VGSK 915.5395 458.777 (2+) 3.26 S 
Lys432 NLGK+96VGSK 897.5287 449.772 (2+) 3.27 S 
Arg485 R+96PCFSALEVDETYVPK 1948.9631 650.996 (3+) 9.07 G S 
Cys487 RPC+114FSALEVDETYVPK 1966.9724 656.999 (3+) 9.07 S 
Lys525 K+114QTALVELVK 1241.7596 621.887 (2+) 7.71 S 
Lys525 K+96QTALVELVK 1223.7491 408.924 (3+) 7.76 S 
Cys567 ADDKETC+114FAEEGKK 1683.7666 562.263 (3+) 4.82 G 
4-hydroxy-nonenal (HNE)  
His9 SEVAH+156R 853.4664 427.740 (2+) 5.01 G S 
His67 SLH+156TLFGDK 1172.6442 587.329 (2+) 10.70 S 
His128 LVRPEVDVMCTAFH+156DNEETFLK 2748.355 917.460 (3+) 11.62 S 
Arg186 LDELR+156DEGK 1229.6497 410.890 (3+) 7.98 G S 
Cys265 YIC+156ENQDSISSK 1541.7289 771.872 (2+) 9.05 G S 
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Lys276 LK+156ECC+57EKPLLEK 1644.8835 549.302 (3+) 7.74 G 
Cys289 SHC+156IAEVENDEMPADLPSLAADFVESK 3072.4399 1025.488 (3+) 12.45 S 
His338 RH+156PDYSVVLLLR 1622.9518 812.483 (2+) 10.70 S 
His338 H+156PDYSVVLLLR 1466.8524 489.958 (3+) 12.14 S 
Cys392 QNC+156ELFEQLGEYK 1755.8402 879.429 (2+) 11.95 S 
Arg410 FQNALLVR+156YTK 1507.8785 754.947 (2+) 10.36 S 
Arg410 FQNALLVR+138YTK 1489.8680 745.941 (2+) 10.59 G S 
Lys414 K+156VPQVSTPTLVEVSR 1795.0471 599.356 (3+) 8.97 S 
Lys432 NLGK+138VGSK 939.5760 470.795 (2+) 6.99 S 
Lys432 NLGK+156VGSK 957.5867 479.801 (2+) 6.99 S 
His440 H+156PEAK 736.4120 369.213 (2+) 4.84 S 
Arg485 R+138PCFSALEVDETYVPK 1991.0093 664.677 (3+) 10.73 S 
Arg485 R+156PCFSALEVDETYVPK 2009.0183 671.015 (3+) 10.72 S 
Cys487 RPC+156FSALEVDETYVPK 2009.0215 671.015 (3+) 10.58 S 
Lys525 K+156QTALVELVK 1283.8062 428.943 (3+) 9.42 S 
Lys525 K+138QTALVELVK 1265.7961 422.939 (3+) 9.52 S 
Cys567 ADDKETC+156FAEEGKK 1725.8132 576.278 (3+) 7.20 G 
 
With this bottom-up proteomic approach only one histidine residue (His68) could be 
identified on insulin modified by both HHE and HNE, either by Michael addition or by Schiff-
base formation, and independently from the digestion protocol used. For HSA, the analysis 
was more complex due to the protein size. A total of 27 amino acid residues were found to 
be modified by HHE, while 17 amino acid residues were found to be modified by HNE. Most 
of these residues were cysteine (Cys) and lysine (Lys) but histidine (His) and arginine (Arg) 
modifications were also detected. Some residues, for example Lys12, Cys75, Cys101, 
Cys124, Lys190, Cys200, Lys212, Arg218 and Lys378, were found to be exclusively 





In contrast to the sequence coverage observations, comparison of the two digestion 
approaches in terms of modified peptides detection showed that SMART digest, even 
though it had lower sequence coverage, allowed the detection of more modified peptides, 
either by HHE or HNE (Figure 4.9). Around 60-70% of peptides found to be modified were 
produced from SMART digest while under 10% were produced by in-gel digestion. Only 20-
30% of the peptides listed in Table 4.3 were generated by both digestion approaches. 
 





Selection of the appropriate chromatography for LC-MS analysis of lipoxidized proteins 
is a key step in proteomics specially in intact protein analysis. The diversity of proteins in 
shape, size or charge result in different interaction with column affecting its elution. Protein 
lipoxidation increases its complexity, hydrophobicity and charge resulting in a different 
interaction with chromatographic columns. The aim of the study reported in this chapter was 
to compare different chromatography methods for the separation of untreated protein 
isoforms as well as aldehyde-modified proteins. Three methods were tested: anion 
exchange, cation exchange and reverse phase chromatography. The proteins used to test 
the methods were insulin, ubiquitin and human serum albumin, either untreated or 
HHE/HNE-treated. The ion exchange methods presented in this study were based on a pH 
gradient using ammonium acetate and ammonium formate as the high pH eluent and acetic 
acid and formic acid as the low pH eluent. For these methods, the isoelectric point of each 
protein was important since the elution from the column would depend on the protein net 
charge, being eluted from the column once the pH from the mobile phase met the protein 
pI leaving it with neutral net charge. The ion exchange methods tested worked better for 
native protein isoform separation than lipoxidized proteins. It was hypothesized that these 
methods could be used to separate lipoxidized proteins since the oxidized lipid 
modifications could change the net charge of a protein. However, only cation exchange 
chromatography was able to distinctively separate HNE-modified ubiquitin and insulin, while 
MS data confirmed the modified proteins eluting slightly later than unmodified, no clear 
separation was observed at any other condition. Anion exchange chromatography was able 
to separate several isoforms of insulin and human serum albumin, the two proteins for which 
the PIs fit within the pH range of the gradient used. These observations confirm that each 
IEC method should be tailored to the pI of the protein of interest. However, for an ion 
exchange method to be coupled on-line to mass spectrometry, the choice of buffers needs 
to be compatible. This limits the buffers that can be used and therefore limiting the pH 
ranges that can be covered and consequently the proteins that are suitable for separations 
using these methods. Therefore, the anion exchange chromatography method used in this 
study shown interesting preliminary results in human serum albumin isoform separation 
which could potentially be applied to a clinical purpose. This method showed the same 
degree of separation with a similar HSA isoforms chromatogram as previously reported by 
Leblanc et al , which used a salt-gradient instead of pH gradient method for HSA isoforms 
separation [381]. Even though both methods were able to separate the isoforms and are 
both suitable for on-line coupling to MS, the pH gradient described in this chapter is quicker 
(20 min) when compared to theirs (80 min), which makes it more appealing for a potential 
clinical application. In contrast, this method was not able to separate lipoxidized HSA as 
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this was so heavily modified that no distinct peaks were observed. The proteins were 
modified on a 1:10 ratio so possibly a 1:1 ratio of modification would improve the separation 
of lipoxidized HSA. In conclusion, this chapter shows that the anion exchange 
chromatography method could be an easy and rapid tool for clinical application for HSA 
isoform separation and further validation of this method should be conducted with clinical 
samples. For example, plasma from diabetic or Alzheimer’s disease patients could be used 
to validate the method as for these the glycated isoforms of human serum albumin have 
been suggested as a biomarker [383, 384]. It was also possible to observe that the 
separation was easier for smaller proteins rather than large, for which multiple charges can 
influence the separation but most importantly the MS analysis. To improve this limitation, a 
middle down approach could have been applied for larger proteins such as human serum 
albumin [385]. On the other hand, reverse-phase chromatography showed to be the best 
separation method tested for lipoxidized-protein separation. The aldehyde modification on 
the proteins caused a changed in hydrophobicity, causing a change in retention time and 
allowing for the modified-proteins to be separated, not only according to the different 
degrees of modification but also separated unmodified from modified protein. Reverse-
phase chromatography is the commonly used method for intact protein analysis and here it 
was shown to be the best for quick separation of lipoxidized proteins. Even though ion 
exchange chromatography is being proposed as a good alternative to reverse phase in 
other applications than lipoxidation, such as basic drugs determination [386], the fact that 
this is not coupled to mass spectrometry does not limit the solvents that can be used and 
potentially improves the application of this method. However, for lipoxidized protein 
analysis, the coupling to MS for charcaterization is essential and ion exchange is not as 
good as reverse-phase chromatography for separation of these. 
Bottom-up LC-MS/MS analysis of insulin, ubiquitin and HSA were performed to localize 
the oxPTM hotspots of these proteins. In order to obtain the peptides, the samples were 
digested by in-gel or SMART digestion. The latest corresponds to a kit from Thermo which 
consists of an improved in-solution trypsin digestion in which trypsin is linked to beads and 
digests the proteins with an easy and quick protocol that obtains peptides in minutes. 
Additionally, it requires less samples manipulation since no reduction or alkylation is 
necessary. On the other hand, for in-gel digestion, more sample preparation is required 
such as to run a denaturing gel (SDS-PAGE), as the protein is cleaved into peptides in the 
later steps, which can take up to 2 days. In terms of sequence coverage, in-gel digestion 
shown higher percentage than SMART digestion, possibly due to less sample complexity 
and better detection of the fewer peptides present. However, a higher number of 
modification hotspots were identified using the later. While in-solution and in-gel digestion 
are two well-used approaches to prepare a bottom–up proteomic sample, in-gel digestion 
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has several advantages including simplification of samples of greater complexity before 
mass spectrometry analysis potentially contributing to the higher sequence coverage 
observed [216, 387]. In-solution digestion have the advantage of being a straightforward 
method where fewer things can go wrong. Additionally, it requires less protein and the 
peptides extraction efficiency is higher, which might justify the higher number of modification 
hotspots identified [388, 389]. Several amino acid residues were found to be modified by 
HHE and HNE, including some lysine, histidine and cysteine residues which have been 
previously reported modified by short-chain aldehydes [217]. However, in contrast to 
previous studies [286], the HSA cys34 was not found to be modified by either of the 
aldehyde treatments used in this study. This might be due to the size of the tryptic peptide 
containing this residue, which could give low ion intensity making its detection challenging. 
In conclusion, the study reported in this chapter demonstrated that ion exchange 
chromatography methods are rising as a good alternative for protein separation and here it 
was shown to be the best specifically in isoform separation. This could then be potentially 
used in clinical applications where isoform separation is relevant for example in the 
assessment of glycated isoforms of human serum albumin in diabetes. However, reverse 
phase chromatography remained the better method for lipoxidized proteins separation in 
agreement to previous studies, and the quick method reported here showed promising 
preliminary results in separation of proteins by degree of modification, and therefore 
potential application of this to investigate degree of lipoxidized proteins in human plasma 














Chapter 5. Short-chain lipid peroxidation products form 
covalent adducts with pyruvate kinase and inhibit its 





Tumour cells, as other highly proliferative cells, show upregulation of aerobic glycolysis, 
also known as the Warburg effect [270, 390]. They are also known to have altered redox 
balance, with higher cellular levels of reactive oxygen species as well as increased antioxidant 
concentrations[390, 391], and this pro-oxidative status is a requirement for their proliferative 
state through changes in metabolic reprograming [391, 392]. These changes may be achieved 
by modulation of enzymatic activities, as many enzymes in glycolysis are sensitive to cellular 
redox balance, including glyceraldehyde-3-phosphate dehydrogenase (GAPDH), pyruvate 
kinase M2 (PKM2), and phosphofructokinase (PFK) [393]. For example, the oxidation of the 
cysteine residue in the catalytic site of GAPDH leads to inhibition of its activity [394-396]. PFK 
can be regulated under oxidative stress by modifications of PFKFB3, which catalyzes the 
formation of fructose-2,6-bisphosphate, a potent allosteric inhibitor of PGFK, as modification 
of PFKFB3 on a cysteine residue located near the substrate binding pocket and cause 
decrease in its catalytic activity [397]. However, few studies have been conducted on the effect 
of oxidative stress on pyruvate kinase. 
Pyruvate kinase is the last enzyme of glycolysis and catalyses the conversion of 
phosphoenolpyruvate and ADP to pyruvate and ATP. It has been suggested to be a key player 
in the Warburg effect, since its activity can be modulated by allosteric regulation in tumour 
cells. Tumours, and other proliferating cells, have higher expression of the PKM2 isoform 
which is subject to allosteric regulation and lower activity compared to the non-allosteric PKM1 
isoform found in the majority of tissues [398, 399]. While PKM1 exists in the active tetrameric 
form, PKM2 occurs in equilibrium between monomer, dimer and the active tetramer [398]. This 
can be regulated by a wide variety of molecules, for example, the upstream glycolytic 
metabolite fructose-1,6-bisphosphate (F1,6BP), which stabilizes the tetramer, and in its the 
absence PKM2 activity drops to 4% [400-402]. Owing to its complement of nucleophilic amino 
acids such as cysteine residues, pyruvate kinase can also be inhibited by oxidants such as 
H2O2 [401, 403, 404]. Even though this modification is reversible and can recovered with a 
reducing agent, oxidation of pyruvate kinase can affect substrate binding, binding of allosteric 
regulators or multimerization [405]. Thus, oxidation has been suggested as a mechanism for 
inhibiting pyruvate kinase, for example in lung cancer cells [403]. It has been proposed that 
inhibition of pyruvate kinase leads to rerouting of glycolytic intermediates into the pentose 
phosphate pathway in order to generate NADPH and maintain reduced glutathione levels, 
facilitating cell survival in a pro-oxidative status [406]. In fact, accumulation of PEP has been 
shown to stimulate the pentose phosphate pathway by a feedback loop in the eukaryotic model 
S. cerevisiae [407]. Such metabolomic changes allow tumour cells to meet the increased 




While hydrogen peroxide or peroxynitrite can affect glycolytic enzymes directly, more 
reactive oxidants such as hydroxyl radicals can damage other cellular components such as 
lipids and cause lipid peroxidation. Oxidation of polyunsaturated fatty acids results in a wide 
range of products including short-chain aldehydes that are reactive and can cause covalent 
modifications of proteins [20, 31]. This process is known as lipoxidation and can occur via 
formation of Schiff’s base or Michael adducts on nucleophilic amino acids including lysine, 
histidine or cysteine [409, 410], as described in chapter 1. These adducts have been shown to 
occur both in vitro and in vivo, and links to inflammatory diseases such as atherosclerosis and 
Alzheimer’s disease have also been reported [410]. 
The 6-carbon aldehyde 4-hydroxyhexenal (HHE) is one of the major lipid peroxidation 
products of ω-3 PUFAs; it has very comparable reactivity to HNE, usually referred to as the 
the most toxic of this class of lipid oxidation product, and therefore of potential importance in 
disease [113]. The 3-carbon compound malondialdehyde (MDA) is the most studied aldehyde 
[411] and as it is bifunctional it has the potential to crosslink proteins [129]. Acrolein is another 
3-carbon aldehyde more commonly associated with tobacco smoke and processed foods 
[412], but which can also occur as a breakdown product of lipid peroxidation [74]. Acrolein is 
highly reactive, and it has been associated apoptosis and disruption of inflammation and 
antioxidant defence regulation [71, 80]. These aldehydes, an in particular HNE, have been 
suggested to have both pro-tumorigenic and anti-cancer effects depending on their levels. 
Aldehyde adducts with proteins and DNA can be mutagenic and carcinogenic [413], and have 
been reported to inhibit cell proliferation and angiogenesis as well as inducing differentiation 
and apoptosis in tumor cell lines [414]. Despite the known links between lipoxidation and 
cancer, little attention has been focused on the study of lipid peroxidation-derived aldehydes 
on glycolytic enzymes involved in the Warburg effect. GAPDH appears to be particularly 
susceptible to lipoxidation and it has been reported to be modified by HNE in vitro [163] and 
by acrolein in mouse carcinoma cells treated in culture [272, 415, 416]. In another study, the 
sites and mechanism of GAPDH modification by acrylamide, acrolein and methylvinyl ketone 
were compared [417]. Acrylamide caused the greatest inhibition of the enzyme activity and it 
was directly related with the modification on Cys152, located in the GAPDH active site. In 
contrast, lipoxidation of pyruvate kinase is still largely unexplored with only one study reporting 
the potential for HNE and its di-carbonyl analogue 4-oxononenal (ONE) to inactivate PKM2 
[273].  
In view of the gap in knowledge on the interactions of short chain reactive aldehydes with 
pyruvate kinase, we investigated the modification of this protein by acrolein, malondialdehyde 
and 4-hydroxyhexanal using LC-MS/MS to map the sites of modification following treatment in 
vitro. We then determined the effects of these treatments on PKM2 activity, both in vitro and 
in the cultured cell line MCF-7, and assessed their impact on cell viability, with the aim of 
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determining the potential of different aldehydes reactivity to contribute to metabolic remodelling 
via PKM2. The metabolic changes in the cell line MCF-7 caused by acrolein were also 
assessed by 1H NMR in collaboration with the University of Birmingham.  
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5.2. Material and Methods 
 
5.2.1. Synthesis of 4-hydroxy-2(E)-hexenal  
4-hydroxy-2(E)-hexenal (HHE) was a kind donation from  and was obtained by cross-
metathesis between acrolein and 1-penten-3-ol with Hoveyda-Grubbs catalyst in good yield 
(68%), following the two published procedures [418, 419]. 1H NMR (300 MHz, Aceton-d6) δ 
9.57 (d, J = 7.9 Hz, 1H), 6.96 (dd, J = 15.6, 4.4 Hz, 1H), 6.22 (ddd, J = 15.6, 7.9, 1.7 Hz, 1H), 
4.32 (ddt, J = 9.5, 6.7, 3.2 Hz, 1H), 4.22 (d, J = 4.9 Hz, 1H), 1.83 – 1.42 (m, 2H), 0.94 (t, J = 
7.4 Hz, 3H) ; 13C NMR (75 MHz, Aceton-d6) δ 193.1, 160.3, 130.3, 71.3, 29.2, 8.9. 
 
5.2.2. Treatment of pyruvate kinase with aldehydes in vitro 
Pyruvate kinase from rabbit muscle (EC2.7.1.40) was prepared at 2.5 mg/mL in phosphate 
buffer (7 mM sodium phosphate monobasic and 10 mM disodium phosphate dibasic, pH7.4) 
and treated with acrolein (ACR), malondialdehyde (MDA) (prepared via acid hydrolysis of 
1,1,3,3-tetramethoxypropane) or 4-hydroxy-2(E)-hexenal (HHE) at 2 µM, 10 µM, 20 µM, 38 
µM, 100 µM, 200 µM, 380 µM, 500 µM, 760 µM, 1mM or 5 mM, and allowed to react for 10 
minutes, 30 minutes, 1 hour, 2 hours or 4 hours at 37 °C. Following the reaction, to stabilize 
any adducts sodium borohydride (NaBH4) was added to the reaction to a final concentration of 
5 mM and the reaction left for a further 30 minutes at room temperature. This step was omitted 
when the treated pyruvate kinase was used immediately in the enzymatic activity assay. 
 
5.2.3. Cell culture and aldehyde treatment 
MCF-7 cells were cultured in DMEM (Gibco, UK) supplemented with 10% fetal bovine 
serum (FBS), 100 U/mL penicillin and 100 μg/mL streptomycin in a humidified incubator at 37 
°C and 5% CO2. For each aldehyde treatment, cells were seeded into new flasks at a cell 
density of 106 /mL and 10x stock solutions of ACR, MDA or HHE in phosphate buffered 
containing 0.9% NaCl pH 7.4 were added to the culture media to give final concentrations of 
2, 10, 20, 100 or 200 µM and incubated for 2, 4 or 24 hours. Biological triplicates were 
performed. 
 
5.2.4. XTT cell viability assay 
MCF-7 cells were cultured in a 96-well plate at 105 cells per well. The treatments with 
aldehydes were performed at the concentrations and times described above. XTT [2,3-bis-(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] was dissolved in sterile 
medium to a final concentration of 1 mg/mL. A 10 mM solution PMS (N-methyl dibenzopyrazine 
methyl sulfate) solution was prepared in phosphate buffer saline (PBS). Immediately prior the 
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start of the assay, 10 µL of PMS was added to 4 mL of XTT solution; 25 µL of PMS/XTT mixture 
was added to each well and the plate incubated in the dark for 2 h at 37 °C before reading the 
absorbance at 450 nm. The assay was performed with both technical and biological triplicates. 
 
5.2.5. Cell harvesting, lysis and protein concentration assessment 
Cells were harvested using pre-warmed trypsin-EDTA solution followed by centrifugation 
at 150 g for 5 min at 4 °C and lysed in lysis buffer (50 mM Tris-HCl pH 7.5, 1 mM EDTA, 150 
mM NaCl, 1% Triton X-100) supplemented immediately prior to usage with cOmplete™ EDTA-
free Protease Inhibitor Cocktail (Sigma Aldrich, UK) according to the manufacturer’s 
instructions. After 15 minutes incubation on ice, the samples were centrifuged at 17,000 g for 
2 minutes and the supernatant (cytosolic extract) was retained. The total protein concentration 
was determined by the Bradford assay using Pierce™ Coomassie Plus Assay Reagent 
(ThermoFisher Scientific, UK) in a 96-well plate: 5 µL of sample or standard per well were 
mixed with 250 µL of Coomassie reagent and after 10 mins the absorbance was read at 595 
nm. Samples were analysed for enzymatic activity immediately. 
 
5.2.6. Pyruvate kinase activity assays 
Pyruvate kinase activity was measured using a coupled assay using the pyruvate-
dependent conversion of NADH to NAD+ by lactate dehydrogenase as the reporter. For 
analysis of the effects on pyruvate kinase in vitro, 5 µL of the aldehyde-treated pyruvate kinase 
(equivalent to 1U) were added to a cuvette containing 30 µL of 45 mM adenosine 5′-
diphosphate (ADP), 30 µL of 45 mM phosphoenolpyruvate (PEP), 30 µL of 6.6 mM β-
nicotinamide adenine dinucleotide reduced form (NADH) and 5 µL of 200 U/mL lactate 
dehydrogenase (LDH) in 900 µL of 50 mM imidazole-HCl buffer pH 7.6, to give a final volume 
of 1 mL. The reaction at 25 °C was monitored at 340 nm for 10 minutes and the initial rate of 
reaction in μmol NADH utilized /min was calculated. For analysis of pyruvate kinase activity 
following cell treatments, the cytosolic extract was substituted for the commercial pyruvate 
kinase preparation. 
 
5.2.7. Protein in-solution digestion 
To 100 µL of aldehyde-treated pyruvate kinase prepared as described above, 100 µL of 
RapiGest SF (Waters, UK) were added and the solution vortexed. DTT was then added to a 
final concentration of 5 mM and the reaction incubated at 60 °C for 30 minutes. Cysteine 
alkylation was then performed by adding iodoacetamide to a final concentration of 15 mM and 
incubating in the dark for 30 min at room temperature. Trypsin (Trypsin Gold, Mass 
Spectrometry Grade, Promega, Southampton, UK) was added to a final concentration of 7 
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µg/mL and the samples were incubated overnight at 37 °C. To prepare samples for LC/MS, 
trifluoroacetic acid (TFA) was added to a final concentration of 0.5% and the reaction incubated 
at 37 °C for 45 min, during which time a precipitate formed. Acid-treated samples were 
centrifuged at 13000 rpm for 10 min then the supernatant carefully transferred to another tube 
and dried in a centrifugal evaporator and stored dry at -20 °C. Samples were resuspended in 
H2O/acetonitrile (98%/2%), 0.1% formic acid prior to MS analysis. 
 
5.2.8. Cellular extract in-gel digestion 
MCF-7 cells were grown as described in 2.4, but in 75 cm2 flasks. Cells were harvested by 
trypsinization and resuspended at 2x106 cells/mL in DMEM containing penicillin, streptomycin 
and 10% bovine calf serum. For each treatment, 5 mL of cells were seeded in a 25 cm2 flask, 
topped up with 4.5 mL of medium, and treated with 0.5 mL of a 10x stock of acrolein to yield 
final concentrations of 10 or 200 µM. At the end of the treatment, cells were harvested and 
extracted as described in 2.6. Extracts of 1x107 cells were run on a 7.5% denaturing 
polyacrylamide gel followed by in-gel digestion of the bands corresponding to pyruvate kinase 
according to a previously described protocol [217]. The resulting tryptic peptides were 
analysed by LC-MS/MS as described for the treatments in vitro. 
 
5.2.9. Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Analysis 
Peptides were separated and analysed using an Ultimate 3000 system (Thermo Scientific, 
Hemel Hempstead, UK) coupled to a 5600 TripleTOF (ABSciex, Warrington, UK). The analysis 
was performed as previously described [298] and as detailed in section 2.2.6. 
 
5.2.10. Database Searches 
The Mascot® probability based search engine (Matrix Science, London, version 2.4.0) was 
used to interrogate the SwissProt 2019_03primary database. LC-MS .wiff files of each sample 
were searched for protein identification and oxidative post-translational 
modifications(oxPTMs). For protein identification, variable modifications of methionine 
oxidation and carbamidomethyl cysteine were used. For the analysis of the lipoxidation 
products, the initial searches additionally used a variable modification list including reduced 
and unreduced ACR(mass changes of 56.06 Da, 58.08 Da, 40.06 Da, 94.11 Da, 56.06 
Da,76.09 Da), MDA (mass changes of 54.05 Da, 56.06 Da, 134.13 Da,36.03 Da and 26.04 
Da) or HHE (mass changes of 114.14 Da, 93.13 Da,78.11 Da) adducts at cysteine, lysine and 
histidine residues. Other parameters for the searches were as follows: Enzyme: Trypsin; 
Peptide tolerance: ± 0.6 Da; MS/MS tolerance: ± 0.6 Da; Peptide charge state:+2, +3; Max 
Missed cleavages: 1; #13C: 0; Quantitation: None; Instrument:   ESI-QUAD-TOF;   Data   
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format:   Mascot   Generic; Experimental mass values: Monoisotopic; Taxonomy: Chordata. 
All data identifying modifications were manually validated before inclusion 
 
5.2.11. Protein structure visualization using PyMOL 
The PyMOL Molecular Graphics System (Version 1.2r3pre, Schrödinger, LLC) was used 
for molecular visualization of the crystal structure of pyruvate kinase. The .pdb file containing 
the known crystal structure of PKM from rabbit muscle (P11974) and from Human (P14618) 
were downloaded from Uniprot. Backbone structures and space filing modules were created 
using the dropdown menus available on PyMOL. Hydrophobicity mapping was performed 
using the script called "Color h". This script colours the amino acid residues based on the 
Eisenberg hydrophobicity scale [420]. 
 
5.2.12. Glycolysis Stress Test with Seahorse XF Extracellular Flux Analyzer 
The Glycolytic Stress Test was used to monitor cellular glycolysis upon acrolein treatment. 
Prior to the assay, the cartridge was hydrated with calibrate solution in a non-CO2 incubator at 
37 ⁰C. On the day of the assay, the XF Glycolysis Stress Test Assay Medium was prepared 
as non-buffered DMEM XF Base Medium supplemented by 2 mM L-glutamine. The lack of 
buffer is critical to detect pH changes. Cells were seeded to a 24-well XF Cell Culture 
Microplate plate at 20,000 cells/well and treated with 2, 10 or 100 μM for 2 hours. Meanwhile, 
the glucose, oligomycin, and 2-deoxy-D-glucose were left at room temperature for 15 min, 
diluted to 10mM and loaded into the cartridge. After the treatment, the media was removed, 
the cells were washed with non-buffered DMEM medium, the assay medium was added, and 
the plate incubated in a non-CO2 incubator at 37 ⁰C for 1 hour. During the assay, glucose was 
injected first to a final concentration of 1 μM and cells catabolize it through glycolysis producing 
protons causing an increase in the extracellular acidification rate (ECAR). The second injection 
was oligomycin, to a final concentration of 1 μM, which inhibits mitochondrial ATP production 
and drives the cells to a maximum glycolytic capacity. Finally, 2-DG was injected to a final 
concentration of 1 μM inhibiting glycolysis and confirming that the ECAR generated in the 
assay is due to glycolysis. After the experiment, the protein concentration in each well was 
measured by Bradford Assay and ECAR values were normalized to protein concentration. The 
Seahorse XF Glycolysis Stress Test Report Generator automatically calculated the Seahorse 
XF Glycolysis Stress Test parameters and  exported them as an Excel file. 
 
5.2.13. NMR sample preparation 
Samples were prepared according to Saborano, R. et al. [275]. MCF-7 cells were grown 
as described in 2.4 to 80% confluency. To achieve optimal reproducibility, the metabolite 
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extraction from the MCF-7 cell line was performed with ice-cold solvents to reduce all metabolic 
processes. Initially the cells were washed 2-3 times with ice cold PBS to remove residual 
media, then 400 μL of cold methanol was added to immediately quench metabolism. Cells 
were scraped off the flask and the solution transferred to a glass vial, followed by chloroform 
extraction to obtain and separate the organic and polar phase. Briefly, 200 μL of chloroform 
were added, followed by 30 seconds vortex and the addition of further 200 μL of chloroform 
and 300 μL of water. After vortex, samples were left on ice for 10 minutes, followed by 
centrifugation for 10 minutes at 4000 rpm and the polar layer was then transferred to a clean 
tube and dried under vacuum for later NMR analysis. 
 
5.2.14. NMR acquisition and analysis 
All data collection and data analysis were performed in collaboration with University of 
Birmingham and according to Saborano, et al. [275]. Data collection was carried out using a 
Bruker 600MHz Avance III spectrometer using a 1.7mm cryoprobe. Dried polar metabolites 
were re-suspended in sodium phosphate buffer in 90% water and 10% D2O (0.1 mol/L, pH 
7.00) containing 3-trimethylsilyl-2,2,3,3-d4-propionate (TMSP) as an internal chemical shift 
standard, to acquire 1D 1H NMR spectra.  1D 1H-NOESY spectra were collected at 298 K with 
a 12 ppm spectral width, 32k data points and 128 scans. Spectra were processed using 
Metabolab [421] programmes within Matlab, version R2017b (MathWorks, Massachusetts, 
United State). Prior to Fourier transformation, each free induction decay (FID) was zero-filled 
to 65536 points and multiplied by an exponential function equivalent to a 0.3 Hz line 
broadening. All spectra were aligned on TMSP, a spline baseline correction was applied, the 
water and TMSP regions were excluded and Probabilistic Quotient Normalization (PQN) was 
applied to account for dilution of complex biological mixtures. Resonances were assigned 
using Chenomx 8.1 spectral database (Alberta, Canada, 2015), and comparing with the 
chemical shifts in the Human Metabolome Database (HMDB) [422]. 
 
5.2.15. Statistical analysis 
Data were analysed with Graph Pad Prism using one-way ANOVA for single time point 
(Figure 5.4, Figure 5.5 and Figure 5.7) and using two-way ANOVA for multiple time point 
(Figure 5.6 and Figure 5.10), both with Dunnett’s multiple comparisons test, comparing the 
values of each treated sample to the mean of the untreated control, normalized to 100%. Two-
way ANOVA with Dunnett’s multiple comparison test was also used for Figure 5.14 to compare 
the values of each metabolite in treated sample to the untreated control. Data are shown as 





5.3.1. Identification and mapping of lipoxidation on pyruvate kinase  
An LC-MS/MS bottom-up approach was used to investigate the in vitro modification of 
pyruvate kinase by ACR, MDA and HHE in order to map the sites of modification. Each peptide 
found modified by comparison to a database using the MASCOT® software was confirmed by 
de novo sequencing of the MS/MS spectrum [217] (examples for each aldehyde are shown in 
Figure 5.1). Following this approach, 11 acrolein-modified peptides, 10 HHE-modified 
peptides and 9 MDA-modified peptides were identified based on their peptide molecular 
weight, mass/charge ratio and charge of the peptide ion, MS/MS ion score and LC retention 
time (Table 5.1). The majority of the identified adducts occurred on lysine and cysteine 
residues, although some histidine adducts were identified. The mapping of the modified 
residues onto the enzyme 3D structure is shown in Figure 5.2. Pyruvate kinase showed 
different susceptibility to modification by each aldehyde as the residues modified were 
substantially different. ACR and HHE are both α,β-unsaturated aldehydes, therefore a similar 
profile of modification was expected. However, HHE formed adducts on Cys152, Lys188, 
Lys247, His379 that were not detected with acrolein, whereas acrolein uniquely modified 
Lys66, Lys166, Lys207 and His464. MDA gave a rather different profile, as only lysine adducts 
were identified, and modifications on Lys115, Lys224 and Lys270 were unique to this 





Figure 5.1. MS/MS spectra of modified pyruvate kinase tryptic peptides. LC-MS/MS was carried 
out as described in the experimental section, and peptides identified by Mascot searches as containing 
adducts were manually validated. (A) CLAAALIVLTESGR modified on the cysteine residue by acrolein 
forming a Michael adduct; (B) Michael adduct of HHE of the cysteine residue of CDENILWLDYK; (C) 
GDLGIEIPAEKVFLAQK modified by MDA as a Schiff’s base on lysine. The y and b ions indicated by 
the arrows confirm the peptide sequence and the modification on the cysteine or lysine residues 
respectively. Figure from [423].
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Table 5.1. Pyruvate kinase residues modified after 10 min treatment at high aldehyde concentrations in vitro. 
Modified 
Residues 


























Cys49 SB 44NTGIIC+56TIGPASR56  1357.70 1357.83 679.9 (2+) 52 27.76 - - - ✓ 
Cys49 MA 44NTGIIC+58TIGPASR56 1359.72 1359.84 680.9 (2+) 54 27.69 - ✓ ✓ ✓ 
Lys66 MA 63EMIK+58SGMNVAR73 1292.66 1292.81 431.9 (3+) 16 21.87 - - ✓ ✓ 
Lys166 MA 163NIC*K+58VVDVGSK173 1275.68 1275.81 638.9 (2+) 13 21.94 - - ✓ ✓ 
Lys207 SB 207K+40GVNLPGAAVDLPAVSEK224 1804.01 1804.19 602.4 (3+) 62 31.00 - - - ✓ 
Cys326 MA 320AGKPVIC+58ATQMLESMIK336 1876.98 1876.17 626.7 (3+) 19 52.72 - - - ✓ 
Cys358 MA 343AEGSDVANAVLDGADC+58IMLSGETAK367 2494.16 2494.37 832.5 (3+) 37 49.48 ✓ - - - 
Lys367 MA 343AEGSDVANAVLDGADC*IMLSGETAK+58GDYPLEAVR376 3551.67 3551.99 889.0 (4+) 26 47.52 - ✓ - - 
Lys393 MA 393K+58LFELAR400 1062.61 1062.72 532.4 (2+) 27 29.34 - - ✓ ✓ 
Lys393 SB 393K+40LFELAR400 1060.59 1060.63 531.3 (2+) 9 21.87 - - ✓ ✓ 
Cys423 MA 423C+58LAAALIVLTESGR436 1473.82 1473.96 737.9 (2+) 89 51.53 - - - ✓ 
His464 SB 462QAH+40LYR467 826.44 826.51 414.3 (2+) 21 21.03 ✓ - - - 
Cys474 MA 468GIFPVVC+58K475 975.55 975.63 460.8 (2+) 31 30.97 ✓ ✓ ✓ ✓ 
Lys475 MA 468GIFPVVC*K+58DPVQEAWAEDVDLR489 2599.30 2599.51 867.5 (3+) 57 53.72 - - ✓ ✓ 
 4-hydroxy-hexenal   
Cys152 SB 152C+96DENILWLDYK162 1506.71 1506.86 754.44 (2+) 24 39.35 - ✓ ✓ ✓ 
Cys152 MA 152C+114DENILWLDYK162 1524.72 1524.72 763.43 (2+) 72 33.52 ✓ ✓ ✓ ✓ 
Lys188 MA 187QK+114GPDFLVTEVENGGFLGSK206 2235.14 2235.34 746.12 (3+) 17 35.84 - - - ✓ 
Lys247 SB 247K+96AADVHEVR255 1119.60 1119.73 374.25 (3+) 27 18.23 - - - ✓ 
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Cys326 SB 320AGKPVIC+96ATQMLESMIKKPRPTR342 2650.45 2650.72 531.15 (5+) 14 38.00 - - - ✓ 
Cys326 MA 320AGKPVIC+114ATQMLESMIKKPRPTR342 2668.46 2668.72 445.79 (6+) 13 29.35 - - - ✓ 
Cys358 MA 343AEGSDVANAVLDGADC+114IMLSGETAK367 2550.18 2550.42 851.15 (3+) 36 36.37 - ✓ ✓ ✓ 
His379 MA 377MQH+114LIAR383 981.54 981.64 491.83 (2+) 13 19.81 - - ✓ ✓ 
His391 MA 384EAEAAMFH+114R392 1174.54 1174.67 392.56 (3+) 10 21.82 - - - ✓ 
Lys393 MA 393K+114LFEELAR400 1118.63 1118.72 560.37 (2+) 26 29.38 - ✓ ✓ ✓ 
Cys423 SB 423C+96LAAALIVLTESGR436 1529.85 1529.98 765.99 (2+) 76 40.94 ✓ ✓ ✓ ✓ 
Cys474 MA 468GIFPVVC+114K475 975.55 975.62 488.82 (2+) 26 28.22 - - ✓ ✓ 
Lys475 MA 468GIFPVVCK+114DPVQEAWAEDVDLR489 2599.29 2599.49 867.50 (3+) 85 33.83 - - - ✓ 
 Malondialdehyde 
Lys115 SB 93TATESFASDPILYRPVAVALDTK+54GPEIR120 3070.59 3070.81 768.71 (4+) 42 34.07 - ✓ - ✓ 
Lys135 SB 126GSGTAEVELK+54K136 1171.61 1171.52 391.51 (3+) 52 18.74 - ✓ ✓ - 
Lys188 SB 187QK+54GPDFLVTEVENGGFLGSK206 2175.08 2175.21 726.08 (3+) 94 34.69 ✓ ✓ ✓ ✓ 
Lys207 SB 207K+54GVNLPGAAVDLPAVSEK224 1817.99 1818.03 607.02 (3+) 70 28.67 ✓ ✓ ✓ ✓ 
Lys224 SB 208GVNLPGAAVDLPAVSEK+54DIQDLK230 2402.27 2402.45 801.82 (3+) 87 33.97 - ✓ ✓ ✓ 
Lys270 SB 267IISK+54IENHEGVR278 1447.78 1447.74 483.59 (3+) 82 23.05 - - - ✓ 
Lys305 SB 295GDLGIEIPAEK+54VFLAQK311 1881.03 1881.08 628.03 (3+) 48 34.80 - - - ✓ 
Lys393 SB 393K+54LFEELAR400 1058.58 1058.57 530.29 (2+) 37 27.85 ✓ ✓ ✓ ✓ 
Lys475 SB 468GIFPVVC*K+54DPVQEAWAEDVDLR489 2596.26 2596.49 866.50 (3+) 72 36.79 ✓ ✓ ✓ ✓ 
a (subscript) – amino acid position in the mature protein 
b (superscript) - mass difference corresponding to the modification 




Figure 5.2. Mapping of lipoxidation adducts to the crystal structure of pyruvate kinase. Backbone 
structure with modified residues indicated in space-fill form, showing the location of adducts of acrolein 
(A), HHE (B) and MDA (C). The modified residues are color-coded with orange indicating those found 
only at 380 µM, green for those found additionally at 760 µM and blue for ones found additionally at 5 




The identified modifications were also mapped onto space-filling models mapped for 
hydrophobicity of the solvent-accessible surface to evaluate if the hydrophobicity may affect 
the location of the modification.  The surface hydrophobicity is indicated in red in Figure 5.3; 
no clear correlation was identified between the hydrophobicity and the site of modification. 
Nonetheless, it was observed that acrolein was able to penetrate more readily into narrow 
pockets in the enzyme in comparison to HHE. 
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Figure 5.3. Space filling models of pyruvate kinase showing surface hydrophobicity and sites of 
adduction at high aldehyde concentrations. Surface views with increasing hydrophobicity shown in 
darker red. The location of adducts of acrolein (A), HHE (B) and MDA (C) are shown color-coded with 
orange indicating those found only at 380 µM, green for those found additionally at 760 µM and blue for 
ones found additionally at 5 mM. Figure from [423]. 
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5.3.2. Inhibition of pyruvate kinase activity following treatment in vitro 
The effect of the same treatment time and concentrations on pyruvate kinase activity were 
determined in vitro by a coupled spectrophotometric assay. It is worth noting that the isoform 
used for the in vitro study was PKM1 from rabbit muscle. A significant dose-dependent effect 
on the activity of pyruvate kinase was observed for all acrolein and HHE treatments. In 
contrast, MDA at lower concentration had no effect and an impact on the activity was only 
observed at the highest concentration of 5 mM. The activity of pyruvate kinase as percentage 
of control and the number of modified peptides detected as a percentage of the total number 
of modifiable tryptic peptides in the protein are shown in Figure 5.4. A clear inverse relationship 
between the enzymatic activity and the number of modifications can be seen. HHE gave the 
highest maximum number of modified peptides, followed by acrolein, and MDA was the lowest, 
reflecting the fact that only lysine residues can be modified by MDA. However, at 380 µM 





Figure 5.4. Inverse relationship between the dose-dependent effect of aldehydes on the activity 
of pyruvate kinase in vitro and the percentage of modified pyruvate kinase peptides identified. 
Pyruvate kinase was treated with 38 µM, 380 µM, 760 µM and 5 mM final concentrations of acrolein, 4-
hydroxy-hexenal or malondialdehyde for 10 minutes before the assessment of its activity by 
spectrophotometric assay of NADH oxidation at 340 nm (n=4; Mean ± SEM; * p<0.1 ** p<0.01 *** 
p<0.001 **** p<0.0001). Peptide modification was determined from the total number of modified peptides 
as a % of the total modifiable peptides in the sequence. Figure from [423]. 
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The concentration range of aldehydes used for mapping of the sites of modification was 
significantly higher than the concentrations that have been measured for these aldehydes in 
their free form in plasma. Hence, the effects of a wider range of treatment concentrations, that 
included physiological (2 µM) to pathophysiological (20-100 µM) concentrations, on pyruvate 
kinase activity were tested (Figure 5.5). It can be seen that acrolein caused a dose-dependent 
decrease in the activity of pyruvate kinase, with 70% activity at 100 µM and 200 µM, 40% at 
500 µM and 10% at 1 mM treatment, corresponding to substantially more inhibition than either 
of the other aldehydes.  
Figure 5.5. Dose-dependent effect of short treatments with acrolein, 4-hydroxy-hexenal and 
malondialdehyde on the activity of in-vitro pyruvate kinase. Pyruvate kinase was treated with 2 µM, 
20 µM, 100 µM, 200 µM, 500 µM and 1 mM of each aldehyde for 10 minutes before the assessment of 
its activity (n=3; Mean ± SEM; * p<0.1 ** p<0.01 *** p<0.001 **** p<0.0001). Figure from [423]. 
177 
 
5.3.3. The effect of longer treatment times on activity and lipoxidation of pyruvate 
kinase  
It was noted that the treatment concentrations required to cause significant inhibition were 
high, and it was hypothesized that this might relate to the very short incubation times tested 
initially (10 minutes), despite the fact that the reaction of acrolein with protein was expected to 
be rapid.  Therefore, further experiments were carried out with longer incubations of 30 minutes 
to 4 hours with the lower range of concentrations for each aldehyde (Figure 5.6).  
In general, longer incubations resulted in more extensive inhibition of activity showing a 
time-dependent trend for acrolein and HHE treatments. Acrolein above 10 µM caused 
significant effect on the activity after 1 hour reaction with only 40% activity remaining in the 
100 µM treatment. Increasing the time of reaction to 2 hours caused a decrease in activity to 
approximately 20% at the same concentration, and further inhibition was observed with 4 hours 
reaction. At 10 µM acrolein, a known pathophysiological concentration [269, 424], only 40% 
remaining activity was observed after 4 hours reaction. In the case of HHE, a treatment 
concentration of 100 µM caused a time-dependent effect on the activity, with 70% remaining 
after 30 mins, 55% after 1 hour, 40% after 2 hours and 30% after 4 hours. The 4 hour treatment 
also showed a significant dose-dependent effect. Comparing the two aldehydes, acrolein 
caused more inhibition of pyruvate kinase activity. MDA did not show a clear dose or time-
dependent effect on the activity; however, significant inhibition was observed at all 




Figure 5.6. Effect of longer treatments with acrolein, 4-hydroxy-hexenal and malondialdehyde on 
the activity of pyruvate kinase in vitro. Pyruvate kinase was treated with 2 µM, 10 µM, 20 µM and 
100 µM of each aldehyde for 30 minutes, 1 hour, 2 hours or 4 hours before the assessment of its activity 
(n=3; Mean ± SEM; * p<0.1 ** p<0.01, *** p<0.001 and **** p<0.0001). Figure from [423].  
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The same bottom-up LC-MS/MS approach from 3.1 allowed the identification of 10 
peptides modified by acrolein and 4 peptides modified by HHE after 4 hour treatments (Table 
5.2). Mostly the same adducts were observed after 2 hour treatments (Table 5.3), with the 
exception of three residues, Lys166, Lys207 and His391, which were only found at 4 hours 
and two residues, Lys188 and His464, which were only found at 2 hours. Apart from MDA  
where no adducts could be detected, all the amino acid residues found modified with the longer 




Table 5.2. Pyruvate kinase residues modified after 4 hours treatment with low concentrations of aldehydes. 
Modified 
Residues 


























Cys49 MA 44NTGIIC+58TIGPASR56 1359.72 1359.61 680.81 (2+) 80 15.97 -     
Cys152 MA 152C+58DENILWLDYK162 1468.69 1468.58 735.29 (2+) 91 19.57      
Lys166 MA 163NIC*K+58VVDVGSK173 1275.68 1275.57 426.19 (3+) 26 11.56 - - - -  
Lys207 MA 207K+58GVNLPGAAVDLPAVSEK224 1822.02 1821.83 608.28 (3+) 16 16.21 - - - -  
Lys207 MA 207K+96GVNLPGAAVDLPAVSEK224 1860.04 1859.89 620.97 (3+) 44 16.47 - - - -  
Cys358 MA 343AEGSDVANAVLDGADC+58IMLSGETAK367 2494.16 2493.97 832.33 (3+) 118 21.22 - - -   
His391 MA 384EAEAAMFH+58R392 1118.52 1118.41 373.81 (3+) 46 11.64 - - - -  
Lys393 MA 393K+58LFELAR400 1062.61 1062.51 355.18 (3+) 37 14.66 - - - -  
Lys393 MA 393K+96LFELAR400 1100.62 1100.52 367.84 (3+) 39 14.83 - - - -  
Cys423 MA 423C+58LAAALIVLTESGR436 1473.82 1473.71 737.86 (2+) 108 20.72 -     
Cys474 MA 468GIFPVVC+58K475 919.52 919.44 460.72 (2+) 47 17.13 -     
Lys475 MA 468GIFPVVC*K+58DPVQEAWAEDVDLR489 2543.27 2543.10 848.71 (3+) 103 19.99 - - -   
 4-hydroxy-2-hexenal    
Cys152 SB 152C+96DENILWLDYK162 1506.71 1506.61 754.31 (2+) 18 22.46 - - - -  
Cys152 MA 152C+114DENILWLDYK162 1524.72 1524.59 763.30 (2+) 46 20.12      
Cys423 MA 423C+114LAAALIVLTESGR436 1529.85 1529.72 765.87 (2+) 77 22.37      
Cys474 MA 468GIFPVVC+114K475 975.55 975.44 488.73 (2+) 26 16.76 - -    
Lys475 MA 468GIFPVVCK+114DPVQEAWAEDVDLR489 2599.29 2599.11 867.38 (3+) 91 18.97 - -    
 Malondialdehyde  
No modifications detected 
181 
 
a (subscript) – amino acid position in the mature protein 
b (superscript) - mass difference corresponding to the modification 
Michael addition (MA) or Schiff-base formation (SB) 
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Table 5.3. Pyruvate kinase residues modified after 2 hours treatment with low concentrations of aldehydes 
Modified 
Residues 


























Cys49 MA 44NTGIIC+58TIGPASR56 1359.72 1359.62 680.82 (2+) 81 16.41      
Cys152 MA 152C+58DENILWLDYK162 1468.69 1468.59 735.30 (2+) 95 19.92      
Lys188 SB 187QK+40GPDFLVTEVENGGFLGSK206 2161.11 2160.92 721.31 (3+) 67 21.15 - -    
Cys358 MA 343AEGSDVANAVLDGADC+58IMLSGETAK367 2494.16 2493.99 832.34 (3+) 105 21.57 - -    
Lys393 MA 393K+58LFELAR400 1062.61 1062.52 532.27 (2+) 27 15.07 - - - -  
Cys423 MA 423C+58LAAALIVLTESGR436 1473.82 1473.72 737.87 (2+) 87 21.15      
His464 SB 462QAH+40LYR467 826.44 826.34 414.18 (2+) 15 10.37 - - - -  
Cys474 MA 468GIFPVVC+58K475 919.52 919.44 460.73 (2+) 48 17.48 -     
Lys475 MA 468GIFPVVC*K+58DPVQEAWAEDVDLR489 2543.27 2543.10 848.71 (3+) 129 20.14 - - -   
 4-hydroxy-2-hexenal    
Cys152 MA 152C+114DENILWLDYK162 1524.72 1524.59 763.30 (2+) 85 20.23      
Cys423 MA 423C+114LAAALIVLTESGR436 1529.85 1529.71 765.87 (2+) 95 20.20      
Cys474 MA 468GIFPVVC+114K475 975.55 975.44 488.73 (2+) 22 16.96 - -    
Lys475 MA 468GIFPVVCK+114DPVQEAWAEDVDLR489 2599.29 2599.09 867.37 (3+) 70 19.94 - -    
 Malondialdehyde 
 No modifications detected 
a (subscript) – amino acid position in the mature protein 
b (superscript) - mass difference corresponding to the modification 
Michael addiction (MA) or Schiff-base formation (SB) 
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As observed for shorter treatment times, there was an inverse relationship between 
enzyme activity and percentage of peptides modified for longer treatments, although the 
total level of modification was significantly lower for these lower treatment concentrations 
(Figure 5.7).  
 
Figure 5.7. Inverse relationship between the dose-dependent effect of aldehydes on the 
activity of pyruvate kinase in vitro and the percentage of modified pyruvate kinase peptides 
identified. Pyruvate kinase was treated with 2 µM, 10 µM, 20 µM and 100 µM of each aldehyde for 
2 hours or 4 hours before the assessment of its activity (n=3; Mean ± SEM; * p<0.1 ** p<0.01, *** 
p<0.001 and **** p<0.0001). Figure from [423]. 
The sites of modifications for these treatments were also mapped to the 3D structure 
and are shown in Figure 5.8, where it can be seen that cysteine residues were the most 
sensitive to both acrolein and HHE modification. These were also mapped onto the 
hydrophobicity models (Figure 5.9) but once again no obvious correlation between the sites 




Figure 5.8. Mapping of lipoxidation adducts formed at low concentrations for 4 h treatments. 
Backbone structure with modified residues indicated in space-fill form, showing the location of 
adducts of acrolein at 2 h (A); acrolein at 4 h (B) and HHE at both time points (C). The modified 
residues are color-coded with yellow indicating those found only at 10 µM, orange for those found 
additionally at 20 µM, green for those found additionally at 100 µM and blue for ones found 




Figure 5.9. Space filling models of pyruvate kinase showing surface hydrophobicity and sites 
of adduction at low treatment concentrations. Surface views with hydrophobicity mapped in red 
and showing the location of adducts of acrolein (A), HHE (B) and MDA (C). The modified residues 
are color-coded with yellow indicating those found only at 10 µM, orange for those found additionally 
at 20 µM, green  for those found additionally at 100 µM and blue for ones found additionally at 200 




5.3.4. Comparison of aldehyde effects on MCF-7 cell pyruvate kinase activity and 
cell viability 
To investigate the ability of the aldehydes to cause inhibition of pyruvate kinase in a 
cellular environment, MCF-7 cells were treated in culture with aldehydes and their impact 
on extractable pyruvate kinase activity and cell viability was tested. The data here presented 
was acquired in collaboration with two placement students. These results are published, 
and the students contribution was acknowledged as second and third authors [423].  
Cells were treated with the lower range of concentration tested in vitro for acrolein, MDA 
and HHE for 2 hours or 24 hours (Figure 5.10). Two hour treatments at 10 μM acrolein 
inhibited the activity of pyruvate kinase to 20% of control (Figure 5.10A), while higher 
concentration treatments had a more severe effect on the activity of the enzyme. 
Interestingly, cellular pyruvate kinase activity seemed to be less sensitive to 24-hour 
acrolein treatment with 2-10 µM acrolein, although at higher concentrations the effect was 
very similar to 2 hours. In contrast, the cell viability showed a slightly different response to 
treatments at the two time points. Neither treatment time with acrolein caused significant 
loss of cell viability until concentrations of 100 µM (Figure 5.10B). HHE caused a similar, 
though more gradual, decrease in the enzymatic activity. The 2 h treatment at 10 μM 
inhibited the activity of pyruvate kinase to 60% of control (Figure 5.10C) and higher 
concentration treatments caused an even more severe effect. Similar to acrolein, pyruvate 
kinase activity seemed to be less sensitive to 24-hour HHE treatment at all concentrations, 
but in contrast with acrolein, these treatments only caused a maximum of 20% of loss in 
cell viability even at higher concentration treatments (Figure 5.10D). The effect of MDA on 
the cellular pyruvate kinase activity was similar to, though smaller than HHE (Figure 5.10E). 
While the concentration-dependent loss of activity appeared greater for the 2 hour 
treatment, MDA caused no significant loss of viability at any concentration or time point, in 




Figure 5.10. Dose- and time-dependence of aldehyde treatment on the activity of pyruvate 
kinase and viability of aldehyde-treated MCF-7 cells. Pyruvate kinase activity is shown on the left 
for acrolein (A), 4-hydroxyl-2(E)-hexenal (C) and malondialdehyde (E), while cell viability is shown 
on the right: acrolein (B), 4-hydroxyl-2(E)-hexenal (D) and malondialdehyde (F). Cells were treated 
with 2 µM, 10 µM, 20 µM, 100 µM and 200 µM of each aldehyde for 2 hours or 24 hours before 
proteins were extracted and 10 µg of extract were used for pyruvate kinase activity to be assessed. 
Cell viability assays were performed with n=3 for MDA and HHE and n=4 for ACR (Mean ± SEM; * 
p<0.1 ** p<0.01, *** p<0.001 and **** p<0.0001). * Comparison between treatments and control for 
each incubation time. # comparison between incubation times. Figure from [423] (This data was 




LC-MS/MS analysis of the cell extracts after 10 µM and 200 µM acrolein treatment 
allowed for modifications of cellular pyruvate kinase to be mapped. Although the sequence 
coverage was low, modifications on Cys152 and Cys358 were detected (Table 5.4 and 
Figure 5.11). This data agrees with the data from the in vitro treatments, where it was 
identified that these residues were highly susceptible to adduct formation. 
 











200 µM 24h 29% ACR (+58Da) Cys152 CDENILWLDYK 61 
200 µM 2h 32% ACR (+58Da) Cys152 CDENILWLDYK 42 
10 µM 24h 47% - - - - 
10 µM 2h 51% ACR (+56Da) Cys358 AEGSDVANAVLDGADCIMLSGETAK 82 
Control 2h 49% none - - - 




Figure 5.11. MS/MS spectra of different pyruvate kinase tryptic peptide from MCF-7 cellular 
extracts. CDENILWLDYK (A) and AEGSDVANAVLDGADCIMLSGETAK (B) modified on a cysteine 
residue by ACR. The y and b ions indicated by the arrows confirm the peptide sequence and the 
modification on the cysteine residue. Figure from [423].  
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5.3.5. Acrolein effect on the MCF-7 cells metabolism 
The previous sections suggest pyruvate kinase activity to be inhibit in cell by treatment 
with acrolein. To assess the effect of the treatment on glycolysis, the extracellular 
acidification rate (ECAR) was measured through real-time and live cell analysis upon 2 
hours of acrolein treatment, using a Seahorse XF Analyzer. Figure 5.12  shows the ECAR 
profile for MCF-7 cells untreated (control) and acrolein treatment at different concentrations. 
 
 
Figure 5.12. Extracellular acidification rate (ECAR) profile of untreated and acrolein-treated 
MCF-7. Cells were treated with 2, 10 or 100 μM acrolein prior to the assay. Addition of glucose at 15 
min promoted glycolysis and the acidification increase by release of protons (H+) by the cells. 
Oligomycin inhibits ATP synthase, driving glycolysis to its maximum rate. Later, a competitive 
inhibitor of glucose (2-DG) is added to shut down glycolysis. 
Upon acrolein treatment, a dose-dependent decrease on the glycolytic capacity was 
observed. Glycolytic capacity is the maximum ECAR reached by a cell after addition of 
oligomycin which effectively shuts down oxidative phosphorylation and drives the cell to use 
glycolysis to its maximum capacity.  
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To further investigate the effect of the inhibition of pyruvate kinase in a cellular 
metabolism, the metabolomic profile of MCF-7 cells was analysed before and after acrolein 
treatment. Figure 5.13 shows the standard 1H NMR spectrum of the metabolites extract 




Figure 5.13. Representative 1H NMR spectrum of the metabolome of MCF-7 cells. Some 
assignments are indicated: three-letter codes are used for amino acids, ADP - adenosine 
diphosphate, ATP - adenosine triphosphate, BCAA - branched chain amino acids, NAD - 




The low frequency region (δ 0-3) shows resonances from several amino acids including 
the branched chain amino acids, alanine, threonine and glutamate, as well as organic acids 
such as lactate and acetate. In the mid-frequency region (δ 3-5.5) additional metabolites 
were detected, including glycine, choline-containing compounds, fructose and serine. The 
high-frequency region (δ 5.5-9) is characterized by signals arising from aromatic amino 
acids such as phenylalanine and tyrosine, organic acids such as fumarate and nucleotides 
such as ADP, ATP and NAD+. It is worth noting the high intensity of the peak corresponding 
to lactate in the low frequency region, which is likely to occur as these are cancer cells and 
therefore known to convert most of glucose to lactate regardless of the availability of O2 (the 
Warburg effect) [270]. In total, 27 compounds were identified in the cells providing 
significant information on the metabolic composition and setting the basis for interpreting 
the effect of acrolein exposure. MCF-7 cells were exposed to 2 μM, 10 μM and 100 μM 
acrolein for 2 and 24 hours followed by metabolites extraction for analysis. The 
concentrations and time range of the treatments were chosen based on the cell viability 
results presented in Figure 5.10. Figure 5.14 shows the 1H NMR spectra for two hour 





Figure 5.14. 1H NMR spectra of the metabolome of MCF-7 cells untreated and upon treatment 
with 2 μM, 10 μM and 100 μM acrolein for two hours. 
A visual comparison of the four spectra allows for some differences to be proposed, 
such as a decrease in the levels of lactate, glutamate and fumarate in the exposed cells. 
Additionally, these spectra demonstrate that acrolein caused the metabolome of MCF-7 
cells to change in a concentration-dependent manner, with higher concentrations causing 
stronger effects. To better evaluate the effect of acrolein on the metabolome at different 
concentrations and times of treatment, the peaks from the spectra were integrated and the 
intensity of 18 metabolites is shown in Figure 5.15. The metabolites chosen for integration 
were based on the non-ambiguity of their identification, no overlap with other peaks on the 




Figure 5.15. Dose and time-dependence of acrolein treatment on the metabolism of MCF-7 
cells.  Cells were exposed to 2 µM, 10 µM and 100 µM of acrolein for 2 hours or 24 hours followed 
by metabolites extraction and analysed by 1H NMR. (n=3; Mean ± SEM; * p<0.1 ** p<0.01 *** p<0.001 
**** p<0.0001). * Comparison between treatments and control for each incubation time. # comparison 
between incubation times. 
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The metabolome analysis showed that there was a concentration- and time-dependent 
effect of acrolein in the cellular metabolism including metabolites from glycolysis, the TCA 
cycle and amino acid metabolism. At 2h of exposure to μM acrolein, valine and 
phenylalanine were lower than in the control. A higher concentration of 10 μM acrolein 
showed further decrease in valine and an increase in aspartate, while for phenylalanine and 
all the other metabolites no changes were observed. However, 100 μM acrolein completely 
changed the cellular metabolism with pyroglutamate, methionine and glucose higher than 
the control, and almost all of the other metabolites identified were lower than the control 
including alanine, glutamate, aspartate, glycine, lactate, threonine and fumarate. The profile 
at 24 hours was similar, but a more pronounced metabolic response was apparent for 
almost all metabolites at this time-point. Aspartate was observed to be lower than the 
control at 24 hours, in contrast to 2 hours. Also for 2 μM acrolein, it was observed that there 
was an increase in lactate, and for 10 μM acrolein the levels of threonine were lower for the 
24 hour treatment in comparison to the 2 hour. Additionally, alanine and glutamate 




Pyruvate kinase is an important regulatory enzyme in glycolysis, and changes in its 
expression level, isoform profile and activity have been linked to the switch to aerobic 
glycolysis in cancer and proliferating cells [350]. Cancer cells also have an altered redox 
status [392] leading to increased lipid peroxidation and the formation of electrophilic short-
chain carbonyl species, but previously there have been few studies of the effects of these 
carbonyl species on pyruvate kinase. To address this question, the inhibition of pyruvate 
kinase activity was measured following treatment with acrolein, HHE and MDA in vitro, and 
the formation of protein-aldehyde adducts was monitored  by LC-MS/MS. A clear inverse 
relationship was observed between the extent of adduct formation and the activity of 
pyruvate kinase for all three aldehydes, and acrolein was found to cause the greatest 
inhibition. MDA had no significant effect until much higher concentrations were used, 
probably due to its chemistry that only allows for reaction with lysines to form Schiff’s base 
adducts. However, like the other aldehydes, it can also cause cross-linking.  
The mass spectrometry analysis of the profiles of modification showed different 
susceptibility of pyruvate kinase residues to each aldehyde. The extent of inhibition was 
dependent on the length of incubation and the treatment concentration, with longer 
treatments causing loss of activity at lower and physiological concentrations, suggesting 
that reversibility of these adducts was not a significant factor. Pyruvate kinase extracted 
from treated cells showed higher susceptibility to modification, indicated by a greater loss 
of activity at lower concentration than found in vitro, and no correlation with the loss of cell 
viability was observed, suggesting that the loss of activity is not due to general cell 
dysfunction. It has been reported previously that tumour cells can survive and proliferate 
with very low pyruvate kinase activity [425], supporting the suggestion that loss of pyruvate 
kinase activity does not result in cell death. The susceptibility of individual residues to 
modification varied according to the aldehyde, and even ACR and HHE, which are both α,β-
alkenals, showed different modification profiles. Although there were six common residues 
(Cys326, Cys358, Lys393, Cys423, Cys474, Lys475) modified by these aldehydes following 
short treatments at higher concentrations, there were also several differences. This may be 
due to the smaller size of acrolein and a corresponding ability to access more buried 
residues, such as Cys49, Lys207 and His464. Some additional residues modified by HHE 
seemed to be surface accessible, including Lys188 and Lys247, and it is unclear why these 
were not adducted by acrolein; mapping of the surface hydrophobicity did not suggest that 
modification with the longer or shorter aldehydes correlated strongly with this factor. The 
only overlap between the three aldehydes were the modifications on Lys393 and Lys475. It 
is important to note that other modifications might have been present but not detected by 
the methods used, such as cross-linking.  
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It is important to attempt to understand the potential functional effects of the identified 
modifications on different residues. Two of the cysteine residues found modified by acrolein 
and HHE have been previously reported to be modified by oxidation [405] or electrophilic 
attack by HNE and ONE [273]. While Cys326 was only modified at higher concentration, 
Cys358 was modified at lower concentration. Cys326 is buried in the tetramer form but 
accessible in the monomeric form, and a modification at this site could prevent the 
reformation of the active tetramer [405], or destabilize the intact tetramer. In PKM1 this 
residue is protected, which is likely to account for the requirement of a high concentration 
of aldehyde to detect its modification. Cys358 is located close to the substrate binding site, 
and has previously been reported to regulate pyruvate kinase activity by oxidation, 
promoting tumour growth and survival in a pro-oxidative cellular status [403]. Cys423 was 
another cysteine residues shown to be sensitive to ACR and HHE adduct formation, which 
together with Cys152. Cys423 is located at the subunit interface, and a modification on this 
residue could also potentially destabilize the tetrameric form. Cys424 plays a role in protein-
protein interaction and allosteric regulation by F-2,6-bP, and has been reported to be 
modified by electrophilic carbonyl species [273]. However, this residue is only present in the 
PKM2 isoform and therefore was not found modified in the in vitro study described here. 
Lysine residues can also be modified, and it is important to understand their role in the 
enzyme activity. For example, Lys305 was found modified at the highest MDA treatment 
and modification of this residue by acetylation had been reported to reduce pyruvate kinase 
activity by lowering the affinity for PEP, or triggering the degradation of the enzyme itself 
under nutrient-deplete conditions [426].  
The inverse relationship between pyruvate kinase activity and the percentage of 
modified peptides observed suggests that the accumulation of adducts, rather than a 
modification on a specific residue, contributes to conformational change leading to major 
loss of activity. However, the modification on a single residue cannot be discounted as a 
possible cause of the loss in activity. For instance, losses in activity were observed at 38 
μM acrolein and HHE after 10 mins and 10 μM after 4 hour treatments, thus the adducts 
detected on these conditions (Cys 152, Cys358, Cys423, His 464, Cys474) are most likely 
to be involved. The fact that MDA did not cause an inhibition of activity on short treatments, 
but the modification of many lysines were still detected by LC-MS/MS, suggests that none 
of these residues are essential for the normal functioning of the enzyme. Instead these 
residues may well be acting as surface decoys for modification to prevent oxidative damage 
to more critical residues. The eventual loss of activity above 1 mM MDA is probably a result 
of conformational changes and unfolding of the protein, rather than modification on specific 
amino acid residues. Nevertheless, lysine residues have been reported to be involved in 
the regulation of pyruvate kinase, for example Lys433 can interact with phosphotyrosine-
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containing proteins leading to the inhibition of the enzyme by release of F-1,6-bP [427-429]. 
On the other hand, proteolysis has also been shown to be inhibited by crosslinking of lysine 
residues on enzymes [55]. 
The extractable pyruvate kinase activity in the human breast cancer cell line MCF-7 was 
found to be extremely susceptible to cellular acrolein treatment, with more than 80% loss of 
activity after 2 hours of 10 μM acrolein, in contrast to an inhibition of about 30% in vitro with 
the same treatment. MDA also had a much stronger inhibitory effect on cellular pyruvate 
kinase, compared to the minimal effect on activity in vitro, whereas the effects of HHE in 
vitro and in vivo were similar. It is important to note that the treatments in vitro and in cells 
cannot be directly compared, as the in vitro worked was carried out using the PKM1 form 
from rabbit muscle, whereas the MCF-7 cells have been shown to mainly contain the PKM2 
isoform [430]. PKM2 can be allosterically regulated and readily dissociates into dimers or 
monomers with much lower activity, in contrast to PKM1 which is found constitutively in the 
active, tetrameric form. Despite the large number of different proteins in cells, pyruvate 
kinase was highly susceptible to inactivation by the aldehyde treatment. However, it is not 
clear which mechanism, irreversible modification, increased degradation or decreased 
synthesis of the enzyme, lead to the loss of activity. Previous studies on HNE and ONE 
using click chemistry followed by shot-gun proteomics identified isoforms M1, M2 and R as 
susceptible to lipoxidation [431], and another study reported PKM2 to be modified by the 
same compounds in human colorectal carcinoma (RK) cells [273]. These observations 
support the hypothesis that the loss in activity is related to direct pyruvate kinase 
modification by the aldehydes. 
Interestingly, for all treatments the loss of activity at low treatment concentrations was 
less pronounced after 24 hours than 2 hours, which suggest that during longer treatment 
defence mechanisms are activated by the cell to overcome the loss of activity. In fact, 
pyruvate kinase has a relatively high turnover rate with half-life of 0.7 days [432], which 
could explain the recovery of enzyme activity at 24 hours at lower concentrations of 
aldehyde, although this turnover rate was not measured under the lipoxidative stress 
conditions of the experiments described in this thesis. It is also known that electrophilic 
modification of proteins, by HNE or analogues, signals for protein degradation and recycling 
by the 20S proteasome [433]. However, high concentration treatments can cause cross-
linking [434] and protein aggregation, which inhibits the proteasome and leads to cell death 
[435].  
During transformation of cells to a tumorigenic phenotype, pyruvate kinase isoforms and 
activity have been reported to change in order to switch to aerobic glycolysis (the Warburg 
effect) [398], resulting in an increase in the production of lactate by glucose-dependent 
pathways. This study suggests that oxidative modification can also change PKM2 activity 
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and consequently cause changes in metabolic response. It has been suggested that 
inhibition of pyruvate kinase causes a backing-up of metabolites in glycolysis as far at 
glucose-6-phosphate, leading to an increased flux through the pentose phosphate pathway 
that facilitates antioxidant defence and the synthesis of nucleotides [406]. Despite the low 
activity of pyruvate kinase, cancer cells are still able to maintain high lactate production, so 
it was suggested that rather than complete inhibition of pyruvate kinase, PKM2 has a high 
Km for PEP which results in a different flux through glycolysis supporting both lactate 
production and pentose phosphate pathway [436]. However, pyruvate kinase is highly 
susceptible to oxidative and electrophilic attack, and there is evidence of elevated levels of 
oxidants and antioxidants in cancer [437]. This is supported by the data presented in this 
study as well as others [273, 403, 405, 407]. In the case of inhibition by electrophilic species, 
it seems likely that increased flux through the pentose phosphate pathway and altered 
metabolic state increases protein synthesis and maintains cellular functioning. 
The decrease in the glycolytic capacity of the cells upon acrolein treatment, confirms 
the data discussed above suggesting that upon treatment the cellular glycolysis is reduced, 
and cells switch their metabolism for cell survival and proliferation. Additionally, an NMR 
based metabolomics approach was used to confirm these changes in the cellular metabolic 
state. As discussed above, acrolein decreased the activity of pyruvate kinase and 
consequently the amount of pyruvate being produced through glycolysis. However, the 
treatments did not show any effect on the cell viability until 100 μM acrolein was reached 
suggesting that the cells were changing their metabolism and surviving despite the 
decrease in pyruvate kinase activity. The results of the metabolome analysis showed that 
acrolein induced changes in amino acid, energy and oxidative stress-related metabolism. 
The decrease in pyruvate generated from glucose metabolism resulted in utilization of 
alternative pathways to overcome this, since pyruvate is crucial in cancer cells for 
conversion into lactate required for invasion and metastasis [438]. This hypothesis was 
confirmed by no statistically significant differences being observed in the amount of lactate 
after treatments, where only 100 μM acrolein after 24 hours was able to induce a decrease. 
The reduced pyruvate kinase activity was compensated for in MCF-7 cells by the production 
of pyruvate and macromolecules via glucose independent pathways. It has been reported 
that alanine consumption is increased when pyruvate levels decrease [439], and the 
decrease in alanine and glutamate observed at 24 hours treatment suggests that these 
could be being used by the MCF7 cells to fuel the tricarboxylic acid (TCA) cycle, lipid 
metabolism and to be converted to pyruvate [440]. Another alternative is for pyruvate to be 
produced from tyrosine, which itself can be produced from phenylalanine [441], and both of 
these aromatic amino acids showed a significant decrease at 24 hours treatment, 
suggesting that this may be another pathway which the cells are using to overcoming the 
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lack of pyruvate generation from glucose. Tyrosine can also be converted to fumarate [442], 
but the decrease in the levels of fumarate observed suggests that this pathway is not being 
activated, or that fumarate is readily being converted into other metabolites. In fact, cancer 
cells tend to favour the conversion of pyruvate into lactate rather than using the TCA cycle, 
so the use of aromatic amino acids to produce pyruvate over supporting the TCA cycle 
might be expected. A limitation of this metabolomic approach was that no metabolites from 
the pentose phosphate pathway were detected, so no inferences can be made from these 
results on whether metabolism is directed towards this pathway. However, accumulation of 
glucose was not observed, except at the highest acrolein concentration, suggesting that 
glucose was still being used despite the inhibition of pyruvate kinase. 
Several other amino acids were found to vary in response to acrolein in addition to the 
ones mentioned above, and these different amino acids are involved in different metabolic 
pathways. For example, valine is metabolised to carbohydrates, leucine to fats and 
isoleucine to both. After acrolein treatment, isoleucine, valine and threonine were found 
significantly decreased after 24 hours, which could be an indicator either of their metabolism 
towards protein synthesis or to form a series of coenzyme A compounds that can be further 
oxidized for use in the TCA cycle in the forms of acetyl and succinyl CoA [443], contributing 
to the energy metabolism. Another amino acid found to vary upon acrolein treatment was 
glycine, which significantly decreased at 24 hours in an acrolein concentration-dependent 
manner. Glycine is the simplest amino acid and can be utilized for the biosynthesis of 
glutathione, creatine, nucleic acids and uric acid [444], suggesting that its decrease might 
be link with the production of antioxidant defences. In fact, the simultaneous decrease of 
glycine and glutamate at 10 μM and 100 μM at 24 hours might suggest an increase in the 
biosynthesis of glutathione in order to provide protection against the oxidative stress 
generated [445] and to promote the detoxification of acrolein [446, 447]. GSH-ACR adducts 
have been previously detected in B16-BL6 mouse melanoma cells exposed to cigarette 
smoke extract [448] and these adducts were promptly reduced and excreted to the 
extracellular fluid resulting in the detoxification of acrolein. The same group showed that 
this mechanism of detoxification of acrolein also occurs in non-cancerous cells [449]. The 
decrease in glutamate might also be related to the increase in pyroglutamate, an analogue 
of glutamate produced by the loss of a water molecule [450]. Even though its biological role 
is still not completely understood, free pyroglutamate is known to have a role in 
osmoprotection and its de novo synthesis usually occurs in response to osmotic stress 
[451]. Pyroglutamate also has an anti-diabetic effect in type 2 diabetes suggesting a role in 
lipid metabolism, although the mechanism is still not clear [452]. Figure 5.16 summarises 




Figure 5.16. Cellular glycolysis and TCA cycle metabolism. Diagram representing the metabolic 
changes detected by 1H NMR and summarizing the changes discussed above. Green arrows 
represent the most active reactions according to the observed changes in the levels of each 
metabolite. These point to a change in metabolism to compensate the loss of pyruvate kinase by 
promoting pyruvate formation through amino acids and fuelling the TCA cycle metabolism via other 
ways other than glycolysis. The channelling of glycolysis intermediates into the pentose phosphate 




All of the metabolic changes discussed above, either for compensation of lower 
production of pyruvate from glucose or increase in antioxidant defences, were all detected 
significantly after 24 hour treatments but not after 2 hours, which strengths the hypothesis 
of time being needed to activate these defence mechanisms, and also justifies the reduced 
loss of activity after 24 hours. It is also worth noting that the treatments presented in this 
study reflect an acute acrolein exposure allowing the cells to adapt to the treatment; a 
chronic exposure such as in inflammatory disease might show a different metabolic 
response. 
In summary, this study has provided novel data on the susceptibility of the key glycolytic 
enzyme pyruvate kinase to modification by 3 aldehydes with different chemical reactivities: 
acrolein (an alkenal), HHE (a hydroxyalkenal), and MDA (a dicarbonyl), and has shown that 
they cause differential inhibition of activity both in vitro and in a breast cancer cell line. 
Pyruvate kinase in MCF-7 cells was extremely susceptible to inhibition and modification by 
acrolein, which is a carcinogen present in tobacco smoke as well as a product of lipid 
peroxidation. Metabolomic analysis of MCF-7 cells upon acrolein treatment revealed a 
cellular metabolic change that could suggest an additional mechanism by which this 














Chapter 6. Effect of reactive short-chain aldehydes on 




The cytoskeleton is the principal machinery responsible for maintaining cell shape and 
mechanics. It is commonly divided in terms of its functional subsystems into actin filaments 
(AFs), microtubules (MTs), and intermediate filaments (IFs), according to their size and 
protein content. However, recent studies show that key cellular functions such as cell 
division are dependent on strong crosstalk between all three subsystems [453, 454].  
Microtubules are the largest type of filament (about 25 nm in diameter) and are made of 
α/β-tubulin heterodimers, which assemble into a polar, cylindrical structure in the presence 
of GTP [455]. This is responsible for cell shape, organelle positioning, cell polarity and 
segregation of chromosomes during cell division [456]. The different functional 
specialization can be acquired by interaction with microtubules-associated proteins (MAPs) 
but also by the “tubulin code” which consists of a combination of differential expression of 
α- and β-tubulin isotypes and tubulin post-translational modifications [457, 458]. Actin is the 
most abundant protein in many cells and the component of microtubules. Humans have 
three genes for α-actin, one gene for β-actin, and two genes for γ-actin [459]. Actin has a 
strong tendency to polymerize into filaments, which consist of two strands of subunits in 
right-handed helices staggered by half the length of an actin monomer (2.7 nm) [460, 461]. 
These are responsible for providing structure and support to internal movements, including 
interaction with myosin motor proteins [462], intracellular transport [463], cellular structure 
[464], muscle contraction [465] and cytokinesis [466]. 
Intermediate filaments are made of filamentous proteins that have no known enzymatic 
activity but have a conserved substructure necessary for their self-assembly into 
intermediate filaments (which are about 10 nm diameter). The various intermediate 
filaments provide each cell type with a unique cytoskeletal network, which can be 
considered as ‘identity cards’ for cell and tissue differentiation [467]. This extensive 
cytoplasmic network connects the cell cortex to intracellular organelles, conferring an 
advantage for intermediate filaments in coordinating cell activities [468]. Intermediate-
filament proteins can be divided into five types on the basis of primary and gene structure, 
assembly properties and tissue distribution. Keratins (types I and II) form necessary 
heteropolymers in epithelial cells, while vimentin, desmin, glial fibrillary acidic protein 
(GFAP) and peripherin (type III) form homopolymer intermediate filaments. Neurofilament 
proteins (type IV) include three neurofilament subunits (NF-L, NF-M and NF-H), as well as 
nestin, syncoilin and α-internexin. Lastly, the nuclear intermediate filaments (type V) consist 
of protein lamin A, B1, B2 and C [454, 469]. 
Vimentin is a coiled-coil protein composed mainly of α-helical regions linked by 
connecting segments. Even though a crystal structure for the full-length monomeric or 
tetrameric vimentin is not yet available, molecular modelling proposes that monomers 
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assemble into parallel dimers first, which in turn associate antiparallelly into tetramers 
resulting in the structural units for polymerization [470]. These forms robust filaments 
extended from the nuclear periphery to the cell membrane, and are therefore responsible 
for several cell activities, including organelle positioning, cell migration and adhesion, and 
cell signalling [471-476]. Vimentin filaments are able to interact with signalling proteins and 
are known to bind to phosphorylated ERK, modulating MAPK cascade signaling [477]. Due 
to such important roles, vimentin has critical implications in pathophysiological conditions. 
It is recognized as an active factor in cancer [478] and as an autoantigen in rheumatic fever 
and rheumatoid arthritis [479, 480]. Additionally, it is involved in wound healing and 
consequent excessive scarring [481, 482], and has a facilitating role in viral infections [483, 
484]. The assembly of the vimentin network is regulated by interaction with microtubules 
and their associated proteins [454, 485]. Under stress conditions, post-translational 
modifications such as phosphorylation, nitrosylation or carbonylation may also be involved 
in the regulation of vimentin network [486-489].  
In a pathophysiological environment, cells increase the production of oxidants such as 
hydrogen peroxide, which can directly affect proteins or generate more reactive compounds 
such as hydroxyl radicals that can cause damage to cellular components, as well as lipid 
peroxidation. Short-chain aldehydes are one of the many products of the peroxidation of 
lipids and due to their high reactivity can cause covalent modifications and crosslink of 
proteins, altering their structure and consequently function [20, 31]. Lipoxidation can occur 
via Schiff’s base formation with lysine residues or formation of Michael adducts on histidine, 
cysteine or lysine residues [281] and its products have been found in inflammatory diseases 
such as atherosclerosis and Alzheimer’s disease [282]. The lipid peroxidation product 4-
hydroxynonenal (HNE) is by far the most studied however other aldehydes deserve some 
consideration [490]. The 6-carbon 4-hydroxyhexenal (HHE) is one of the major lipid 
peroxidation products of ω-3 polyunsaturated fatty acids (PUFAs) with comparable 
reactivity to HNE [113]. The 3-carbon compound malondialdehyde (MDA) is the most 
studied in parallel with HNE and due to its bifunctionality has the potential to crosslink 
proteins [104, 129]. Another 3-carbon aldehyde is acrolein, more commonly associated with 
tobacco smoke 31, it is highly reactive, especially with thiol groups of proteins, and it has 
been associated with apoptosis, inflammation and antioxidant defence regulation [71, 80]. 
Intermediate filaments are highly sensitive to oxidative and electrophilic stress, and their 
proteins such as vimentin, GAFP and lamin have been previously reported as direct targets 
not only of oxidation and nitrosylation as stated above but also of lipoxidation [491-493]. 
MDA and glyoxal (GO) have been shown to play a role in fibrosis and impaired wound-
healing processes mediated by vimentin disruption and deciliation [494]. The smoke 
component acrolein was reported to target vimentin and cause cross-linking in lung cells 
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[495] and vimentin network rearrangement/disruption in human gingival fibroblasts [496]. 
More recently, the pre-incubation in vitro wildtype vimentin with HNE before polymerization 
was shown to result in shorter filaments. This effect was slightly attenuated by mutation of 
the residue Cys328, required for polymerization,; however, the levels of total adducts 
detected by western blot did not change since HNE could form adducts with other residues 
such as histidine and lysine [497]. In fact, it has been previously reported that Cys328 is 
required for the normal function of vimentin under resting conditions and for its plasticity in 
response to oxidative stress. The dual function of the single cysteine residue on vimentin is 
related to its modulation by zinc levels. Zinc was shown to regulate vimentin polymerization 
and cysteine modification, suggesting that this specific residue has a zinc binding role on 
vimentin [498]. Lipoxidation of the single cysteine residue Cys328 by cyclopentenone 
prostaglandins (cyPG), a reactive lipid type generated by inflammation, has been previously 
reported. This covalent adduct between the  lipid and Cys328 caused a rearrangement of 
the vimentin network [492, 499]. 
As yet, there have been no comparative studies of Cys328-mediated effects of different 
small aldehydes on vimentin. Therefore the aim of this study was to address the importance 
of Cys328 in vimentin organization, by comparison of the network upon treatment of cells 
expressing wildtype vs cells expressing mutant Cys328S with acrolein, malondialdehyde 
and 4-hydroxyhexenal. Moreover, the ability of the vimentin network to reorganize 24 hours 
after treatment with acrolein and malondialdehyde was also assessed by overnight 
monitoring of the vimentin network organization.  
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6.2. Material and Methods 
6.2.1. Cell culture and aldehyde treatment 
Adrenal carcinoma SW13/cl.2 cells are a well-known model for vimentin cellular studies 
due to their lack of cytoplasmic intermediate filaments [500]. These cells allow for the effects 
of vimentin to be study without interference from the endogenous protein. Cells were 
cultured in p100 dishes in DMEM with 10% (v/v) fetal bovine serum (FBS) and antibiotics 
(100 U/ml penicillin and 100μg/ml streptomycin). For network visualization, cells were co-
transfected with RFP//vimentin plasmids, expressing untagged vimentin plus GFP-vimentin 
for time-lapse microscopy. SW13/cl.2 cells untransfected or stably transfected with 
RFP//vimentin wild type (wt) or RFP//vimentin C328S mutant, have been described 
previously [498]. For time-lapse experiments, transient transfections were carried out in p35 
dishes divided in 4 compartments at 70% confluence using Lipofectamine 2000. Briefly, 1 
μg of DNA (0.8 μg of RFP//vim wt and 0.2 μg of GFP-vimentin wt) and 3 μL of Lipofectamine 
were used per dish. Transfections were carried out in medium without antibiotics for 48 h. 
Imaging of live cells was performed 48 h after transfection. For single-point experiments, 
treatments were carried out in serum free medium and cells were seeded into a 12-well with 
glass coverslip plate. Cells at 80% confluence were treated with 10 μM ACR or HHE, or 30 
μM MDA for 1, 2 or 24 hours. These concentrations have been previously reported as 
pathophysiological levels in human plasma. Aldehydes were prepared as a 10x stock in 
water and filtered with 0.22 μm filter unit (Merk Millipore, Cork, Ireland) for sterilization, 
before being added to the cells for treatment. For time-lapse microscopy, the treatments 
were added immediately before the visualization for monitoring of the effect. 
 
6.2.2. Fluorescence microscopy and cell imaging 
Cells treated with the different compounds were visualized by confocal microscopy on 
Leica SP2 or SP5 microscopes. Images were acquired every 0.5μm and single sections or 
overall projections are shown, as indicated. For immunofluorescence, cells were fixed with 
4% (w/v) paraformaldehyde for 25 min at room temperature, permeabilized with 0.1% (v/v) 
Triton-X100 in PBS and blocked with 1% (w/v) BSA in PBS. Antibodies were used at 1:200 
dilution in blocking solution. For the detection of full-length vimentin the V9 antibody was 
employed. Filamentous actin (f-actin) was stained with Phalloidin-Alexa568 (Molecular 
Probes) following the manufacturer’s instructions.  Nuclei were counterstained with DAPI (3 
μg/ml). Measurements of cell area were obtained with ImageJ. Time-lapse microscopy was 
carried out in a multidimensional microscopy system Leica AF6000 LX in a humidified 5% 
CO2 atmosphere at 37 ºC. Green fluorescence and differential interference contrast (DIC) 




6.2.3. Statistical analysis 
All experiments were performed at least three times. The results are presented as mean 
values and the error bars are the standard error of the mean (mean ± SEM). Two-way 
analysis of variance (ANOVA) was used with the Dunnett’s correction to evaluate significant 
differences among samples. A value of P < 0.05 was considered to be statistically 




6.3.1. Effect of short-chain aldehydes on vimentin network by confocal microscopy 
The aim of this chapter was to evaluate the effect of the lipid peroxidation products short-
chain aldehydes on the intermediate filaments network. The main filament studied in was 
vimentin, which is responsible for cell structure and organelle positioning. Therefore, SW-
13/cl.2 cells expressing wildtype vimentin were treated with 10 μM acrolein, 10 μM 4-
hydroxyhexenal and 30 μM malondialdehyde, and the effect on the vimentin network was 
assessed by confocal microscopy. Figure 6.1 shows the overlay channels of the 
immunofluorescence for vimentin in green and for nuclei in blue for the 3 time points and 
the three aldehydes tested. 
 
Figure 6.1. Effect of acrolein, 4-hydroxyhexenal and malondialdehyde on vimentin 
organization in cells. SW13/cl.2 cells stably transfected with RFP//vimentin wt were treated with 10 
μm ACR and HHE and 30 μM MDA for 1, 2 or 24 hours after which cells were fixes and vimentin 
network analysed by immunofluorescence. Scale bars, 20 μm. V9 antibody detected vimentin (green) 




All aldehydes tested caused a disorganization the vimentin filament network resulting in 
an accumulation around the nucleus. This effect was particularly evident for the 2 hours 
treatment, even though it was also observed for the other two time points. A small recovery 
of this network appears to occur 24 hours after the treatments. In order to assess these 
changes in the vimentin network better and investigate vimentin accumulation/aggregation, 
the vimentin and actin networks were compared (Figure 6.2).  
 
Figure 6.2. Comparison of actin and vimentin networks organization after acrolein, 4-
hydroxyhexenal and malondialdehyde treatment. SW13/cl.2 cells stably transfected with 
RFP//vimentin wt were treated with 10 μm ACR and HHE and 30 μM MDA for 1, 2 or 24 hours, after 
which cells were fixed and the vimentin network analysed by immunofluorescence. Scale bars, 20 
μm. V9 antibody (1:200) detected vimentin (green) and filamentous actin was stained with Phalloidin-
Alexa568 (red). 
The actin network helped to outline the cells and therefore assess the area covered by 
the vimentin network. While for the control samples the vimentin seemed to occupy almost 
the whole cell, after the treatments it was possible to observe an aggregation of this filament 
and consequently that it appeared to occupy less area within the cell. After 2 hours 
treatment this aggregation was very clear when compared with the control for the same time 
point. After only 1 hour of treatment the same effect can be observed, although to a smaller 
extent. For better quantification of this effect, the area of actin was used as the area of the 
whole cell and the ratio vimentin/actin was calculated (Figure 6.3). All conditions tested 
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were found to be statistically different from their respective controls (Figure 6.3A). After 1 
hour treatment, HHE appeared to cause the most accumulation of the vimentin network, 
while for acrolein 2 hours appeared most effective, although no statistically significant 
differences were confirmed between the different aldehydes at any time point. Figure 6.3B 
shows the same percentages represented as % of control, where the ratio for each control 
was set as 100% and all the other percentages calculated accordingly. This was performed 
to perceive more clearly the differences between conditions. Statistically significant 
differences were only observed for acrolein between the time points of 1 and 2 hours. Even 
though no statistical difference was observed between 24 hours and the other time points, 
a trend suggests a small recovery of the vimentin network overnight. 
 
Figure 6.3. Relative quantification of vimentin cell distribution. Variance in vimentin/actin ratio 
to assess the effect of the aldehyde’s treatment on the vimentin network. (A) vimentin/actin ratio 
expressed in percentage for control (no treatment), ACR at 10 μM, MDA at 30 μM and HHE 10 μM; 
(B) vimentin/actin ratio normalized as percentage of control, comparison between time points. (n=9; 
Mean ± SEM; * p<0.1 ** p<0.01, *** p<0.001 and **** p<0.0001) * Comparison of conditions with 




6.3.2. Mutation of Cys328 confers protection from lipoxidation on the vimentin network  
To assess the importance of the only cysteine residue in the vimentin amino acid 
sequence, a same cell line with mutant vimentin was used in which the cysteine residue on 
the position 328 was substituted by a serine, described as C328S throughout the chapter. 
Figure 6.4 shows the overlap of the immunofluorescence for vimentin and for nuclei for the 
3 time points and the three aldehydes tested on this mutant cell line. 
 
Figure 6.4. Effect of acrolein, 4-hydroxyhexenal and malondialdehyde on vimentin 
organization in cells. SW13/cl.2 cells stably transfected with RFP//vimentin Cys328Ser (C328S) 
were treated with 10 μm ACR and HHE and 30 μM MDA for 1, 2 or 24 hours after which cells were 
fixed and vimentin network analysed by immunofluorescence. Scale bars, 20 μm. V9 antibody 
(1:200) detected vimentin (green) and nuclei were counterstained with DAPI (blue). 
The vimentin network of the control samples from the mutant cell line already shows 
some degree of disruption when compared with the control samples from Figure 6.3. An 
aggregation of vimentin was also observed for this cell line after treatment, although to a 
smaller extent than the aggregation observed previously for the wild type. Similarly, a small 
recovery of the network appeared to be happening 24 hours after the treatments and these 




Figure 6.5. Comparison of actin and vimentin networks organization after acrolein, 4-
hydroxyhexenal and malondialdehyde treatment. SW13/cl.2 cells stably transfected with 
RFP//vimentin Cys328Ser (C328S) were treated with 10 μm ACR and HHE and 30 μM MDA for 1, 2 
or 24 hours, after which cells were fixed and vimentin network analysed by immunofluorescence. 
Scale bars, 20 μm. V9 antibody detected vimentin (green) and filamentous actin was stained with 
Phalloidin-Alexa568 (red). 
The vimentin network seemed to occupy almost the whole cell in the control samples 
as well as after the aldehyde treatments. In Figure 6.5, some perinuclear accumulation 
aggregation of vimentin after HHE treatment for 1 and 2 hours was observed. However, 
these only represent a small group of cells, and other cells in the same plate did not show 
the same effect (data not shown). So for better determination of this effect and accounting 
for the three replicates data, the area of actin was used as the area of the whole cell and 
the ratio vimentin/actin was calculated (Figure 6.6). Figure 6.6A shows the ratio between 
vimentin and actin network areas for the mutant cell line. The vimentin C328S mutant 
showed attenuated responses to the aldehyde treatments, being more resistant to these. 
When compared with the control samples, only MDA showed a significant effect after 1 hour 
treatment while ACR showed a significant effect after 2 and 24 hours treatment. Similarly 
to the wild type (Figure 6.6B), only ACR showed a difference between conditions 
significantly decreasing the ratio after 2 hours when compared with 1 hour treatment. The 
results indicate that the mutation on the only cysteine residue of vimentin protected the 





Figure 6.6. Relative quantification of vimentin cell distribution. Variance in vimentin/actin ratio 
to assess the effect of the aldehyde’s treatment on the vimentin network. (A) vimentin/actin ratio 
expressed in percentage for untreated and treated C238S mutant cells; (B) vimentin/actin ratio 
expressed in percentage for untreated and treated SW13 cell line, which is the same as shown in 
Figure 6.3A for comparison. (n=3; Mean ± SEM; * p<0.1 ** p<0.01, *** p<0.001 and **** p<0.0001)  




6.3.3. Monitoring the effect of ACR and MDA treatment by time-lapse microscopy 
In order to investigate the possibility that the vimentin network slightly recovered 
overnight after the treatments (section 6.3.1), the effect of ACR and MDA on the vimentin 
network was assessed by time-lapse microscopy. In this way the same group of cells was 
monitored throughout the experiment. Micrographs were taken before the treatment was 
added and after the treatment each 30 minutes for the first 4 hours and then every hour 
overnight (Figure 6.7). The quality of the pictures is lower than the quality in the previous 
figures because the intensity of the laser and the time of exposure were decreased in order 
to limit its impact on cell survival. Two different groups of cells were monitored overnight 
after exposure to 10 μM of acrolein. For both groups of cells, it was clear that the first 4 
hours of treatment caused a disorganization of the vimentin network resulting in its 
accumulation. However, Figure 6.7A indicates that the overnight monitoring did not detect 
a recovery of the vimentin network. In fact, after 8 hours of treatments the cells appeared 
to be dead. In contrast, in Figure 6.7B which monitored a different group of cells, a recovery 
of the network appeared to occur from 6 to 16 hours after the acrolein treatment was used. 
 
Figure 6.7. Time-lapse microscopy monitoring of cells treated with 10 μM acrolein. 
Micrographs were taken every 30 minutes for the first 4 hours and then every hour overnight. Here 
are shown the pictures taken 1, 2, 4, 6, 8, 10 and 12 hours after the treatment. Two different positions 
of the dish, A and B, followed the effect of the same treatment a different group of cells. Micrographs 




The same experiment was performed after cell treatment with 30 μM of 
malondialdehyde (Figure 6.8). Similarly to the effect observed after acrolein treatment, the 
first four hours after MDA treatment resulted in an accumulation of vimentin that can be 
observed by the increase in intensity of the green fluorescence. Once again, the recovery 
of the vimentin network after treatment was not observed overnight. In fact, 10 hours after 
the treatment it was possible to observe cell death resulting in the release of its content. 
 
Figure 6.8. Time-lapse microscopy monitoring of cells treated with 30 μM malondialdehyde. 
Micrographs were taken every 30 minutes for the first 4 hours and then every hour overnight. The 
images taken 1, 2, 4, 7, 10, 13 and 16 hours after the treatment are shown. Micrographs consist of 




Vimentin plays a key role in normal functioning of cells and during pathophysiological 
conditions in addition to its structural function. Among other roles, vimentin is responsible 
for organelle positioning and facilitates wound repair [498]. This protein is also known to be 
a critical sensor for oxidative stress and a target for lipoxidation by electrophilic lipids [488, 
498]. Due to the lack in studies on the Cys328-mediated effect of short-chain aldehydes on 
vimentin, the main aim of the study reported in this chapter was to assess the effect of 
acrolein, malondialdehyde and 4-hydroyhexenal in vimentin network organization as well 
as determine the importance of the only cysteine residue in the vimentin sequence. The 
concentration of each aldehyde used has previously been reported as a pathophysiological 
concentration of these free aldehydes in human plasma or serum [31, 269]. The cell line 
used was the SW13/cl.2 cells stably transfected with RFP//vimentin wild type (wt). The 
mutant cell line RFP//vimentin C328S was used to investigate the role of the cysteine 
residue Cys328 in the lipoxidation of vimentin, and RFP//vimentin wt plus GFP-vimentin wt 
transfection was used for time-lapse experiments. 
The results show that treatment of cells with reactive aldehydes results in morphological 
alterations of the network including a marked reorganization and accumulation around the 
nucleus. All aldehydes showed the ability to reduce the area of vimentin in the cell, an 
indication of its aggregation around the nucleus. In fact, the juxtanuclear condensation of 
cytoplasmic intermediate filaments like vimentin upon treatment with unsaturated carbonyl 
species has previously been reported [493, 498]. Intermediate filament remodelling can be 
a mediator of cell damage or a mechanism of defence, therefore the biological implications 
of the lipoxidation-associated aggregation is still not completely understood. Acrolein and 
HHE showed to cause the highest vimentin aggregation. Juxtanuclear aggregation of 
vimentin filament caused by lipoxidation has been previously described in fibroblasts and in 
epithelial cells after acrolein and HNE, respectively [496, 497]. Moreover, mutation of 
Cys328 resulted in protection against the lipoxidation effect and only acrolein was able to 
cause a slight aggregation of vimentin overnight. Cys328 is the only cysteine residue on 
vimentin and it has been reported to be susceptible to modification by reactive aldehydes 
such as HNE in biological systems [489]. The results in this chapter confirmed Cys328 as 
a major target of lipoxidation since its mutation to serine conferred protection. Mutation of 
this cysteine has showed protection against other electrophilic species [492, 498, 499] and 
demonstrated Cys328 to be a hot spot for posttranslational modifications in vimentin [497, 
501, 502]. Cysteine residues are commonly susceptible to modification on several protein 
apart from vimentin [493, 503]. Filament disruption upon lipoxidation is not just an issue with 
vimentin. Other intermediate filaments, for example GFAP, have been reported to show the 
same effect on the network upon lipoxidation and this protein also has a conserved cysteine 
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residue Cys294 which plays a crucial role in organization and assembly of the filaments 
[493]. Overall, these studies confirm that these conserved cysteine residues in intermediate 
filaments are sensors for stress and its mutation confers protection against oxidative stress. 
In early experiments there was some evidence of a trend to cellular recovery of vimentin 
network at 24 hours, even though the data were not significantly different. However, in this 
experiment, different groups of cells were studied for each time point. To overcome this 
limitation, a time-lapse experiment was set up in order to follow the same cells and monitor 
the changes in vimentin overnight after treatment. During the first four hours the 
juxtanuclear aggregation was confirmed, however the time lapse microscopy approach did 
not confirm the recovery of the network overnight and cell death was observed. The cell 
death might be caused by phototoxicity resulting from cumulative exposure, as little cell 
death was observed in the end-point experiments, even though the intensity of the laser 
and its phototoxicity were taken into consideration when planning the experiment 
parameters and a lower intensity and short exposure times of the laser were chosen [504]. 
Moreover, these aldehyde concentrations were not supposed to be cytotoxic as described 
in section 5.3.4. The phototoxicity of the laser was confirmed by observation under the 
microscope of the cells that were not being monitored overnight, which were confirmed to 
be alive. To overcome this limitation, future experiments should be performed by monitoring 
the cells only once every two hours, for example after the first four hours, to reduce the 
exposure time of the laser to the cells. As information on the first 4 hours has now been 
obtained, this would not need to be reported in a time lapse experiment, decreasing the 
exposure of the cells to the laser and increasing the probability of observing vimentin 
recovery. 
In conclusion, this study demonstrated the effect of electrophilic modification by short-
chain reactive aldehydes on vimentin network organization and localization in cells. The 
observed aggregation of vimentin around the nucleus could be associated with cell 
dysfunction and therefore connected to pathophysiological conditions such as aging, 
inflammatory diseases and cancer. A limitation of this study was the lack of MS data to 
support the hypothesis of Cys328 being a target of lipoxidation. Therefore, MS analysis of 



















7.1. General discussion  
The oxidative modification of lipids containing polyunsaturated fatty acids results in a 
wide diversity of reactive products, including short-chain aldehydes, which are highly 
reactive and able to modify proteins. Lipoxidation products generates at lower levels can be 
related have a signaling role and activate antioxidant defences. However, at higher levels 
these have been linked to many inflammatory diseases, thus their study, as potential 
biomarkers of inflammation, is important. Mass spectrometry-based methods are a key tool 
in proteomic research but there is still a need to improve the detection methods for 
lipoxidation adducts, as these are extremely challenging to detect due to their relative low 
abundance. In this project, a bottom-up approach was able to map aldehyde modifications 
on human serum albumin. However, the incomplete sequence coverage detected by LC-
MS could be improved in order to obtain information on the modification status of other 
residues that were not covered, for example Cys34 which is a major target for modification 
in HSA and several studies and methods have been developed with focus on its detection. 
The sequence coverage can possibly be improved by combination of different proteases to 
digest the protein generating smaller peptides and allowing the detection of Cys34, since 
using trypsin digestion only the peptide containing this residue was too long and gave low 
ion intensity. Protein-protein cross-linking has also previously been shown to occur through 
acrolein modification, including in proteins such as Hsp90, which has a role in the response 
to oxidative stress. However, a limitation of the work reported in this thesis is the lack of 
mass spectrometry analysis of protein crosslinking adducts even though these were 
possibly observed by SDS-PAGE where bands corresponding to double or three times the 
mass of protein in study were observed. It would have been interesting to conduct a study 
by LC-MS/MS for mapping and characterization of these crosslinks and determine hotspots 
for their occurrence in proteins such as human serum albumin. 
Regardless, the tandem mass spectrometry approach used allowed for the detection of 
potential diagnostic ions for adducts of aldehydes with nucleophilic amino acid residues 
such as cysteine, histidine, lysine and arginine. Five diagnostic ions for acrolein and eight 
for 4-hydroxyhexenal adducts with human serum albumin were consistently observed in the 
MS/MS spectra of modified peptides. The diagnostic ions for acrolein modification were 
then used in the development of a multiple reaction monitoring MS-based approached 
focused on their detection in complex biological samples. The transitions 600.4 → 142.1 
and 509.3 → 168.1, which include the reporter ions for lysine and histidine modification 
respectively, were shown to be successful in the detection of acrolein-albumin adducts as 
their signal was detected exclusively in acrolein-treated samples, both for in vitro modified 
human serum albumin and human plasma. Therefore the novel MRM method developed 
identified promising transitions for acrolein-albumin adduct detection and proved to be 
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highly selective for acrolein modification. Previously reported targeted methods developed 
for albumin modification detection required protein extraction from plasma due to 
interference from other proteins [314]; however, for the method described here, sample 
preparation was kept to a minimum by only diluting the plasma and the transitions were 
detected with minimal background noise. Further validation of this targeted method using 
clinical samples is still necessary to understand its potential application in the detection of 
acrolein-albumin adducts in case of disease, such as from type 2 diabetes mellitus patients 
[505], Alzheimer’s disease or any type of cancer, with lung cancer being the most applicable 
as acrolein in a major component of tobacco smoke. Hopefully the success of this method, 
developed using the reporter ions described in chapter 2, will encourage other methods to 
be developed with a similar approach for other protein modifications, including using the 
other reporter ions reported in this thesis. 
Chlorine containing aldehydes have previously been reported to be produced during 
neutrophil activation and to accumulate, for example, in atherosclerotic plaques [147]. There 
is still a lack in knowledge on their impact on cell function, as they have the potential to 
modify proteins and therefore directly cause structural and functional changes. Additionally, 
their reactivity in comparison with other aldehydes such as those mentioned above, and the 
products formed after chloroaldehyde modification of proteins is still largely unexplored. An 
alternative method to directly convert hexadecanol into 2-chlorohexadecanal was proposed 
on chapter 3, which was less time-consuming and cheaper than current methods used 
[339]. An MS-based approach allowed the charcaterization of 2-chlorohexadecanal 
modification of human serum albumin and consequently the detection of a reporter ion for 
2-ClHDA-lysine adducts. Previous studies reported that 2-ClHDA reacts with cysteine 
residues by nucleophilic attack on C-Cl retaining the carbonyl group [199]. However, the 
mass of the lysine residue reported in this thesis corresponds to the Schiff-base formation 
with additional loss of HCl, showing that analysis of 2-chloroaldehyde adducts is more 
complex than other aldehydes, due to the different types of modifications that can arise 
depending on the amino acid residue modified. Further analysis of 2-ClHDA adducts by MS 
is needed to confirm the sensitivity of the reporter ion m/z 323 to detect 2-ClHDA-lysine 
adducts. In addition, the purity of the synthetic 2-ClHDA could be improved by flash 
chromatography or HPLC for extraction of the chloroaldehyde and removal of impurities 
that could interfere with future experiments. For example, to assess the cellular effect of 2-
ClHDA it is important that its purity is high to ensure that the effects observed are due to 
chloroaldehyde treatment instead of its impurities. In the work reported in chapter 3, the 
synthetic 2-ClHDA was reacted with human serum albumin for mapping and 
characterization of its modifications, however other properties of this aldehydes could be 
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explored apart from its reactivity with proteins such as antimicrobial inspired by the 
properties of other chlorine containing compounds as hypochlorous acid (HOCl). 
Proteomic analysis is challenging due to the dynamic range of proteins and mass 
spectrometry approaches are distinctively suited to handle this complexity [345]. However, 
upfront separation is required for mass spectrometry application in the study of protein 
isoforms and localization of post-translational modifications, for example [361, 362]. 
Therefore, chromatographic coupling as a separation technique for peptides and proteins 
is a key step in mass spectrometry analysis, and liquid chromatography is the most common 
method for small molecule separation. Anion exchange chromatography turned out to be 
the best separation method tested for protein isoform separation with, for example, up to 
seven isoforms being separated for human serum albumin. The pH gradient used produced 
a similar separation pattern to a previously reported salt-gradient for HSA isoform 
separation [381], but the method described in this thesis was able to separate these 
isoforms in ¼ of the time required by the previous method, increasing its potential for a 
clinical application. Even though anion exchange chromatography showed promising 
results as a quick alternative for human serum albumin isoform separation, this separation 
method should now be validated for plasma samples from healthy volunteers, to determine 
its potential to separate albumin isoforms in a complex sample and understand the sample 
preparations required for the success of this separation. After these have been established, 
the method should be tested to quantify different protein isoforms in case of diseases, for 
example to quantify the different glycated isoforms of albumin in diabetic patients as these 
could be used as a prognosis tool. The choice of the right separation method is important 
for the characterization of intact proteins for mass spectrometry, improving their detection 
and allowing the diagnosis of different diseases such as cancer, where distinction between 
isoforms is vital [352]. Ion exchange chromatography has been proposed as a good 
alternative to reverse phase [386], but for lipoxidized protein separation it was observed 
that reverse-phase chromatography was still the best method as it was able to separate 
HHE and HNE-modified proteins with different degrees of modification, as well as 
separating unmodified from modified protein. This level of separation was not obtained with 
ion exchange chromatography. The intact protein MS analysis was powerful for 
identification of modification in small proteins such as insulin and ubiquitin, however for 
larger proteins such as human serum albumin for which multiple charges can influence the 
MS analysis. So, the separation and top-down analysis of large proteins turned out to be a 
major challenge and new approaches could be used, such as the middle-down proteomic 
approach, for the full characterization of PTMs on human serum albumin. This approach 
has been previously successfully applied for other large molecules characterization such as 
monoclonal antibodies [239]. 
222 
 
Due to their ability to directly modified proteins, short-chain aldehydes are been 
proposed as compounds able to change protein structure and function, and therefore having 
a role in the onset of several diseases such as cancer. Despite this known link between 
lipoxidation and cancer, little attention has been focused on the study of the effect of 
aldehydes on glycolytic enzymes involved in the modulation of the cancer metabolism into 
aerobic glycolysis [270, 390]. Some studies have reported aldehyde modification of 
GAPDH, both in vitro and in mouse models [163, 272, 506], but lipoxidation of pyruvate 
kinase is still largely unexplored, with only one study reporting its inactivation by HNE and 
ONE [273]. To understand to effects of acrolein, HHE and MDA on pyruvate kinase, the 
PKM1 was modified in vitro and several hotspots for modification were found by LC-MS/MS 
to be at or close to the active and the allosteric sites, which might explain the loss of 
enzymatic activity observed. The effect of the same aldehydes on cellular pyruvate kinase 
(PKM2) found this enzyme to be highly susceptible to modification, and its activity was 
inhibited under pathophysiological concentrations in a time- and dose-dependent manner, 
with acrolein appearing to be the most toxic of the aldehydes tested. Some of the 
modifications mapped in vitro were also detected by MS on the pyruvate kinase extracted 
from these cells. An altered cellular metabolism upon exposure to acrolein was observed to 
counteract the decrease in pyruvate being produced, suggesting that this aldehyde may 
contribute to mechanisms of tumorigenesis via pyruvate kinase inhibition. In fact, acrolein 
is a major component in tobacco smoke and this could be one of its mechanisms of action 
as a carcinogen. Further experiments should be conducted on a non-cancerous cell line in 
order to study the ability of acrolein, and other aldehydes, to switch the cell metabolism to 
a cancerous state and better understand the underlying mechanisms.  
In contrast, intermediate filaments have no known enzymatic activity but their extensive 
cytoplasmatic network confers on them a role in coordinating cell activities [468]. Vimentin 
is an intermediate filament that is able to interact with signaling proteins and have critical 
contribution in pathophysiological conditions as cancer [477]. Under stress conditions, post-
translational modifications of vimentin such as phosphorylation and nitrosylation have been 
reported to regulate the vimentin network.  In particular, the cysteine residue 328 on 
vimentin is known to be required for its response to oxidative stress [497, 498]. Due to the 
lack of studies regarding the Cys328-mediated effect of short-chain aldehydes on vimentin 
organization, this issue was addressed in this thesis with a comparative study of the network 
upon treatment of cells expressing wildtype or mutant Cys328S with acrolein, HHE and 
MDA. The three aldehydes were able to cause morphological alterations, including vimentin 
aggregation around the nucleus, which had also been reported to happen upon treatment 
with unsaturated carbonyl species [493, 498]. This remodelling of intermediate filaments is 
usually linked to mediation of cell damage or as a mechanism of defence, but the biological 
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implication of aldehyde-mediated aggregation is still not completely understood. Cys328 
was shown to be a target for lipoxidation as its mutation conferred protection from 
lipoxidation on the vimentin network. Cysteine residues have been reported as common 
targets of oxidative modification; nonetheless LC-MS/MS analysis of the cellular protein 
extract should be performed to confirm the modification of this specific residue in vimentin. 
For further confirmation that the aggregation of vimentin upon aldehyde treatment was 
Cys328-mediated, the protein cellular extract should be analysed by LC-MS/MS for 
mapping of the modification. This would be important not just to confirm cysteine 
modification but also to find other modified residues that might be relevant for vimentin 
network assembly. 
To note that from all the aldehydes tested in this thesis, acrolein was generally the more 
modifying and toxic aldehyde. This observation was consistent across the in vitro and the 
different cellular work. 
 
7.2. Summary and perspectives 
The research presented in this thesis has provided a novel method for detection  of 
aldehyde adducts, as well as highlighting some of their cellular effects. However, further 
studies are still required in order to completely understand the effect of these aldehydic 
short-chain lipid peroxidation products. The lack of sensitive methods for aldehyde-protein 
adducts has held back progress in the use of these as clinical biomarkers. The development 
of targeted methods appeared to be promising candidates for application in measurement 
of aldehyde-albumin adducts in clinical samples due to their selectivity although further 
optimization would be required for high sensitivity. The improvement of upfront 
chromatography methods for their separation in combination with these targeted MS 
methods seems to be the way of moving the field forward. 
In summary, the work presented in this thesis has contributed to the mapping of 
aldehydic short-chain lipid peroxidation products modifications on proteins, the 
development of novel methods for their detection, and the assessment of their effects on 
cellular proteins and general metabolism. These cellular changes might underlie 
pathological conditions such as cancer, diabetes or other inflammatory diseases, and 
therefore be used as biomarkers for their diagnosis and prognosis. While much work is still 
needed to fully understand the mechanisms behind these effects, the research presented 
in this thesis is an important contribution towards a more complete understanding of the 
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9.1 List of aldehyde modifications 
 
Table 9.1. Aldehyde modifications searched on MASCOT. Specificity site, monoisotopic and 










Composition Proposed structure 
Acrolein 








H, K 40.031 40.064 C3H4 
 
FDP-lysine K 94.042 94.111 C6H6O 
 












Composition Proposed structure 
4-hydroxy-2-hexenal (HHE) 




C, H, K, R 96.058 96.127 C6H8O 
 














Composition Proposed structure 
4-hydroxy-nonenal (HNE) 
Michael C, H, K, W 156.115 156.222 C9H16O2 
 
















Composition Proposed structure 
Malondialdehyde (MDA) 




K 56.026 56.063 C3H4O 
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